**References Digestive Wellness 4th Edition**

**Author’s Preface**

Hanaway, P. (2009, July 17-19). *Fire in the Gut Part I: Assessment of Oxidative Stress and Inflammation in Gastrointestinal Dysfunction.* Paper presented at the Advanced Practice Module: Restoring Gastrointestinal Equilibrium, Washington DC.

Hanaway, P., Lipski, E., Lukaczer, D., Mullin, G., & Sult, T. . (2010, February 19-21). *Restoring Gastroentestinal Equilibrium: Practical Pplications for Understanding, Assessing, and Treating Gut Dysbunction* Paper presented at the Restoring Gastroentestinal Equilibrium: Practical Pplications for Understanding, Assessing, and Treating Gut Dysbunction, Austin, TX.

Jones, D. S., Hofmann, L., & Quinn, S. . (2009). 21st Century Medicine: A Nw Model for Medical Education and Practice. Gig Harbor, WA: Institute for Functional Medicine.**(**[**Jones, 2009**](#_ENREF_1_3)**)**

**Part I: Fundamentals**

**Chapter 1:**

ASDReports. (October 2008). World Gastrointestinal Disorders Market 2008-2023 Retrieved 4-2, 2009, from <http://www.asdreports.com/shopexd.asp?id=344>

Cohen, S. (2005). Keynote Presentation at the Eight International Congress of Behavioral Medicine: the Pittsburgh common cold studies: psychosocial predictors of susceptibility to respiratory infectious illness. *Int J Behav Med, 12*(3), 123-131. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16083315>. doi: 10.1207/s15327558ijbm1203\_1

Kallio, P., Kolehmainen, M., Laaksonen, D. E., Kekalainen, J., Salopuro, T., Sivenius, K., et al. (2007). Dietary carbohydrate modification induces alterations in gene expression in abdominal subcutaneous adipose tissue in persons with the metabolic syndrome: the FUNGENUT Study. *Am J Clin Nutr, 85*(5), 1417-1427. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17490981>. doi: 85/5/1417 [pii]

Ornish, D., Magbanua, M. J., Weidner, G., Weinberg, V., Kemp, C., Green, C., et al. (2008). Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. *Proc Natl Acad Sci U S A, 105*(24), 8369-8374. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18559852>. doi: 0803080105 [pii] 10.1073/pnas.0803080105

Pert, C. B. (1997). *Molecules of emotion : why you feel the way you feel*. New York, NY: Scribner.

ASDReports. (October 2008). World Gastrointestinal Disorders Market 2008-2023 Retrieved 4-2, 2009, from <http://www.asdreports.com/shopexd.asp?id=344>

Cohen, S. (2005). Keynote Presentation at the Eight International Congress of Behavioral Medicine: the Pittsburgh common cold studies: psychosocial predictors of susceptibility to respiratory infectious illness. *Int J Behav Med, 12*(3), 123-131. <http://www.ncbi.nlm.nih.gov/pubmed/16083315> doi: 10.1207/s15327558ijbm1203\_1

Jones, D. S., Hofmann, L., & Quinn, S. . (2009). 21st Century Medicine: A Nw Model for Medical Education and Practice. Gig Harbor, WA: Institute for Functional Medicine.

**Chapter 2: A Voyage through the Digestive System**

Barrett, K. E., Barman, MS., Boitano, S., Brooks, H.L. (2010). *Ganong's Review of Medical Physiology, 23rd Edition*. New York, NY: McGraw Hill/Lange.

Bland, J., & Benum, S. H. (1997). *The 20-day rejuvenation diet program : with the revolutionary Phytonutrient Diet*. New Canaan, Conn.: Keats Pub.

Gershon, M. D. (1998). *The second brain : the scientific basis of gut instinct and a groundbreaking new understanding of nervous disorders of the stomach and intestine* (1st ed.). New York, NY: HarperCollinsPublishers.

Gropper SS, S. J., Groff JL. (2004). *Advanced Nutrition and Human Metabolism*. Belmont CA: Thompson Wadsworth.

Keshav, S. (2004). *The Gastrointestinal System at a Glance*: Blackwell Science.

Liska DA, B. J. (2006). “Digestion and Excretion” *Textbook of Functional Medicine* (pp. 198). Gig Harbor, WA: Institute for Functional Medicine.

MacKay, D. (2003). Can CAM therapies help reduce antibiotic resistance? *Altern Med Rev, 8*(1), 28-42. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12611559>

Mahan, L., Escott-Stump, S. . (2008). *Krause's Food and Nutrition Therapy, 12th edition.* . St. Louis, MO Saunders Elsevier.

Martin, L. (1999). What is the function of the human appendix? Did it once have a purpose that has since been lost? *Scientific American*(October 21). <http://www.scientificamerican.com/article.cfm?id=what-is-the-function-of-t>

Thompson, T. (1997). *Approach to Gastrointestinal Immune Dysfunc¬tion and Related Health Problems.* Paper presented at the 4th International Functional Medicine Symposium, Aspen, CO.

**Part II The DIGIN Model and the 5 Rs**

Hanaway, P., Lipski, E., Lukaczer, D., Mullin, G., & Sult, T. (2010, February 19-21). *Restoring Gastroentestinal Equilibrium: Practical Pplications for Understanding, Assessing, and Treating Gut Dysbunction* Paper presented at the Restoring Gastroentestinal Equilibrium: Practical Pplications for Understanding, Assessing, and Treating Gut Dysbunction, Austin, TX. Also presented in 2009 in Los Angeles, and Washington, DC.

**Chapter 3 Digestion/Absorption: Replace and Repair**

Bender DA. (2002). *Introduction to Nuturiton and Metabolism, 3rd edition,* . London: Taylor and Francis Pub.

Brody, T. (1999). *Nutritional biochemistry* (2nd. ed.). San Diego: Academic Press.

Castell, D. (1975). Diet and the lower esophageal sphincter. *A J Clin Nut, 28*, 1296-1298.

de Witte, T. J., Geerdink, P. J., Lamers, C. B., Boerbooms, A. M., & van der Korst, J. K. (1979). Hypochlorhydria and hypergastrinaemia in rheumatoid arthritis. *Ann Rheum Dis, 38*(1), 14-17. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=434940>

Eastell, R., Vieira, N. E., Yergey, A. L., Wahner, H. W., Silverstein, M. N., Kumar, R., & Riggs, B. L. (1992). Pernicious anaemia as a risk factor for osteoporosis. *Clin Sci (Lond), 82*(6), 681-685. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1320549>

Fuller, D. (1999). *The healing power of enzymes*. New York: Forbes Custom Pub.

Gaskin DJ., I. J. (2009). Lactose Maldigestion Revisited: Diagnosis, Prevalence in Ethnic MInorities, and Dietary Recommendations to Overcome it. [6-3-10]. *Amer J of Lifestyle Medicine, May/June*, 212-217.

Gudmand-Hoyer, E., & Skovbjerg, H. (1996). Disaccharide digestion and maldigestion. *Scand J Gastroenterol Suppl, 216*, 111-121. <http://www.ncbi.nlm.nih.gov/pubmed/8726284>

Hanaway, P., Lipski, E., Lukaczer, D., Mullin, G., & Sult, T. . (2010, February 19-21). *Restoring Gastroentestinal Equilibrium: Practical Pplications for Understanding, Assessing, and Treating Gut Dysbunction* Paper presented at the Restoring Gastroentestinal Equilibrium: Practical Pplications for Understanding, Assessing, and Treating Gut Dysbunction, Austin, TX.

Lehninger, A. L., Nelson, D. L., & Cox, M. M. (1993). *Principles of biochemistry* (2nd ed.). New York, NY: Worth Publishers.

Mamadou, M. (1999). “Oral Enzymes: Facts and Concepts”. Houston, TX: Transformation Enzyme Corp. .

Murray M, P. J. (1999). *Textbook of Natural Medicine, Second Edition*. NY: Churchill Livingstone, division of Harcourt Brace.

Wright, J. (2001). *Why Stomach Acid is Good for You*. Lanham, MD: M. Evans.

**Chapter 4 Intestinal Permeability/Leaky Membranes**

Bahna, S. (2001). Unusual presentations of food allergy. *Ann Allergy Asthma Immunol, 86*, 414-420.

Barau, E., & Dupont, C. (1990). Modifications of intestinal permeability during food provocation procedures in pediatric irritable bowel syndrome. *J Pediatr Gastroenterol Nutr, 11*(1), 72-77. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2117653>

Brun, P., Castagliuolo, I., Di Leo, V., Buda, A., Pinzani, M., Palu, G., & Martines, D. (2007). Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. *Am J Physiol Gastrointest Liver Physiol, 292*(2), G518-525. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17023554>

<http://ajpgi.physiology.org/cgi/reprint/292/2/G518.pdf> doi: 00024.2006 [pii]

10.1152/ajpgi.00024.2006

Carratu, R., Secondulfo, M., de Magistris, L., Iafusco, D., Urio, A., Carbone, M. G., . . . Prisco, F. (1999). Altered intestinal permeability to mannitol in diabetes mellitus type I. *J Pediatr Gastroenterol Nutr, 28*(3), 264-269. <http://www.ncbi.nlm.nih.gov/pubmed/10067726>

D'Eufemia, P., Celli, M., Finocchiaro, R., Pacifico, L., Viozzi, L., Zaccagnini, M., . . . Giardini, O. (1996). Abnormal intestinal permeability in children with autism. *Acta Paediatr, 85*(9), 1076-1079. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8888921>

D'Inca, R., Annese, V., di Leo, V., Latiano, A., Quaino, V., Abazia, C., . . . Sturniolo, G. C. (2006). Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease. *Aliment Pharmacol Ther, 23*(10), 1455-1461. <http://www.ncbi.nlm.nih.gov/pubmed/16669960> doi: APT2916 [pii]10.1111/j.1365-2036.2006.02916.x

Dagci, H., Ustun, S., Taner, M. S., Ersoz, G., Karacasu, F., & Budak, S. (2002). Protozoon infections and intestinal permeability. *Acta Trop, 81*(1), 1-5. <http://www.ncbi.nlm.nih.gov/pubmed/11755426> doi: S0001706X01001917 [pii]

Escobar, H., et al,. (1992). "Intestinal Permeability to 51Cr-EDTA and Orocecal Transit Time and Cystic Fibrosis". *Journal of Pediatric Gastroenterology and Nutrition, 14*(2), 204-207.

Feng, D., Xu, W., Chen, G., Hang, C., Gao, H., & Yin, H. (2007). Influence of glutamine on intestinal inflammatory response, mucosa structure alterations and apoptosis following traumatic brain injury in rats. *J Int Med Res, 35*(5), 644-656. <http://www.ncbi.nlm.nih.gov/pubmed/17900404>

Galland, L. (2008). *Gastrointestinal Dysregulation: Connections to Chronic Disease*. Gig Harbor, WA: Institute for Functional Medicine.

Hang, C. H., Shi, J. X., Li, J. S., Wu, W., & Yin, H. X. (2003). Alterations of intestinal mucosa structure and barrier function following traumatic brain injury in rats. *World J Gastroenterol, 9*(12), 2776-2781. <http://www.ncbi.nlm.nih.gov/pubmed/14669332>

Holden, W., Orchard, T., & Wordsworth, P. (2003). Enteropathic arthritis. *Rheum Dis Clin North Am, 29*(3), 513-530, viii. <http://www.ncbi.nlm.nih.gov/pubmed/12951865>

Hollander, D. (1999). Intestinal permeability, leaky gut, and intestinal disorders. *Curr Gastroenterol Rep, 1*(5), 410-416. <http://www.ncbi.nlm.nih.gov/pubmed/10980980>

Humbert, P., Bidet, A., Treffel, P., Drobacheff, C., & Agache, P. (1991). Intestinal permeability in patients with psoriasis. *J Dermatol Sci, 2*(4), 324-326. <http://www.ncbi.nlm.nih.gov/pubmed/1911568>

Kuitunen, M., Saukkonen, T., Ilonen, J., Akerblom, H. K., & Savilahti, E. (2002). Intestinal permeability to mannitol and lactulose in children with type 1 diabetes with the HLA-DQB1\*02 allele. *Autoimmunity, 35*(5), 365-368. <http://www.ncbi.nlm.nih.gov/pubmed/12515291>

Lammers, K. M., Lu, R., Brownley, J., Lu, B., Gerard, C., Thomas, K., . . . Fasano, A. (2008). Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. *Gastroenterology, 135*(1), 194-204 e193. <http://www.ncbi.nlm.nih.gov/pubmed/18485912> doi: S0016-5085(08)00459-9 [pii]10.1053/j.gastro.2008.03.023

Lipski, E. (1998). *Leaky gut syndrome : what to do about a health threat that can cause arthrities, allergies and a host of other illnesses*. New Canaan, Conn.: Keats Pub.

Liu, Y., Xu, B., & Cai, X. (1995). [The role of intestinal permeability in the pathogenesis of ankylosing spondylitis]. *Zhonghua Nei Ke Za Zhi, 34*(2), 91-94. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7796664>

Picco, P., Gattorno, M., Marchese, N., Vignola, S., Sormani, M. P., Barabino, A., & Buoncompagni, A. (2000). Increased gut permeability in juvenile chronic arthritides. A multivariate analysis of the diagnostic parameters. *Clin Exp Rheumatol, 18*(6), 773-778. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11138347>

Ryan, C. M., Yarmush, M. L., Burke, J. F., & Tompkins, R. G. (1992). Increased gut permeability early after burns correlates with the extent of burn injury. *Crit Care Med, 20*(11), 1508-1512. <http://www.ncbi.nlm.nih.gov/pubmed/1424691>

Sapone, A., de Magistris, L., Pietzak, M., Clemente, M. G., Tripathi, A., Cucca, F., . . . Fasano, A. (2006). Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. *Diabetes, 55*(5), 1443-1449. <http://www.ncbi.nlm.nih.gov/pubmed/16644703> doi: 55/5/1443 [pii]

Secondulfo, M., Iafusco, D., Carratu, R., deMagistris, L., Sapone, A., Generoso, M., . . . Esposito, V. (2004). Ultrastructural mucosal alterations and increased intestinal permeability in non-celiac, type I diabetic patients. *Dig Liver Dis, 36*(1), 35-45. <http://www.ncbi.nlm.nih.gov/pubmed/14971814>

Sturniolo, G. C., Fries, W., Mazzon, E., Di Leo, V., Barollo, M., & D'Inca, R. (2002). Effect of zinc supplementation on intestinal permeability in experimental colitis. *J Lab Clin Med, 139*(5), 311-315. <http://www.ncbi.nlm.nih.gov/pubmed/12032492> doi: S0022214302044177 [pii]

Tripathi, A., Lammers, K. M., Goldblum, S., Shea-Donohue, T., Netzel-Arnett, S., Buzza, M. S., . . . Fasano, A. (2009). Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. *Proc Natl Acad Sci U S A, 106*(39), 16799-16804. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19805376> doi: 0906773106 [pii]10.1073/pnas.0906773106

Vaarala, O., Atkinson, M. A., & Neu, J. (2008). The "perfect storm" for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. *Diabetes, 57*(10), 2555-2562. <http://www.ncbi.nlm.nih.gov/pubmed/18820210>

<http://diabetes.diabetesjournals.org/content/57/10/2555.full.pdf> doi: 57/10/2555 [pii]

10.2337/db08-0331

Visser, J., Rozing, J., Sapone, A., Lammers, K., & Fasano, A. (2009). Tight junctions, intestinal permeability, and autoimmunity: celiac disease and type 1 diabetes paradigms. *Ann N Y Acad Sci, 1165*, 195-205. <http://www.ncbi.nlm.nih.gov/pubmed/19538307>

<http://onlinelibrary.wiley.com/doi/10.1111/j.1749-6632.2009.04037.x/abstract> doi: NYAS04037 [pii] 10.1111/j.1749-6632.2009.04037.x

Wang, S. J., Kao, C. H., Chen, D. U., & Lan, J. L. (1992). Intestinal permeability test in systemic lupus erythematosus. *Zhonghua Yi Xue Za Zhi (Taipei), 49*(1), 29-33. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1312382>

Yacyshyn, B., Meddings, J., Sadowski, D., & Bowen-Yacyshyn, M. B. (1996). Multiple sclerosis patients have peripheral blood CD45RO+ B cells and increased intestinal permeability. *Dig Dis Sci, 41*(12), 2493-2498. <http://www.ncbi.nlm.nih.gov/pubmed/9011463>

Zhou, Y., Jiang, Z., & Sun, Y. (1999). [Glutamine dipeptide enriched enteral nutrition improving gut permeability in sever burns]. *Zhonghua Yi Xue Za Zhi, 79*(11), 825-827. <http://www.ncbi.nlm.nih.gov/pubmed/11715489>

**Chapter 5 The GI Microbiome: “Aliens Have Overtaken My Body!”**

**Chapter 6 The GI Microbiome: Probiotics Naturally from Food and Supplements**

**Chapter 7 The GI Microbiome: Dysbiosis, a Good Neighborhood Gone Bad**

**Chapter 8 The GI Microbiome: Specific and Common Dysbiosis Infections**

Alam, N. H., & Ashraf, H. (2003). Treatment of infectious diarrhea in children. *Paediatr Drugs, 5*(3), 151-165. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12608880>.

Annet E. J. van Merode, H. C. v. d. M., Henk J. Busscher, and Bastiaan P. Krom\*. Influence of Culture Heterogeneity in Cell Surface Charge on

Adhesion and Biofilm Formation by Enterococcus faecalis. JOURNAL OF BACTERIOLOGY, 188(7), 2421-2426 doi: doi:10.1128/JB.188.7.2421-2426.2006

Arias-Moliz, M. T., Ferrer-Luque, C. M., Espigares-Garcia, M., & Baca, P. (2009). Enterococcus faecalis biofilms eradication by root canal irrigants. *J Endod, 35*(5), 711-714. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19410089>. doi: S0099-2399(09)00087-9 [pii]10.1016/j.joen.2009.01.018

Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., Mende, D. R., . . . Bork, P. (2011). Enterotypes of the human gut microbiome. *Nature*. <http://www.ncbi.nlm.nih.gov/pubmed/21654744> <http://www.nature.com/nature/journal/vaop/ncurrent/pdf/nature10187.pdf> doi: 10.1038/nature10187 nature10187 [pii]

Biffi, A., Coradini, D., Larsen, R., Riva, L., & Di Fronzo, G. (1997). Antiproliferative effect of fermented milk on the growth of a human breast cancer cell line. *Nutr Cancer, 28*(1), 93-99. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/9200156>.

Blaser M.J., C. Y., Reibman J. (2008). Does Helicobacter pylori protect against asthma and allergy *Gut* (Gut published online 14 Jan 2008 ed.): BMJ.

Bousvaros, A., Guandalini, S., Baldassano, R. N., Botelho, C., Evans, J., Ferry, G. D., et al. (2005). A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. *Inflamm Bowel Dis, 11*(9), 833-839. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/16116318>. doi: 00054725-200509000-00008 [pii]

Campieri, C., Campieri, M., Bertuzzi, V., Swennen, E., Matteuzzi, D., Stefoni, S., et al. (2001). Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. *Kidney Int, 60*(3), 1097-1105. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/11532105>. doi: kid906 [pii]

10.1046/j.1523-1755.2001.0600031097.x

Cani, P. D., & Delzenne, N. M. (2009). Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota. *Curr Opin Pharmacol, 9*(6), 737-743. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19628432> doi: S1471-4892(09)00092-7 [pii]10.1016/j.coph.2009.06.016

Claus, S. P., Tsang, T. M., Wang, Y., Cloarec, O., Skordi, E., Martin, F.-P., . . . Nicholson, J. K. (2008). Systemic multicompartmental effects of the gut microbiome on mouse metabolic phenotypes. *Molecular Systems Biology, 4*. doi: 10.1038/msb.2008.56

Consumer-Lab. (2003). Product Review: Probiotic Supplements and Foods. Retrieved from

Cordain, L. E., S Boyd; Sebastian, Anthony; Mann, Neil; Lindeberg, Staffan; Watkins, Bruce A; O’Keefe,James H; Brand-Miller, Janette. (2005). Origins and evolution of the Western diet: health implications for the 21st century. *A J Clin Nut, 81*(2), 341-354.

Czerucka, D., Nano, J. L., Bernasconi, P., & Rampal, P. (1991). [Response of the IRD intestinal epithelial cell line to Clostridium difficile toxins A and B in rats. Effect of Saccharomyces boulardii]. *Gastroenterol Clin Biol, 15*(1), 22-27. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/1849105>.

Czerucka, D., Piche, T., & Rampal, P. (2007). Review article: yeast as probiotics -Saccharomyces boulardii. *Alimentary Pharmacology & Therapeutics, 26*(6), 767-778. doi: 10.1111/j.1365-2036.2007.03442.x

De Vrese M, S. J. (2008). *“Probiotics, Prebiotics, and Synbiotics”* (Vol. ) Berlin/Heidlebert: Springer

Do, V. T., Baird, B. G., & Kockler, D. R. Probiotics for Maintaining Remission of Ulcerative Colitis in Adults (March). *Ann Pharmacother*. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20124461>. doi: aph.1M498 [pii]10.1345/aph.1M498

Flanagan, J. L., & Willcox, M. D. (2009). Role of lactoferrin in the tear film. *Biochimie, 91*(1), 35-43. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18718499>. doi: S0300-9084(08)00229-0 [pii]10.1016/j.biochi.2008.07.007

Frank, D. N., & Pace, N. R. (2008). Gastrointestinal microbiology enters the metagenomics era. *Curr Opin Gastroenterol, 24*(1), 4-10. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18043225> doi: 10.1097/MOG.0b013e3282f2b0e800001574-200801000-00003 [pii]

Gaddy, J. A., & Actis, L. A. (2009). Regulation of Acinetobacter baumannii biofilm formation. *Future Microbiol, 4*, 273-278. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19327114>. doi: 10.2217/fmb.09.5

Galland, L. (1993). Dysbiosis and Disease. Asheville, NC: Great Smokies Diagnostic Lab and HealthComm International.

Gibson, G. R., Probert, H. M., Loo, J. V., Rastall, R. A., & Roberfroid, M. B. (2004). Dietary modulation of the human colonic microbiota: updating the concept of prebiotics. *Nutr Res Rev, 17*(2), 259-275. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/19079930>

<http://journals.cambridge.org/download.php?file=%2FNRR%2FNRR17_02%2FS0954422404000204a.pdf&code=c79961a563fcce67d4063bbf512011e1>. doi: S0954422404000204 [pii]10.1079/NRR200479

Gibson, G. R., & Roberfroid, M. B. (1995). Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. *J Nutr, 125*(6), 1401-1412. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/7782892>.

Gibson, G. R., & Wang, X. (1994). Regulatory effects of bifidobacteria on the growth of other colonic bacteria. *J Appl Bacteriol, 77*(4), 412-420. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/7989269>.

Guandalini, S. (2002). Use of Lactobacillus-GG in paediatric Crohn's disease. *Dig Liver Dis, 34 Suppl 2*, S63-65. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/12408443>.

Guandalini, S., Pensabene, L., Zikri, M. A., Dias, J. A., Casali, L. G., Hoekstra, H., et al. (2000). Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. *J Pediatr Gastroenterol Nutr, 30*(1), 54-60. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/10630440>.

Halpern, G. (2009). Peptic Ulcer Disease and Helicobacter pylori. In I. Kohlstadt (Ed.), *Food and Nutrients in Disease Management*. Boca Raton, FL: Taylor and Francis.

Hancock, V., Dahl, M., & Klemm, P. Probiotic Escherichia coli strain Nissle 1917 out-competes intestinal pathogens during biofilm formation. *J Med Microbiol*. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20110388>. doi: jmm.0.008672-0 [pii]10.1099/jmm.0.008672-0

Hunter, M. M., & McKay, D. M. (2004). Review article: helminths as therapeutic agents for inflammatory bowel disease. *Aliment Pharmacol Ther, 19*(2), 167-177. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/14723608>. doi: 1803 [pii]

Iweala OI, N. C. (2006). Immune privilege in the gut: the establishment and maintenance of non-responsiveness to dietary antigens and commensal flora. *Immunological Reviews, 213*, 82-100.

Jones, S. E., & Versalovic, J. (2009). Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors. *BMC Microbiol, 9*, 35. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19210794>. doi: 1471-2180-9-35 [pii]10.1186/1471-2180-9-35

Kajiwara, S., Gandhi, H., & Ustunol, Z. (2002). Effect of honey on the growth of and acid production by human intestinal Bifidobacterium spp.: an in vitro comparison with commercial oligosaccharides and inulin. *J Food Prot, 65*(1), 214-218. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/11808799>.

Kalliomaki, M., Collado, M. C., Salminen, S., & Isolauri, E. (2008). Early differences in fecal microbiota composition in children may predict overweight. *Am J Clin Nutr, 87*(3), 534-538. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18326589>. doi: 87/3/534 [pii]

Kalliomaki, M., Salminen, S., Arvilommi, H., Kero, P., Koskinen, P., & Isolauri, E. (2001). Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. *Lancet, 357*(9262), 1076-1079. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11297958>.

Kalliomaki, M., Salminen, S., Poussa, T., Arvilommi, H., & Isolauri, E. (2003). Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. *Lancet, 361*(9372), 1869-1871. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/12788576>. doi: S0140-6736(03)13490-3 [pii]10.1016/S0140-6736(03)13490-3

Kimmey, M. B., Elmer, G. W., Surawicz, C. M., & McFarland, L. V. (1990). Prevention of further recurrences of Clostridium difficile colitis with Saccharomyces boulardii. *Dig Dis Sci, 35*(7), 897-901. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/2364845>.

Kirjavainen, P. V., Ouwehand, A. C., Isolauri, E., & Salminen, S. J. (1998). The ability of probiotic bacteria to bind to human intestinal mucus. *FEMS Microbiol Lett, 167*(2), 185-189. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/9809419>. doi: S0378-1097(98)00387-5 [pii]

Kirjavainen, P. V., Salminen, S. J., & Isolauri, E. (2003). Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. *J Pediatr Gastroenterol Nutr, 36*(2), 223-227. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12548058>.

Kleessen, B., & Blaut, M. (2005). Modulation of gut mucosal biofilms. *Br J Nutr, 93 Suppl 1*, S35-40. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15877893>. doi: S0007114505000784 [pii]

Kligler, B. (2007). Probiotics in Children. *Pediatric Clinics of North America, 54*(6), 949-967. doi: 10.1016/j.pcl.2007.10.002

Kligler, B., Hanaway, P., & Cohrssen, A. (2007). Probiotics in children. *Pediatr Clin North Am, 54*(6), 949-967; xi. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18061785>. doi: S0031-3955(07)00144-7 [pii] 10.1016/j.pcl.2007.10.002

Lee D., M. J. (2008). Small Intestinal Bacterial Overgrowth. *MedicineNet.com*. Retrieved from <http://www.medicinenet.com/script/main/art.asp?articlekey=55091>

Lin, H. C. (2004). Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. *JAMA, 292*(7), 852-858. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15316000>. doi: 10.1001/jama.292.7.852292/7/852 [pii]

Lin, H. C., & Pimentel, M. (2005). Bacterial concepts in irritable bowel syndrome. *Rev Gastroenterol Disord, 5 Suppl 3*, S3-9. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17713456>.

Liska D, Q. S., Lukaczer D, Jones DS, Lerman RH, Bland JS, Costarella L, Schlitz B, Schmidt MA, . (2004). *Clinical Nutrition: A Functional Approach, 2nd edition* Gig Harbor, WA: Institute for Functional Medicine.

Longbottom, C., Ekstrand, K., Zero, D., & Kambara, M. (2009). Novel preventive treatment options. *Monogr Oral Sci, 21*, 156-163. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19494683>. doi: 000224220 [pii]10.1159/000224220

Lukaczer D, M. G., Hanaway P, Lipski E, . (2009, July 17-19). *Clinical Imbalances.* Paper presented at the Restoring Gastrointestinal Equilibrium: Practical Applications for understanding, assessing, and treating gut dysfunction. , Washington DC.

Macfarlane, G. T., & Cummings, J. H. (1999). Probiotics and prebiotics: can regulating the activities of intestinal bacteria benefit health? *BMJ, 318*(7189), 999-1003. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/10195977>.

Macfarlane, G. T., Steed, H., & Macfarlane, S. (2008). Bacterial metabolism and health-related effects of galacto-oligosaccharides and other prebiotics. *J Appl Microbiol, 104*(2), 305-344. doi: JAM3520 [pii]

10.1111/j.1365-2672.2007.03520.x [doi]

Macfarlane, S. (2008). Microbial biofilm communities in the gastrointestinal tract. *J Clin Gastroenterol, 42 Suppl 3 Pt 1*, S142-143. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18806707>. doi: 10.1097/MCG.0b013e31816207df

Macfarlane, S., & Macfarlane, G. T. (2006). Composition and Metabolic Activities of Bacterial Biofilms Colonizing Food Residues in the Human Gut. *Applied and Environmental Microbiology, 72*(9), 6204-6211. doi: 10.1128/aem.00754-06

MacKay, D. (2003). Can CAM therapies help reduce antibiotic resistance? *Altern Med Rev, 8*(1), 28-42. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12611559>.

MedicineNet.com. (2001). Definition of Biofilm. *MedcineNet.com*. Retrieved from

Mitsuoka, T. (1992). Intestinal flora and aging. *Nutr Rev, 50*(12), 438-446. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/1488186>.

Mohammadi, Z. (2009). Local applications of tetracyclines in endodontics and dental trauma: a review. *Dent Today, 28*(1), 95-96, 98, 100-101; quiz 101. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19323332>.

Mullin G, H. P., Lipski E (2009, July 2009). *Gastrointestilnal Dysbiosis: What is it and How to Recognize it.* Paper presented at the Restoring Gastroenterological Equilibrium, Washington DC.

Nostro A, A. S. R., Giuseppe Bisignano,, Andreana Marino, M. A. C., Francesco C. Pizzimenti,, & Pier Luigi Cioni, F. P. a. A. R. B. (2007). Effects of oregano, carvacrol and thymol on Staphylococcus aureus and Staphylococcusepidermidis biofilms. Journal of Medical Microbiology 56, 519-523.

O'May, C. Y., Sanderson, K., Roddam, L. F., Kirov, S. M., & Reid, D. W. (2009). Iron-binding compounds impair Pseudomonas aeruginosa biofilm formation, especially under anaerobic conditions. *J Med Microbiol, 58*(Pt 6), 765-773. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19429753>. doi: 58/6/765 [pii]10.1099/jmm.0.004416-0

Parkar, S. G., Stevenson, D. E., & Skinner, M. A. (2008). The potential influence of fruit polyphenols on colonic microflora and human gut health. *Int J Food Microbiol, 124*(3), 295-298. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18456359>. doi: S0168-1605(08)00140-2 [pii]

10.1016/j.ijfoodmicro.2008.03.017

Pessi, T., Sutas, Y., Hurme, M., & Isolauri, E. (2000). Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG. *Clin Exp Allergy, 30*(12), 1804-1808. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11122221>.

Peterson, J., Garges, S., Giovanni, M., McInnes, P., Wang, L., Schloss, J. A., . . . Guyer, M. (2009). The NIH Human Microbiome Project. *Genome Research, 19*(12), 2317-2323. doi: 10.1101/gr.096651.109

Pietrzak, A., Jastrzebska, I., Chodorowska, G., Maciejewski, R., Dybiec, E., Juszkiewicz-Borowiec, M., et al. (2009). Psoriasis vulgaris and digestive system disorders: is there a linkage? *Folia Histochem Cytobiol, 47*(3), 517-524. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/20164041>. doi: 544150M64W4633V6 [pii]10.2478/v10042-009-0107-y

Pimentel, M. (2008). The prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome: IBS vs healthy controls (not historical definitions). *Gut, 57*(9), 1334-1335; author reply 1335. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18719147>. doi: 57/9/1334-a [pii]

Pizzorno L, P. J., Murray M. (2002). *Natural Medicine Instructions for Patients*. London: Churchill Livingstone.

Plein, K., & Hotz, J. (1993). Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea--a pilot study. *Z Gastroenterol, 31*(2), 129-134. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/8465554>.

Plummer N, Q. P., Crockett C. (2003). Fructooligosaccharides and other prbiotics-FOS. *Townsend letter for doctors and patients*(June).

Psaltis, A. J., Wormald, P. J., Ha, K. R., & Tan, L. W. (2008). Reduced levels of lactoferrin in biofilm-associated chronic rhinosinusitis. *Laryngoscope, 118*(5), 895-901. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18216739>. doi: 10.1097/MLG.0b013e31816381d4

Reid, G. (2001). Probiotic agents to protect the urogenital tract against infection. *Am J Clin Nutr, 73*(2 Suppl), 437S-443S. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/11157354>.

Reid, G., & Bruce, A. W. (2001). Selection of lactobacillus strains for urogenital probiotic applications. *J Infect Dis, 183 Suppl 1*, S77-80. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/11171021>. doi: JID000777 [pii]10.1086/318841

Rio, M. E., Zago Beatriz, L., Garcia, H., & Winter, L. (2002). [The nutritional status change the effectiveness of a dietary supplement of lactic bacteria on the emerging of respiratory tract diseases in children]. *Arch Latinoam Nutr, 52*(1), 29-34. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12214543>.

Roberfroid, M. B. (1998). Prebiotics and synbiotics: concepts and nutritional properties. *Br J Nutr, 80*(4), S197-202. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9924284>.

Rosenfeldt, V., Benfeldt, E., Nielsen, S. D., Michaelsen, K. F., Jeppesen, D. L., Valerius, N. H., et al. (2003). Effect of probiotic Lactobacillus strains in children with atopic dermatitis. *J Allergy Clin Immunol, 111*(2), 389-395. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12589361>.

Saavedra, J. M., Abi-Hanna, A., Moore, N., & Yolken, R. H. (2004). Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety. *Am J Clin Nutr, 79*(2), 261-267. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14749232>.

Salminen, S., Nybom, S., Meriluoto, J., Collado, M. C., Vesterlund, S., & El-Nezami, H. (2010). Interaction of probiotics and pathogens--benefits to human health? *Curr Opin Biotechnol, 21*(2), 157-167. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20413293>. doi: S0958-1669(10)00058-3 [pii]

10.1016/j.copbio.2010.03.016

Salminen, S., & Wright, A. v. (1993). *Lactic acid bacteria*. New York: Dekker.

Saran, S., Gopalan, S., & Krishna, T. P. (2002). Use of fermented foods to combat stunting and failure to thrive. *Nutrition, 18*(5), 393-396. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11985943>.

Sazawal, S., Dhingra, U., Sarkar, A., Dhingra, P., Deb, S., Marwah, D., et al. (2004). Efficacy of milk fortified with a probiotic Bifidobacterium lactis (DR-10TM) and prebiotic galacto-oligosaccharides in prevention of morbidity and on nutritional status. *Asia Pac J Clin Nutr, 13*(Suppl), S28. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15294490>.

Schrezenmeir, J., Heller, K., McCue, M., Llamas, C., Lam, W., Burow, H., et al. (2004). Benefits of oral supplementation with and without synbiotics in young children with acute bacterial infections. *Clin Pediatr (Phila), 43*(3), 239-249. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15094948>.

Sekine, K., Ohta, J., Onishi, M., Tatsuki, T., Shimokawa, Y., Toida, T., et al. (1995). Analysis of antitumor properties of effector cells stimulated with a cell wall preparation (WPG) of Bifidobacterium infantis. *Biol Pharm Bull, 18*(1), 148-153. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/7537575>.

Sellars, R. L. (1991). Acidophilus product. In R. K. Robinson (Ed.), *Therapeutic Properties of Fermented Milks*. London: Chapman and Hall.

Seppo, L., Jauhiainen, T., Poussa, T., & Korpela, R. (2003). A fermented milk high in bioactive peptides has a blood pressure-lowering effect in hypertensive subjects. *Am J Clin Nutr, 77*(2), 326-330. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/12540390>.

Sghir, A., Chow, J. M., & Mackie, R. I. (1998). Continuous culture selection of bifidobacteria and lactobacilli from human faecal samples using fructooligosaccharide as selective substrate. *J Appl Microbiol, 85*(4), 769-777. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/9812388>.

Singhal, S., Dian, D., Keshavarzian, A., Fogg, L., Fields, J. Z., & Farhadi, A. (2010). The Role of Oral Hygiene in Inflammatory Bowel Disease. *Dig Dis Sci*. <http://www.ncbi.nlm.nih.gov/pubmed/20458622> doi: 10.1007/s10620-010-1263-9

Soares, J. A., Roque de Carvalho, M. A., Cunha Santos, S. M., Mendonca, R. M., Ribeiro-Sobrinho, A. P., Brito-Junior, M., et al. (2010). Effectiveness of chemomechanical preparation with alternating use of sodium hypochlorite and EDTA in eliminating intracanal Enterococcus faecalis biofilm. *J Endod, 36*(5), 894-898. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20416441>. doi: S0099-2399(10)00004-X [pii]10.1016/j.joen.2010.01.002

Sultan MI, L. B. (2009). Helicobacter Pylori Infection: Treatment & Medication. Retrieved from <http://emedicine.medscape.com/article/929452-treatment>

Tennyson, C. A., & Friedman, G. (2008). Microecology, obesity, and probiotics. *Curr Opin Endocrinol Diabetes Obes, 15*(5), 422-427. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18769213>. doi: 10.1097/MED.0b013e328308dbfb 01266029-200810000-00006 [pii]

Thein ZM, S. Y., Samaranayake LP. . (2007). Dietary sugars, serum and the biocide chlorhexidine digluconate modify the population and structural dynamics of mixed Candida albicans and Escherichia coli biofilms. . APMIS, 115, 1241-1251.

Turnbaugh PJ, G. J. (2009). <J J Physiol-2009-Turnbaugh Gordon.pdf>. *J. Physiol., 587*(17), 4153-4158. doi: DOI: 10.1113/jphysiol.2009.174136

Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B. L., Duncan, A., Ley, R. E., . . . Gordon, J. I. (2008). A core gut microbiome in obese and lean twins. *Nature, 457*(7228), 480-484. doi: 10.1038/nature07540

Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006). An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature, 444*(7122), 1027-1031. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17183312> doi: nature05414 [pii]10.1038/nature05414

Turroni, F., Ribbera, A., Foroni, E., van Sinderen, D., & Ventura, M. (2008). Human gut microbiota and bifidobacteria: from composition to functionality. *Antonie Van Leeuwenhoek, 94*(1), 35-50. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18338233>. doi: 10.1007/s10482-008-9232-4

Van Niel, C. W., Feudtner, C., Garrison, M. M., & Christakis, D. A. (2002). Lactobacillus therapy for acute infectious diarrhea in children: a meta-analysis. *Pediatrics, 109*(4), 678-684. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/11927715>.

Ventura, M., O'Flaherty, S., Claesson, M. J., Turroni, F., Klaenhammer, T. R., van Sinderen, D., et al. (2008). Genome-scale analyses of health-promoting bacteria: probiogenomics. *Nature Reviews Microbiology, 7*(1), 61-71. doi: 10.1038/nrmicro2047

Xu, J., Mahowald, M. A., Ley, R. E., Lozupone, C. A., Hamady, M., Martens, E. C., . . . Gordon, J. I. (2007). Evolution of symbiotic bacteria in the distal human intestine. *PLoS Biol, 5*(7), e156. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17579514> <http://www.plosbiology.org/article/fetchObjectAttachment.action;jsessionid=669785FCC080E78C609C5AE3CBB77B9A.ambra01?uri=info%3Adoi%2F10.1371%2Fjournal.pbio.0050156&representation=PDF> doi: 06-PLBI-RA-1577 [pii]10.1371/journal.pbio.0050156

**Chapter 9 Fire in the Gut: Immune and Inflammation**

Baker, S. (2009). *Notes on Immunology for Friday Evening Talk*. Paper presented at the Defeat Autism Now, Dallas, TX.

Bevins, C. L., Stange, E. F., & Wehkamp, J. (2009). Decreased Paneth cell defensin expression in ileal Crohn's disease is independent of inflammation, but linked to the NOD2 1007fs genotype. *Gut, 58*(6), 882-883; discussion 883-884. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19433600>. doi: 58/6/882 [pii]

BioHealth-Diagnostics. (2009). Secretory IgA. Retrieved from <http://www.intestinalbarriertest.com/>

Buts, J. P., Bernasconi, P., Vaerman, J. P., & Dive, C. (1990). Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. *Dig Dis Sci, 35*(2), 251-256. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2302983>.

Christopher, J. (2976). *School of Natural Healing*. UT: Christopher Publ.

Coppo, R. (1988). The pathogenetic potential of environmental antigens in IgA nephropathy. *Am J Kidney Dis, 12*(5), 420-424. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3055968>. doi: S0272638688001441 [pii]

Galland, L. (2008). *Gastrointestinal Dysregulation: Connections to Chronic Disease*. Gig Harbor, WA: Institute for Functional Medicine.

Giugliano, D., Ceriello, A., & Esposito, K. (2006). The effects of diet on inflammation: emphasis on the metabolic syndrome. *J Am Coll Cardiol, 48*(4), 677-685. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16904534>. doi: S0735-1097(06)01335-0 [pii]10.1016/j.jacc.2006.03.052

Grethlein SJ, P. J. (2008). Mucosa-Associated Lymphoid Tissue. *Emedicine*. Retrieved from

Hanaway, P. (2009, July 17-19). *Fire in the Gut Part I: Assessment of Oxidative Stress and Inflammation in Gastrointestinal Dysfunction.* Paper presented at the Advanced Practice Module: Restoring Gastrointestinal Equilibrium, Washington DC.

Hart, A. L., Lammers, K., Brigidi, P., Vitali, B., Rizzello, F., Gionchetti, P., et al. (2004). Modulation of human dendritic cell phenotype and function by probiotic bacteria. *Gut, 53*(11), 1602-1609. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15479680>. doi: 53/11/1602 [pii] 10.1136/gut.2003.037325

Hyperhealth. (2008). Hyperhealth Encyclopedia. Hansville, WA 98340: In-Tele-Health-America.

Jahn, H. U., Ullrich, R., Schneider, T., Liehr, R. M., Schieferdecker, H. L., Holst, H., et al. (1996). Immunological and trophical effects of Saccharomyces boulardii on the small intestine in healthy human volunteers. *Digestion, 57*(2), 95-104. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8786007>.

Kono, H., Fujii, H., Asakawa, M., Maki, A., Amemiya, H., Hirai, Y., et al. (2004). Medium-chain triglycerides enhance secretory IgA expression in rat intestine after administration of endotoxin. *Am J Physiol Gastrointest Liver Physiol, 286*(6), G1081-1089. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15132951>. doi: 10.1152/ajpgi.00457.2003286/6/G1081 [pii]

Lord R, B. J. (Ed.). (2009). *Laboratory Evaluations for Integrative and Functional Medicine, 2nd edition*. Duluth, GA: Metametrix Institute.

Nascimbeni, R., Villanacci, V., Bassotti, G., Fisogni, S., Gervasi, M., Rossi, E., et al. (2009). Colonic lymphoid follicles and NOD2/CARD15 mutational status in Crohn's disease. *Br J Surg, 96*(6), 655-662. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19434699>. doi: 10.1002/bjs.6615

Philpott, D. J., & Girardin, S. E. (2009). Crohn's disease-associated Nod2 mutants reduce IL10 transcription. *Nat Immunol, 10*(5), 455-457. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19381138>. doi: ni0509-455 [pii]10.1038/ni0509-455

Rountree, R. (2006). Immune Imbalances and Inflammation. In Q. S. Jones D. (Ed.), *The Textbook of Functional Medicine* (pp. 299-326). Gig Harbor, WA: Institute for Functional Medicine.

Summers, R. W., Elliott, D. E., Qadir, K., Urban, J. F., Jr., Thompson, R., & Weinstock, J. V. (2003). Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. *Am J Gastroenterol, 98*(9), 2034-2041. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14499784>. doi: S0002927003006233 [pii] 10.1111/j.1572-0241.2003.07660.x

Summers, R. W., Elliott, D. E., Urban, J. F., Jr., Thompson, R., & Weinstock, J. V. (2005). Trichuris suis therapy in Crohn's disease. *Gut, 54*(1), 87-90. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15591509>. doi: 54/1/87 [pii]10.1136/gut.2004.041749

Summers, R. W., Elliott, D. E., Urban, J. F., Jr., Thompson, R. A., & Weinstock, J. V. (2005). Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. *Gastroenterology, 128*(4), 825-832. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15825065>. doi: S0016508505000259 [pii]

Torok, H. P., Glas, J., Endres, I., Tonenchi, L., Teshome, M. Y., Wetzke, M., et al. (2009). Epistasis between Toll-like receptor-9 polymorphisms and variants in NOD2 and IL23R modulates susceptibility to Crohn's disease. *Am J Gastroenterol, 104*(7), 1723-1733. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19455129>. doi: ajg2009184 [pii]10.1038/ajg.2009.184

Wald, M. B. (2007). *The Anti-Aging Encyclopedia of Tests and Natural Treatments*. Mount Kisko, NY: Blood Logic Inc.

**Chapter 10 The Enteric Nervous System: The Second Brain**

Brunello, N., Akiskal, H., Boyer, P., Gessa, G. L., Howland, R. H., Langer, S. Z., . . . Wessely, S. (1999). Dysthymia: clinical picture, extent of overlap with chronic fatigue syndrome, neuropharmacological considerations, and new therapeutic vistas. *J Affect Disord, 52*(1-3), 275-290.

Cole, J. A., Rothman, K. J., Cabral, H. J., Zhang, Y., & Farraye, F. A. (2006). Migraine, fibromyalgia, and depression among people with IBS: a prevalence study. *BMC Gastroenterol, 6*, 26. doi: 1471-230X-6-26 [pii] 10.1186/1471-230X-6-26

Drossman, D. A., Toner, B. B., Whitehead, W. E., Diamant, N. E., Dalton, C. B., Duncan, S., . . . Bangdiwala, S. I. (2003). Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. *Gastroenterology, 125*(1), 19-31. doi: S0016508503006693 [pii]

Keshav, S. (2004). *The Gastrointestinal System at a Glance*: Blackwell Science.

Klok MD, J. S., Drent ML., , & ( 2007). The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. *Obes Rev., Jan;8(1):21-34*.

Lutgendorff, F. A., L.M>, & Soderholm, J.D. . (2008). The role of microbiota and probiotics in stress-induced gastro-intestinal damage. . *Curr Mol Med, 8*(4), 282-298. .

Mahan, L., Escott-Stump, S. . (2008). *Krause's Food and Nutrition Therapy, 12th edition.* . St. Louis, MO Saunders Elsevier.

McLean, P. G., Calver, A. R., Alpers, D. H., Collins, S. M., Shanahan, F., & Lee, K. (2009). The emerging role of the microbial-gastrointestinal-neural axis. *Gastroenterology Insights, 1*(1). doi: 10.4081/gi.2009.e3

Toner, B. B., Segal, Z. V., Emmott, S., Myran, D., Ali, A., DiGasbarro, I., & Stuckless, N. (1998). Cognitive-behavioral group therapy for patients with irritable bowel syndrome. *Int J Group Psychother, 48*(2), 215-243.

**Chapter 11 Functional Medicine/Functional Testing**

**Part III Coming Back into Balance**

**Chapter 12 Food Is Your Best Medicine**

Batmanghelidj F. Your Body's Many Cries for Water. Global Health, 1992.

Carbonaro M, MM, et al. "Modulation of antioxidant compounds in organic vs. conventional fruit." J Ag Food Chem 2002;50(19):5458–5462.

Carper J. The Food Pharmacy. Bantam Books, 1989.

Constant J, Jaffe R. "The role of eggs, margarines and fish oils in the nutritional management of coronary artery disease and strokes." Keio J Med 2004;53(3):131–136.

Dallongeville J, Yarnell J, et al. "Fish consumption is associated with lower heart rates." Circulation 2004;109(9):e155–e156.

Donovan P. Guided Health: A Constant Professional Reference. Reston, VA: Health Studies Collegium, 1989.

Eades MR, Eades MD. Protein Power: The High-Protein/Low-Carbohydrate Way to Lose Weight, Feel Fit, and Boost Your Health—in Just Weeks! Bantam Books, 1997.

Erasmus, Udo. Fats That Heal, Fats That Kill. Burnaby, B.C.: Alive Books, ­1993.

Giugliano, D. Ceriello, A. Esposito, K. “The effects of diet on inflammation: emphasis on the metabolic syndrome” J Am Coll Cardiol. 2006 Aug 15;48(4):677-85.

Jaffe, R., and P. Donovan. Guided Health: A Constant Profes­sional Reference. Reston, Va.: Health Studies Collegium Publishing, ­1989.

Jude S, Roger S, et al. "Dietary long-chain omega-3 fatty acids of marine origin: A comparison of their protective effects on coronary heart disease and breast cancers." Prog Biophys Mol Biol 2005

Kromhout D. "N-3 fatty acids and coronary heart disease: Epidemiology from Eskimos to Western populations." J Intern Med Suppl 1989;731:47–51.

Lappe FM. Diet for a Small Planet. Ballantine Books, 1991.

MacKay D. "Can CAM therapies help reduce antibiotic resistance?" Altern Med Rev 2003;8(1):28–42.

Ornish, D., Magbanua, M. J., Weidner, G., Weinberg, V., Kemp, C., Green, C., et al. (2008). Changes in prostate gene expression in men undergoing an intensive nutrition and lifestyle intervention. Proc Natl Acad Sci U S A, 105(24), 8369-8374.

Shauss A. "Dietary fish oil consumption and fish oil supplementation." J. Pizzorno and M. Murray editors, A Textbook for Natural Medicine. Churchill Livingstone. 1991, pp. 1–7.

Shnayerson M, Plotkin M. The Killers Within: The Deadly Rise of Drug-Resistant Bacteria. Little, Brown and Co., 2002.

Schnohr, P., et al. “Egg Consumption and High-Density Lipo­protein Cholesterol.” J Intern Med 235 (1994): ­249–51.

Simopoulos AP. "The traditional diet of Greece and cancer." Eur J Cancer Prev 2004;13(3):219–230.

Shinitsky, M. “Egg Consumption, Serum Cholesterol, and Mem­brane Fluidity.” Biomembranes and Nutrition 195 (1989): ­391–400.

Smith, B. “Organic Foods vs. Supermarket Foods, Element Levels.” Doctor’s Data Labs, ­1993.

Weir, D., and M. Schapiro. Circle of Poison. San Francisco: Institute for Food & Development Policy, ­1981.

Young G, Conquer J. "Omega-3 fatty acids and neuropsychiatric disorders." Reprod Nutr Dev 2005;45(1):1–28.

**Chapter 13 Restorative Foods for Healing**

No additional references.

**Chapter 14 Food Sensitivities, Intolerances, and Allergies**

Arslan Lied, G. (2007). Gastrointestinal food hypersensitivity: symptoms, diagnosis and provocation tests. Turk J Gastroenterol, 18(1), 5-13. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17450488>.

Bade, M. A., Rammeloo, E. M., Hermans, J., de Vries Locher, A. L., de Graaf, E. A., & Mearin, M. L. (1995). [Symptoms of disease and food allergy in children with Down syndrome]. Ned Tijdschr Geneeskd, 139(33), 1680-1684. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7566230>.

Bahna, S. (2001). Unusual presentations of food allergy. Ann Allergy Asthma Immunol, 86, 414-420.

Beausoleil, J. L., Fiedler, J., & Spergel, J. M. (2007). Food Intolerance and childhood asthma: what is the link? Paediatr Drugs, 9(3), 157-163. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17523696>. doi: 934 [pii]

Bischoff, S. C. (2006). Food allergies. Curr Gastroenterol Rep, 8(5), 374-382. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16968604>.

Bischoff, S. C. (2007). Food allergies. Curr Treat Options Gastroenterol, 10(1), 34-43. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17298763>.

Breuer, K., Heratizadeh, A., Wulf, A., Baumann, U., Constien, A., Tetau, D., et al. (2004). Late eczematous reactions to food in children with atopic dermatitis. Clin Exp Allergy, 34(5), 817-824. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15144477>.

Daneshjoo, R., & N, J. T. (2002). Eosinophilic gastroenteritis. Curr Gastroenterol Rep, 4(5), 366-372. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12228038>.

Egger, J., Carter, C. M., Wilson, J., Turner, M. W., & Soothill, J. F. (1983). Is migraine food allergy? A double-blind controlled trial of oligoantigenic diet treatment. Lancet, 2(8355), 865-869. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=6137694>.

Fasano, A. (2005). Clinical presentation of celiac disease in the pediatric population. Gastroenterology, 128(4 Suppl 1), S68-73. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15825129>. doi: S0016508505001848 [pii]

Gadewar, S., & Fasano, A. (2005). Celiac disease: is the atypical really typical? Summary of the recent National Institutes of Health Consensus Conference and latest advances. Curr Gastroenterol Rep, 7(6), 455-461. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16313875>.

Gaskin DJ., I. J. (2009). Lactose Maldigestion Revisited: Diagnosis, Prevalence in Ethnic MInorities, and Dietary Recommendations to Overcome it. [6-3-10]. Amer J of Lifestyle Medicine, May/June, 212-217.

Hanaway, P., Lipski, E., Lukaczer, D., Mullin, G., & Sult, T. . (2010, February 19-21). Restoring Gastroentestinal Equilibrium: Practical Pplications for Understanding, Assessing, and Treating Gut Dysbunction Paper presented at the Restoring Gastroentestinal Equilibrium: Practical Pplications for Understanding, Assessing, and Treating Gut Dysbunction, Austin, TX.

Herman, P. M., & Drost, L. M. (2004). Evaluating the clinical relevance of food sensitivity tests: a single subject experiment. Altern Med Rev, 9(2), 198-207. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15253678>.

Hill, D. J., Heine, R. G., & Hosking, C. S. (2004). The diagnostic value of skin prick testing in children with food allergy. Pediatr Allergy Immunol, 15(5), 435-441. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15482519>. doi: PAI188 [pii] 10.1111/j.1399-3038.2004.00188.x

Hvatum, M., Kanerud, L., Hallgren, R., & Brandtzaeg, P. (2006). The gut-joint axis: cross reactive food antibodies in rheumatoid arthritis. Gut, 55(9), 1240-1247. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/16484508> <http://gut.bmj.com/content/55/9/1240>. doi: gut.2005.076901 [pii] 10.1136/gut.2005.076901

Iweala OI, N. C. (2006). Immune privilege in the gut: the establishment and maintenance of non-responsiveness to dietary antigens and commensal flora. Immunological Reviews, 213, 82-100.

Jesenak, M., & Banovcin, P. (2006). Atopy patch test in the diagnosis of food allergy in children with atopic dermatitis. Acta Medica (Hradec Kralove), 49(4), 199-201. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17438830>.

Jewett, D. L., Fein, G., & Greenberg, M. H. (1990). A double-blind study of symptom provocation to determine food sensitivity. N Engl J Med, 323(7), 429-433. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2374564>.

Jonathan V. Wright, M. (1999). Food Allergy, Food Sensitivity, and Symptoms of Illness. Nutrition & Healing, 6(11), 1-2, 5.

Kalliomaki, M. (2005). Food allergy and irritable bowel syndrome. Curr Opin Gastroenterol. , 21(6), 708-711.

Kemp, A. S. (2007). Egg allergy. Pediatr Allergy Immunol, 18(8), 696-702. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18078424>. doi: PAI679 [pii] 10.1111/j.1399-3038.2007.00679.x

King, D. S. (1988). The reliability and validity of provocative food testing: a critical review. Med Hypotheses, 25(1), 7-16. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3278199>. doi: 0306-9877(88)90039-4 [pii]

Kubincova, L., Payer, J., Killinger, Z., Macugova, I., & Berakova, K. (2007). [Celiac disease--a frequent cause of "idiopathic osteoporosis" in premenopausal and early postmenopausal women]. Vnitr Lek, 53(12), 1296-1302. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18357865>.

Kurowski, K., & Boxer, R. W. (2008). Food allergies: detection and management. Am Fam Physician, 77(12), 1678-1686. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18619076>.

Liden, M., Kristjansson, G., Valtysdottir, S., Venge, P., & Hallgren, R. (2008). Cow's milk protein sensitivity assessed by the mucosal patch technique is related to irritable bowel syndrome in patients with primary Sjogren's syndrome. Clin Exp Allergy, 38(6), 929-935. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/18498540>

<http://onlinelibrary.wiley.com/store/10.1111/j.1365-2222.2008.02983.x/asset/j.1365-2222.2008.02983.x.pdf?v=1&t=gmtokxxm&s=901c8e0a1235b50e22400116b2b3a52d339aa32e>. doi: CEA2983 [pii] 10.1111/j.1365-2222.2008.02983.x

LTD, B. M. G. (2006). About Food Allergies: Immuno Laboratories.

Millichap, J. G., & Yee, M. M. (2003). The diet factor in pediatric and adolescent migraine. Pediatr Neurol, 28(1), 9-15. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12657413>.

Newkirk, M. M., Goldbach-Mansky, R., Senior, B. W., Klippel, J., Schumacher, H. R., Jr., & El-Gabalawy, H. S. (2005). Elevated levels of IgM and IgA antibodies to Proteus mirabilis and IgM antibodies to Escherichia coli are associated with early rheumatoid factor (RF)-positive rheumatoid arthritis. Rheumatology (Oxford), 44(11), 1433-1441. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/16091399>. doi: kei036 [pii] 10.1093/rheumatology/kei036

Nielsen, R. G., Bindslev-Jensen, C., Kruse-Andersen, S., & Husby, S. (2004). Severe Gastroesophageal Reflux Disease and Cow Milk Hypersensitivity in Infants and Children: Disease Association and Evaluation of a New Challenge Procedure. J Pediatr Gastroenterol Nutr, 39(4), 383-391. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15448429>.

Niggemann, B. (2004). Role of oral food challenges in the diagnostic work-up of food allergy in atopic eczema dermatitis syndrome. Allergy, 59 Suppl 78, 32-34. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15245355>.

Niggemann, B., & Beyer, K. (2005). Diagnostic pitfalls in food allergy in children. Allergy, 60(1), 104-107. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15575939>.

Ogawa, H., Nakamura, Y., Tokinaga, K., Sakakura, N., & Yamashita, M. (2005). [Case of interstitial cystitis accompanied by food allergy]. Arerugi, 54(7), 641-645. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16229364>.

Panizon, F. (1987). [Food allergy and psychosomatic medicine. New frontiers]. Pediatr Med Chir, 9(6), 671-677. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3328158>.

Panush, R. S., Stroud, R. M., & Webster, E. M. (1986). Food-induced (allergic) arthritis. Inflammatory arthritis exacerbated by milk. Arthritis Rheum, 29(2), 220-226. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=3513771>.

Pasula, M. J. (1993). The ALCAT test: in vitro procedure for determining food sensitivities. Folia Med Cracov, 34(1-4), 153-157. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8175054>.

Piirainen, L., Pesola, J., Pesola, I., Komulainen, J., & Vaarala, O. (2009). Breastfeeding stimulates total and cow's milk-specific salivary IgA in infants. Pediatr Allergy Immunol, 20(3), 295-298. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/19438984>. doi: PAI776 [pii] 10.1111/j.1399-3038.2008.00776.x

Pohjavuori, E., Viljanen, M., Korpela, R., Kuitunen, M., Tiittanen, M., Vaarala, O., et al. (2004). Lactobacillus GG effect in increasing IFN-gamma production in infants with cow's milk allergy. J Allergy Clin Immunol, 114(1), 131-136. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/15241356>. doi: 10.1016/j.jaci.2004.03.036

S0091674904011686 [pii]

Rottem, M., Darawsha, J., & Zarfin, J. (2004). Atopic dermatits in infants and children in Israel: clinical presentation, allergies and outcome. Isr Med Assoc J, 6(4), 209-212. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15115258>.

Santaella, M. L., Varela, Y., Linares, N., & Disdier, O. M. (2008). Prevalence of autism spectrum disorders in relatives of patients with selective immunoglobulin A deficiency. P R Health Sci J, 27(3), 204-208. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18782963>.

Schnoll, R., Burshteyn, D., & Cea-Aravena, J. (2003). Nutrition in the treatment of attention-deficit hyperactivity disorder: a neglected but important aspect. Appl Psychophysiol Biofeedback, 28(1), 63-75. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12737097>.

Shils, M. E., & Shike, M. (2006). Modern nutrition in health and disease (10th ed.). Philadelphia: Lippincott Williams & Wilkins.

Spergel, J., Pawlowski, NA. (2002). Food Allergy: Mechanisms, Diagnosis, and Management in Children. Pediatrics Clinics of North America, 49(Feb).

Suen R, G. S. (2003). A Critical Review of IgG Immunoglobulins and Food Allergy - Implications in Systemic Health.

Swoger, J. M., Weiler, C. R., & Arora, A. S. (2007). Eosinophilic esophagitis: is it all allergies? Mayo Clin Proc, 82(12), 1541-1549. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18053464>.

Turjanmaa, K. (2002). "Atopy patch tests" in the diagnosis of delayed food hypersensitivity. Allerg Immunol (Paris), 34(3), 95-97. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12012795>.

Vanwijk, F., & Knippels, L. (2007). Initiating mechanisms of food allergy: Oral tolerance versus allergic sensitization. Biomedecine & Pharmacotherapy, 61(1), 8-20. doi: 10.1016/j.biopha.2006.11.003

Vickerstaff-Joneja, J., & Kline, D. (2008). Food Allergies: Type II, III, and IV Hypersensitivities. Today’s Dietitian, Vol. 10(1), 10. Retrieved from <http://www.todaysdietitian.com/newarchives/tdjan2008pg10.shtml>.

Viljanen, M., Savilahti, E., Haahtela, T., Juntunen-Backman, K., Korpela, R., Poussa, T., et al. (2005). Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy, 60(4), 494-500. Retrieved from <http://www.ncbi.nlm.nih.gov/pubmed/15727582>

<http://onlinelibrary.wiley.com/doi/10.1111/j.1398-9995.2004.00514.x/abstract>. doi: ALL514 [pii] 10.1111/j.1398-9995.2004.00514.x

Vojdani, A. (2009). Detection of IgE, IgG, IgA and IgM antibodies against raw and processed food antigens. Nutrition & Metabolism, 6(1), 22. doi: 10.1186/1743-7075-6-22

Vojdani, A., Campbell, A. W., Anyanwu, E., Kashanian, A., Bock, K., & Vojdani, E. (2002). Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A. J Neuroimmunol, 129(1-2), 168-177. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12161033>. doi: S0165572802001807 [pii]

WebMD. (2010, 2-9-2009). Food Allergies and Intolerances Retrieved 6-4-10, 2010, from <http://www.webmd.com/allergies/guide/food-allergy-intolerances>

**Chapter 15 The Elimination Diet, or How to Feel Remarkably Better in Seven Days.**

Christison, G. W., & Ivany, K. (2006). Elimination diets in autism spectrum disorders: any wheat amidst the chaff? J Dev Behav Pediatr, 27(2 Suppl), S162-171. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16685183>. doi: 00004703-200604002-00015 [pii]

Drisko, J., Bischoff, B., Hall, M., & McCallum, R. (2006). Treating irritable bowel syndrome with a food elimination diet followed by food challenge and probiotics. J Am Coll Nutr, 25(6), 514-522. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17229899>. doi: 25/6/514 [pii]

Grazioli, I., Melzi, G., Balsamo, V., Castellucci, G., Castro, M., Catassi, C., et al. (1993). [Food intolerance and irritable bowel syndrome of childhood: clinical efficacy of oral sodium cromoglycate and elimination diet]. Minerva Pediatr, 45(6), 253-258. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8232112>.

Giugliano, D., A. Ceriello, et al. (2006). "The effects of diet on inflammation: emphasis on the metabolic syndrome." J Am Coll Cardiol 48(4): 677-85.

Hafstrom, I., B. Ringertz, et al. (2001). "A vegan diet free of gluten improves the signs and symptoms of rheumatoid arthritis: the effects on arthritis correlate with a reduction in antibodies to food antigens." Rheumatology (Oxford) 40(10): 1175-9.

Jones, V. A., R. J. Dickinson, et al. (1985). "Crohn's disease: maintenance of remission by diet." Lancet 2(8448): 177-80.

Lever, R., C. MacDonald, et al. (1998). "Randomised controlled trial of advice on an egg exclusion diet in young children with atopic eczema and sensitivity to eggs." Pediatr Allergy Immunol 9(1): 13-9.

Lipski, E. (2009). “Elimination Diet”, Restoring Gastroentestinal Equilibrium: Practical Pplications for Understanding, Assessing, and Treating Gut Dysbunction Paper presented at the Restoring Gastroentestinal Equilibrium: Practical Pplications for Understanding, Assessing, and Treating Gut Dysbunction, Washington, DC.

Lunardi, C., Bambara, L. M., Biasi, D., Zagni, P., Caramaschi, P., & Pacor, M. L. (1992). Elimination diet in the treatment of selected patients with hypersensitivity vasculitis. Clin Exp Rheumatol, 10(2), 131-135. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1505105>.

Mansfield, L. E., T. R. Vaughan, et al. (1985). "Food allergy and adult migraine: double-blind and mediator confirmation of an allergic etiology." Ann Allergy 55(2): 126-9.

Meggs, W. J. (2004). The Inflammation Cure : How to Combat the Hidden Factor Behind Heart Disease, Arthritis, Asthma, Diabetes, & Other Diseases. New York, NY, McGraw-Hill.

Millichap, J. G. and M. M. Yee (2003). "The diet factor in pediatric and adolescent migraine." Pediatr Neurol 28(1): 9-15.

Nutrient Data Laboratory (2007) Oxygen radical absorbance capacity (ORAC) of selected foods. U.S. Department of Agriculture, Agricultural Research Service, Beltsville Human Nutrition Research Center.

http://www.ars.usda.gov/SP2UserFiles/Place/12354500/Data/ORAC/ORAC07.pdf

Pelsser, L. M., & Buitelaar, J. K. (2002). [Favourable effect of a standard elimination diet on the behavior of young children with attention deficit hyperactivity disorder (ADHD): a pilot study]. Ned Tijdschr Geneeskd, 146(52), 2543-2547. Retrieved from <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12532668>.

Stefanini, G. F., A. Saggioro, et al. (1995). "Oral cromolyn sodium in comparison with elimination diet in the irritable bowel syndrome, diarrheic type. Multicenter study of 428 patients." Scand J Gastroenterol 30(6): 535-41.

van den Bogaerde, J., M. A. Kamm, et al. (2001). "Immune sensitization to food, yeast and bacteria in Crohn's disease." Aliment Pharmacol Ther 15(10): 1647-53.

**Chapter 16 Managing Stress and Finding Balance**

No references used for this chapter.

**Chapter 17 Rebalance Biochemistry: Acid-Alkaline Balance**

Brown, S. E., & Trivieri, L. (2006). *The acid alkaline food guide : a quick reference to foods & their effect on pH levels*. Garden City Park, NY: Square One Publishers.

**Chapter 18 Cleansing and Detoxification**

**Part IV: Natural Therapies for Common Digestive Problems**

**Chapter 19: The Mouth**

Arslan Lied, G. (2007). Gastrointestinal food hypersensitivity: symptoms, diagnosis and provocation tests. *Turk J Gastroenterol, 18*(1), 5-13.

Bollen, C. M., Rompen, E. H., & Demanez, J. P. (1999). [Halitosis: a multidisciplinary problem]. *Rev Med Liege, 54*(1), 32-36.

de Oliveira, C., Watt, R., & Hamer, M. (2010). Toothbrushing, inflammation, and risk of cardiovascular disease: results from Scottish Health Survey. *BMJ, 340*, c2451.

Feller, L., & Blignaut, E. (2005). Halitosis: a review. *SADJ, 60*(1), 17-19.

Higdon, J., Drake V.J., Shane B. (2007). Folic Acid. *Linus Pauling Micronutrient Information Center*. Retrieved from <http://lpi.oregonstate.edu/infocenter/vitamins/fa/index.html#food_source>

Holick, M.F. “Vitamin D: Importance in the Prevention of Cancers, Type 1 Diabetes, Heart Disease, and Osteoporosis.” Am J Clin Nutr 79 (3) (March 2004): ­362–71.

Lazzari, R., et al. “Sideropenic Anemia and Celiac Disease.” Pediatr Med Chir 16, no. 6 (November–December 1994): ­549–50.

Malstrom, M., O.P. Salo, and F. Fyhrquist. “Immunogenetic Markers and Immune Response in Patients with Recurrent Oral Ulceration.” Int J Oral Surg 12, no. 1 (February 1983): ­23–30.

Ofarrelly, C., et al. “Gliadin Antibodies Identify Gluten-Sensitive Oral Ulceration in the Absence of Villous Atrophy.” J Oral Path Med 20, no. 10 (November 1991): ­476–78.

Petersen Vikki, P. R. (2009). *The Gluten Effect: How "Innocent" Wheat is Ruining Your Health*: True Health Publ.

Porter, S.R., C. Scully, and S. Flint. “Hematologic Status in Recurrent Apthous Stomatitis Compared with Other Oral Disease.” Med Oral Path 66, no. 1 (July 1988): ­41–44.

Shibasaki, T. “The Relationship of Nutrition and Dietary Habits to Gingivitis, Dental Calculus Deposit, and Dental Plaque Adhesion in High School Students.” Shoni Shikagaku Zasshi 27, no. 2 (1989): ­415–26.

Siblerud, R.L. “Relationship Between Mercury from Dental Amalgam and Oral Cavity Health.” Ann Dent (Winter 1990): ­6–10.

Singhal, S., Dian, D., Keshavarzian, A., Fogg, L., Fields, J. Z., & Farhadi, A. (2010). The Role of Oral Hygiene in Inflammatory Bowel Disease. *Dig Dis Sci*. doi: 10.1007/s10620-010-1263-9

Suzuki, N., Yoneda, M., Naito, T., Iwamoto, T., Masuo, Y., Yamada, K., . . . Hirofuji, T. (2008). Detection of Helicobacter pylori DNA in the saliva of patients complaining of halitosis. *J Med Microbiol, 57*(Pt 12), 1553-1559. doi: 57/12/1553 [pii] 10.1099/jmm.0.2008/003715-0

**Chapter 20: The Esophagus and Stomach**

“Helicobacter pylori in Peptic Ulcer Disease.” National Institutes of Health Consensus Statement 12, no. 1 (February ­1994).

Ahmad, M., Soetikno, R. M., & Ahmed, A. (2000). The differential diagnosis of eosinophilic esophagitis. *J Clin Gastroenterol, 30*(3), 242-244.

Arora, A. S., & Yamazaki, K. (2004). Eosinophilic esophagitis: asthma of the esophagus? *Clin Gastroenterol Hepatol, 2*(7), 523-530.

Attwood, S. E., Lewis, C. J., Bronder, C. S., Morris, C. D., Armstrong, G. R., & Whittam, J. (2003). Eosinophilic oesophagitis: a novel treatment using Montelukast. *Gut, 52*(2), 181-185.

Batmanghelidj, F. (1995). *Your body's many cries for water : you are not sick, you are thirsty! : don't treat thirst with medications* (2nd ed.). Falls Church, VA: Global Health Solutions.

Bircher, A. J., Gysi, B., Zenklusen, H. R., & Aerni, R. (2000). [Eosinophilic esophagitis associated with recurrent urticaria: is the worm Anisakis simplex involved?]. *Schweiz Med Wochenschr, 130*(47), 1814-1819.

Braden, B., Caspary, W., Borner, N., Vinson, B., & Schneider, A. R. (2009). Clinical effects of STW 5 (Iberogast) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis. *Neurogastroenterol Motil, 21*(6), 632-638, e625. doi: NMO1249 [pii] 10.1111/j.1365-2982.2008.01249.x

Bubenik, G. A., Blask, D. E., Brown, G. M., Maestroni, G. J., Pang, S. F., Reiter, R. J., et al. (1998). Prospects of the clinical utilization of melatonin. *Biol Signals Recept, 7*(4), 195-219. doi: bsi07195 [pii]

Charnow, J. A. “Vitamin A, Fiber May Cut Risk of Duodenal Ulcer.” Med Trib Med News (February 6, 1997): ­15.

Cheung, K. M., Oliver, M. R., Cameron, D. J., Catto-Smith, A. G., & Chow, C. W. (2003). Esophageal eosinophilia in children with dysphagia. *J Pediatr Gastroenterol Nutr, 37*(4), 498-503.

Correa, P., et al. “Chemoprevention of Gastric Dysplasia: Randomized Trial of Antioxidant Supplements and Anti-Helicobacter pylori Therapy.” J Nat Can Inst 2000 (92): ­1881–88.

Cury, E. K., Schraibman, V., & Faintuch, S. (2004). Eosinophilic infiltration of the esophagus: gastroesophageal reflux versus eosinophilic esophagitis in children--discussion on daily practice. *J Pediatr Surg, 39*(2), e4-7.

Dahms, B. B. (2004). Reflux esophagitis: sequelae and differential diagnosis in infants and children including eosinophilic esophagitis. *Pediatr Dev Pathol, 7*(1), 5-16.

Daneshjoo, R., & N, J. T. (2002). Eosinophilic gastroenteritis. *Curr Gastroenterol Rep, 4*(5), 366-372.

Elitsur, Y. (2002). Learning more about eosinophilic esophagitis. *J Pediatr Gastroenterol Nutr, 35*(5), 711-712.

Evrard, S., Louis, H., Kahaleh, M., Zalcman, M., Nagy, N., El Nakadi, I., & Deviere, J. (2004). Idiopathic eosinophilic oesophagitis: atypical presentation of a rare disease. *Acta Gastroenterol Belg, 67*(2), 232-235.

Fogg, M. I., Ruchelli, E., & Spergel, J. M. (2003). Pollen and eosinophilic esophagitis. *J Allergy Clin Immunol, 112*(4), 796-797.

Furuta, G. T., Nurko, S., Bousvaros, A., Antonioli, D., & Badizadegan, K. (2000). The spectrum of pediatric gastroesophageal reflux. *Jama, 284*(24), 3125-3126.

Germann, I., Hagelauer, D., Kelber, O., Vinson, B., Laufer, S., Weiser, D., & Heinle, H. (2006). Antioxidative properties of the gastrointestinal phytopharmaceutical remedy STW 5 (Iberogast). *Phytomedicine, 13 Suppl 5*, 45-50. doi: S0944-7113(06)00073-0 [pii] 10.1016/j.phymed.2006.03.018

Grossman, M., J. Kirsner, and I. Gillespie. “Basal and Histalog-Stimulated Gastric Secretion in Control Subjects and in Patients with Peptic Ulcer or Gastric Cancer.” Gastroenterology 45 (1963): ­15–26.

Gumowski, P., et al. “Chronic Asthma and Rhinitis Due to Candida albicans, Epidermophyton, and Trichophyton.” Ann Allergy 59, no. 1 (July 1987): ­48–51.

Halpern, G. (2009). Peptic Ulcer Disease and Helicobacter pylori. In I. Kohlstadt (Ed.), *Food and Nutrients in Disease Management*. Boca Raton, FL: Taylor and Francis.

Higdon, J., Drake V.J., Shane B. (2007). Folic Acid. *Linus Pauling Micronutrient Information Center*. Retrieved from <http://lpi.oregonstate.edu/infocenter/vitamins/fa/index.html#food_source>

Hoffman, R. 7 Weeks to a Settled Stomach. New York: Pocket Books, ­1990.

Husebye, E., et al. “Fasting Hypochlorhydria with Gram Positive Gastric Flora Is Highly Prevalent in Healthy Old People.” Gut 33 (October 1992): ­133–37.

Iijima, K., et al. “Novel Mechanism of Nitrosative Stress from Dietary Nitrate with Relevance to Gastro-Esophageal Junction Cancers.” Carcinogenesis 24 (12) (December 2003): 1951–60. Published online September 11, 2003. <http://carcin.oopjournals.org/cgi/content/fall/24/12/1951>.

Jancin, B. “Gastroesophageal Disease Linked to Long Antacid Use.” Fam Pract News 26, no. 13 (July 1, 1996): ­12.

Kandil, T. S., Mousa, A. A., El-Gendy, A. A., & Abbas, A. M. (2010). The potential therapeutic effect of melatonin in Gastro-Esophageal Reflux Disease. *BMC Gastroenterol, 10*, 7. doi: 1471-230X-10-7 [pii] 10.1186/1471-230X-10-7

Khan, S., Orenstein, S. R., Di Lorenzo, C., Kocoshis, S. A., Putnam, P. E., Sigurdsson, L., & Shalaby, T. M. (2003). Eosinophilic esophagitis: strictures, impactions, dysphagia. *Dig Dis Sci, 48*(1), 22-29.

Khayyal, M.T., et al. “A Clinical Pharmacological Study of the Potential Beneficial Effects of a Propolis Food Product as an Adjuvant in Asthmatic Patients.” Fundam Clin Pharmacol 17 (1) (February 2003): ­93–102.

Kimikazu, I., J. Kiyonana, and M. Ishikawa. “Studies on Gamma-Oryzanol II—The Anti-Ulcerogenic Action.” Tokushima: Research Institute, Otsuka Pharmaceutical Co., Ltd., ­1976.

Kukuruzovic, R. H., Elliott, E. E., O'Loughlin, E. V., & Markowitz, J. E. (2004). Non-surgical interventions for eosinophilic oesophagitis. *Cochrane Database Syst Rev*(3), CD004065.

Li, M.H., H.L. Zhang, and B.Y. Yang. “Effects of Ginkgo Leave Concentrated Oral Liquor in Treating Asthma.” Chung Kuo Chung Hsi I Chieh Ho Tsa Chih 17, no. 4 (April 1997): ­216–18.

Liacouras, C. A. (2003). Eosinophilic esophagitis in children and adults. *J Pediatr Gastroenterol Nutr, 37 Suppl 1*, S23-28.

Liacouras, C. A., & Markowitz, J. E. (1999). Eosinophilic esophagitis: A subset of eosinophilic gastroenteritis. *Curr Gastroenterol Rep, 1*(3), 253-258.

Lim, J. R., Gupta, S. K., Croffie, J. M., Pfefferkorn, M. D., Molleston, J. P., Corkins, M. R., . . . Fitzgerald, J. F. (2004). White specks in the esophageal mucosa: An endoscopic manifestation of non-reflux eosinophilic esophagitis in children. *Gastrointest Endosc, 59*(7), 835-838.

Markowitz, J. E., & Liacouras, C. A. (2003). Eosinophilic esophagitis. *Gastroenterol Clin North Am, 32*(3), 949-966.

Markowitz, J. E., Spergel, J. M., Ruchelli, E., & Liacouras, C. A. (2003). Elemental diet is an effective treatment for eosinophilic esophagitis in children and adolescents. *Am J Gastroenterol, 98*(4), 777-782.

Maruyama, K., and K. Kashiwzaki. “Clinical Trial of Gamma-Oryzanol on Gastrointestinal Symptoms at 375 Hospitals.” Japan: Department of Internal Medicine, Keio University, ­1977.

Matusiewicz, R. “The Homeopathic Treatment of ­Corticosteroid-Dependent Asthma: A Double-Blind, Placebo-Controlled Study.” Biomedical Therapy 15, no. 4 (1997): ­117–22.

Minakuchi, C., et al. “Effectiveness of Gamma-Oryzanol on Various Gastrointestinal Complaints.” Shinyaku to Rinsho 25, no. 10 (1976): ­29.

Nastaskin, I., Mehdikhani, E., Conklin, J., Park, S., & Pimentel, M. (2006). Studying the overlap between IBS and GERD: a systematic review of the literature. *Dig Dis Sci, 51*(12), 2113-2120. doi: 10.1007/s10620-006-9306-y

NIDDK. (2010). *H. pylori and Peptic Ulcers*. (NIH Publication No. 10–4225 April 2010). Bethesda: NIDDK Retrieved from <http://digestive.niddk.nih.gov/ddiseases/pubs/hpylori/>.

Noel, R. J., Putnam, P. E., & Rothenberg, M. E. (2004). Eosinophilic esophagitis. *N Engl J Med, 351*(9), 940-941.

Pilichiewicz, A. N., Horowitz, M., Russo, A., Maddox, A. F., Jones, K. L., Schemann, M., . . . Feinle-Bisset, C. (2007). Effects of Iberogast on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men. *Am J Gastroenterol, 102*(6), 1276-1283. doi: AJG1142 [pii] 10.1111/j.1572-0241.2007.01142.x

Pimentel, M., Bonorris, G. G., Chow, E. J., & Lin, H. C. (2001). Peppermint oil improves the manometric findings in diffuse esophageal spasm. *J Clin Gastroenterol, 33*(1), 27-31.

Potter, J. W., Saeian, K., Staff, D., Massey, B. T., Komorowski, R. A., Shaker, R., & Hogan, W. J. (2004). Eosinophilic esophagitis in adults: an emerging problem with unique esophageal features. *Gastrointest Endosc, 59*(3), 355-361.

Rance, F., et al. “Food Allergy and Asthma in Children.” Rev Pneumol Clin 59 (2 Part 1) (April 2003): ­109–13.

Resnick, C. “The Effects of Gamma-Oryzanol on Ulcers, Gastritis, Hyperlipidemias, and Menopausal Disorders.” Research review. Tyler Encapsulations, ­1993.

Rode, D. “Comfrey Toxicity Revisited.” Trends Pharmacol Sci 23 (11) (November 2002): ­497–99.

Sant'Anna, A. M., Rolland, S., Fournet, J. C., Yazbeck, S., & Drouin, E. (2004). Eosinophilic Esophagitis in Children: Symptoms, Histology and pH Probe Results. *J Pediatr Gastroenterol Nutr, 39*(4), 373-377.

Seigel, M.A., and B.A. Balciunas. “Medication Can Induce Severe Ulcers.” J Am Dent Assoc 122, no. 10 (September 1991): ­75–77.

Shabert, J. The Ultimate Nutrient Glutamine. Garden City Park, N.Y.: Avery, ­1994.

Shayne P., M. M. (2009). Gastritis and Peptic Ulcer Disease. *emedicine*. Retrieved from <http://emedicine.medscape.com/article/776460-print>

Sigthorsson, G., Tibble, J., Hayllar, J., Menzies, I., Macpherson, A., Moots, R., . . . Bjarnason, I. (1998). Intestinal permeability and inflammation in patients on NSAIDs. *Gut, 43*(4), 506-511.

Singh, G. “Recent Considerations in Nonsteroidal Anti-Inflammatory Drug Gastropathy.” Am J Med 105, no. 1B (July 27, 1998): ­31S–38S.

Sinharay, R. (2004). Gastrointestinal conditions with eosinophilia. *Arch Intern Med, 164*(7), 805-806.

Straumann, A. (2004). [What is your diagnosis? Primary eosinophilic esophagitis]. *Schweiz Rundsch Med Prax, 93*(19), 795-796.

Sueoka, N., Suganuma, M., Sueoka, E., Okabe, S., Matsuyama, S., Imai, K., et al. (2001). A new function of green tea: prevention of lifestyle-related diseases. *Ann N Y Acad Sci, 928*, 274-280.

Sundaram, S., Sunku, B., Nelson, S. P., Sentongo, T., Melin-Aldana, H., Kumar, R., & Li, B. U. (2004). Adherent white plaques: an endoscopic finding in eosinophilic esophagitis. *J Pediatr Gastroenterol Nutr, 38*(2), 208-212.

Swoger, J. M., Weiler, C. R., & Arora, A. S. (2007). Eosinophilic esophagitis: is it all allergies? *Mayo Clin Proc, 82*(12), 1541-1549.

Topkan, E., Yavuz, M. N., Onal, C., & Yavuz, A. A. (2009). Prevention of acute radiation-induced esophagitis with glutamine in non-small cell lung cancer patients treated with radiotherapy: evaluation of clinical and dosimetric parameters. *Lung Cancer, 63*(3), 393-399. doi: S0169-5002(08)00359-0 [pii] 10.1016/j.lungcan.2008.06.015

Vieth, M., & Stolte, M. (2000). [Eosinophilic esophagitis: a largely unknown entity?]. *Z Gastroenterol, 38*(5), 447-448.

Woods, R.K., et al. “Food and Nutrient Intakes and Asthma Risk in Young Adults.” Am J Clin Nutr 78 (3) (September 2003): ­414–21.

Yamaguchi, K., Iwakiri, R., Hara, M., Kikkawa, A., Fujise, T., Ootani, H., et al. (2008). Reflux esophagitis and Helicobacter pylori infection in patients with scleroderma. *Intern Med, 47*(18), 1555-1559. doi: JST.JSTAGE/internalmedicine/47.1128 [pii]

Yoshinari, T. “Usefulness of Hi-Z Fine Granule (Gamma-Oryzanol) for the Treatment of Autonomic Instability in Gastrointestinal System.” Shinyaku to Rinsho 225, no. 3 (1976): ­56.

**Chapter 21: The Liver**

“Hepatitis Viral Load Correlates to Glutathione Levels.” Posit Health News no. 17 (Fall 1998): ­14–15.

Andreone, P., Fiorino, S., Cursaro, C., Gramenzi, A., Margotti, M., Di Giammarino, L., . . . Bernardi, M. (2001). Vitamin E as treatment for chronic hepatitis B: results of a randomized controlled pilot trial. *Antiviral Res, 49*(2), 75-81. doi: S0166-3542(00)00141-8 [pii]

Bayol, S. A., Simbi, B. H., Fowkes, R. C., & Stickland, N. C. (2010). A maternal "junk food" diet in pregnancy and lactation promotes nonalcoholic Fatty liver disease in rat offspring. *Endocrinology, 151*(4), 1451-1461. doi: en.2009-1192 [pii] 10.1210/en.2009-1192

Bean, P. (2002). The use of alternative medicine in the treatment of hepatitis C. *Am Clin Lab, 21*(4), 19-21.

Berkson, B. M. (1999). A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: three case histories. *Med Klin (Munich), 94 Suppl 3*, 84-89.

Bottiglieri, T. “S-Adenosyl-L-Methionine (SAMe): From the Bench to the Bedside—Molecular Basis of a Pleiotrophic Molecule.” Am J Clin Nutr 76 (5) (November 2002): ­1151S-57S.

Cave, M., Deaciuc, I., Mendez, C., Song, Z., Joshi-Barve, S., Barve, S., & McClain, C. (2007). Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. *J Nutr Biochem, 18*(3), 184-195. doi: S0955-2863(06)00273-7 [pii] 10.1016/j.jnutbio.2006.12.006

Chaturvedi, G.N., and R.H. Singh. “Jaundice of Infectious Hepatitis and Its Treatment with an Indigenous Drug, Picrorhiza Kurrooa [sic].” J Res Ind Med 1 (1966): ­1–13.

Collison, K. S., Saleh, S. M., Bakheet, R. H., Al-Rabiah, R. K., Inglis, A. L., Makhoul, N. J., . . . Al-Mohanna, F. A. (2009). Diabetes of the liver: the link between nonalcoholic fatty liver disease and HFCS-55. *Obesity (Silver Spring), 17*(11), 2003-2013. doi: oby200958 [pii] 10.1038/oby.2009.58

Dubey, S.S., G.R. Palodhi, and A.K. Jain. “Ascorbic Acid, Dehydroascorbic Acid, and Glutathione in Liver Disease.” Indian J Physiol Pharmacol 31 (4) (October–December 1987): ­279–83.

Evaluating Silymarin for Chronic Hepatitis C, ­[www.nccam.nih.gov](http://www.nccam.nih.gov)

Frezza, M., et al. “Oral S-Adenosylmethionine in the Symptomatic Treatment of Intrahepatic Cholestasis: A Double-Blind Placebo Controlled Study.” Gastroenterology 99 (1990): ­211–15.

Fujimoto, M., Tsuneyama, K., Kinoshita, H., Goto, H., Takano, Y., Selmi, C., . . . Shimada, Y. (2010). The traditional Japanese formula keishibukuryogan reduces liver injury and inflammation in patients with nonalcoholic fatty liver disease. *Ann N Y Acad Sci, 1190*(1), 151-158. doi: NYAS5265 [pii] 10.1111/j.1749-6632.2009.05265.x

Gorbach, S. L. (2002). Probiotics in the third millennium. *Dig Liver Dis, 34 Suppl 2*, S2-7.

Gulati, R.K., S. Agarwal, and S.S. Agarwal. “Hepatoprotective Studies on Phyllanthus Emblica Linn. and Quercetin.” Indian J Exp Biol 33 (4) (April 1995): ­261–68.

Harnyk, T.P. “The Effect of Plant Preparations on the Malondialdehyde Indices of Patients with Chronic Hepatitis.” Lik Sprava (6) (September 1999): ­129–31.

Hepatitis B Foundation, ­www.hepb.org

Hong, L., Zhao, Y., Han, Y., Guo, W., Wang, J., Li, X., et al. (2007). Reversal of migraine symptoms by Helicobacter pylori eradication therapy in patients with hepatitis-B-related liver cirrhosis. *Helicobacter, 12*(4), 306-308. doi: HEL512 [pii]10.1111/j.1523-5378.2007.00512.x

Jain, S.K., et al. “Oxidative Stress in Chronic Hepatitis C: Not Just a Feature of Late Stage Disease.” J Hepatol 36 (6) (June 2002): ­805–11.

Karamanlioglu, B., et al. “Hepatobiliary Scintigraphy for Evaluating the Hepatotoxic Effect of Halothane and the Protective Effect of Catechin in Comparison with Histo-Chemical Analysis of Liver Tissue.” Nucl Med Commun 23 (1) (January 2002): ­53–59.

Kitchell, B. B. (1984). Heart and liver lipid fatty acid and behavior changes in mice after a diet change. *Life Sci, 34*(17), 1613-1620.

Komar, V.I., and V.S. Vasil’ev. “The Use of Water-Soluble Vitamins in Viral Hepatitis A.” Klin Med (Mosk) 70 (1) (January 1992): ­73–75.

Kumar, K.S., and P.F. Malet. “Nonalcoholic Steatohepatitis.” Mayo Clin Proc 75 (7) (July 2000): ­733–39.

Li, J., L. Zhou, and Y. Zhang. “Studies on the Effects of Tea Catechins Against Hepatitis B Virus Infection.” Zhonghua Yu Fang Yi Xue Za Zhi 35 (6) (November 2001): ­404–7.

Loguercio, C., and A. Federico. “Oxidative Stress in Viral and Alcoholic Hepatitis.” Free Radic Biol Med 34 (1) (January 2003): ­1–10.

Lucena, M.I., et al. “Effects of Silymarin MZ-80 on Oxidative Stress in Patients with Alcoholic Cirrhosis. Results of a Randomized, Double-Blind, Placebo-Controlled Clinical Study.” Int J Clin Pharmacol Ther 40 (1) (January 2002): ­2–8.

Luper, S. “A Review of Plants Used in the Treatment of Liver Disease: Part 1.” Altern Med Rev 3 (6) (December 1998): ­410–21.

Mahmood, S., et al. “Effect of Vitamin E on Serum Aminotransferase and Thioredoxin Levels in Patients with Viral Hepatitis C.” Free Radic Res 37 (7) (July 2003): ­781–85.

Manton, D., N.D., et al. “Non-Alcoholic Steatohepatitis in Children and Adolescents.” MJA 173 (2000): ­476–79.

Marleau, D. Hepnet: ­www.hepnet.com/hepc/uldh98/marleau.html, Saint-Luc Campus, University of ­Montreal.

Moller, E., and R. Schmitt. “A Contribution to the Treatment of Chronic Liver Diseases.” Med Klin 71 (43) (October 22, 1976): ­1831–53.

Moscarella, S., et al. “Lipid Peroxidation, Trace Elements and Vitamin E in Patients with Liver Cirrhosis.” Eur J Gastroenterol Hepatol 6 (1994): ­633–36.

Nseir, W., Nassar, F., & Assy, N. (2010). Soft drinks consumption and nonalcoholic fatty liver disease. *World J Gastroenterol, 16*(21), 2579-2588.

Ouyang, X., Cirillo, P., Sautin, Y., McCall, S., Bruchette, J. L., Diehl, A. M., . . . Abdelmalek, M. F. (2008). Fructose consumption as a risk factor for non-alcoholic fatty liver disease. *J Hepatol, 48*(6), 993-999. doi: S0168-8278(08)00164-5 [pii] 10.1016/j.jhep.2008.02.011

Patrick, L. “Hepatitis C: Epidemiology and Review of Complementary/Alternative Medicine Treatments.” Altern Med Rev 4 (4) (August 1999): ­220–38.

Pessayre, D., A. Mansouri, and B. Fromenty. “Nonalcoholic Steatosis and Steatohepatitis. V. Mitochondrial Dysfunction in Steatohepatitis.” Am J Physiol Gastrointest Liver Physiol 282 (2) (February 2002): ­G193–99.

Sakaida, I., Matsumura, Y., Akiyama, S., Hayashi, K., Ishige, A., & Okita, K. (1998). Herbal medicine Sho-saiko-to (TJ-9) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. *J Hepatol, 28*(2), 298-306. doi: 0168827888800175 [pii]

Schwimmer, J. B., Deutsch, R., Kahen, T., Lavine, J. E., Stanley, C., & Behling, C. (2006). Prevalence of fatty liver in children and adolescents. *Pediatrics, 118*(4), 1388-1393. doi: 118/4/1388 [pii] 10.1542/peds.2006-1212

Seeff, L. B., Curto, T. M., Szabo, G., Everson, G. T., Bonkovsky, H. L., Dienstag, J. L., . . . Ghany, M. G. (2008). Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. *Hepatology, 47*(2), 605-612. doi: 10.1002/hep.22044

Shimizu, I. “Sho-saiko-to: Japanese Herbal Medicine for Protection Against Hepatic Fibrosis and Carcinoma.” J Gastroenterol Hepatol 15 (Suppl) (March 2000): ­S84–S90.

Sueoka, N., Suganuma, M., Sueoka, E., Okabe, S., Matsuyama, S., Imai, K., et al. (2001). A new function of green tea: prevention of lifestyle-related diseases. *Ann N Y Acad Sci, 928*, 274-280.

Tarao, K., Fujiyama, S., Ohkawa, S., Miyakawa, K., Tamai, S., Hirokawa, S., . . . Tanaka, K. (2005). Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis. *Cancer Epidemiol Biomarkers Prev, 14*(1), 164-169. doi: 14/1/164 [pii]

Teselkin, Y.O., et al. “Dihydroquercetin as a Means of Antioxidative Defence in Rats with Tetrachloromethane Hepatitis.” Phytother Res 14 (3) (May 2000): ­160–62.

Thyagarajan, S., et al. “Herbal Medicines for Liver Diseases in India.” J Gastroenterol Hepatol 17 (Suppl 3) (December 2002): S370–76.

Von Herbay, A., et al. “Vitamin E Improves the Aminotransferase Status of Patients Suffering from Viral Hepatitis C: A Randomized, Double-Blind, Placebo-Controlled Study.” Free Radic Res 27 (6) (December 1997): ­599–605.

Watanabe, A., et al. “Nutritional Therapy of Chronic Hepatitis by Whey Protein (Non-Heated).” J Med 31 (5–6) (2000): ­283–302.

Wilhelm, K.P., et al. “Halothane Hepatotoxicity in Glutathione Depleted Rats.” J Appl Toxicol 7 (2) (April 1987): ­105–10.

Yadav, D., et al. “Serum and Liver Micronutrient Antioxidants and Serum Oxidative Stress in Patients with Chronic Hepatitis C.” Am J Gastroenterol 97 (10) (October 2002): ­2634–39.

Yamashiki, M., Nishimura, A., Huang, X. X., Nobori, T., Sakaguchi, S., & Suzuki, H. (1999). Effects of the Japanese herbal medicine "Sho-saiko-to" (TJ-9) on interleukin-12 production in patients with HCV-positive liver cirrhosis. *Dev Immunol, 7*(1), 17-22.

**Chapter 22: The Pancreas**

Akerblom, H. K., Knip, M., & Vaarala, O. (2000). VII International "Onnela" Workshop: gut immune system and type 1 diabetes mellitus held in Janakkala, Finland, June 25-26, 1998. *J Pediatr Endocrinol Metab, 13*(3), 333-337.

Arslan Lied, G. (2007). Gastrointestinal food hypersensitivity: symptoms, diagnosis and provocation tests. *Turk J Gastroenterol, 18*(1), 5-13.

Berthoud, P. (2007). [Diabetes and celiac disease]. *Soins*(714 Suppl), S10, S12-15.

Burkitt, D. (1984). Fiber as protective against gastrointestinal diseases. *Am J Gastroenterol, 79*(4), 249-252.

Burkitt, D. P. (1981). The protective properties of dietary fiber. *N C Med J, 42*(7), 467-471.

Burkitt, D. P. (1988). Dietary fiber and cancer. *J Nutr, 118*(4), 531-533.

Burkitt, D. P., & Trowell, H. C. (1977). Dietary fibre and western diseases. *Ir Med J, 70*(9), 272-277.

Dahlqvist, G. (1995). Celiac disease and insulin-dependent diabetes mellitus--no proof for a causal association. *Acta Paediatr, 84*(12), 1337-1338.

De Block, C. E. (2000). [Diabetes mellitus type 1 and associated organ-specific autoimmunity]. *Verh K Acad Geneeskd Belg, 62*(4), 285-328.

de Luis, D. A., Lahera, M., Canton, R., Boixeda, D., San Roman, A. L., Aller, R., et al. (1998). Association of Helicobacter pylori infection with cardiovascular and cerebrovascular disease in diabetic patients. *Diabetes Care, 21*(7), 1129-1132.

Drago, S., El Asmar, R., Di Pierro, M., Grazia Clemente, M., Tripathi, A., Sapone, A., . . . Fasano, A. (2006). Gliadin, zonulin and gut permeability: Effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. *Scand J Gastroenterol, 41*(4), 408-419. doi: G66681758U25V63P [pii] 10.1080/00365520500235334

Fasano, A. (2008). Physiological, pathological, and therapeutic implications of zonulin-mediated intestinal barrier modulation: living life on the edge of the wall. *Am J Pathol, 173*(5), 1243-1252. doi: ajpath.2008.080192 [pii]10.2353/ajpath.2008.080192

Fasano, A. (2009). Surprises from celiac disease. *Sci Am, 301*(2), 54-61.

Fasano, A. “Celiac Disease: How to Handle a Clinical Chameleon.” N Engl J Med 34 (25) (June 19, 2003): ­2568–70.

Frohlich-Reiterer, E. E., Hofer, S., Kaspers, S., Herbst, A., Kordonouri, O., Schwarz, H. P., et al. (2008). Screening frequency for celiac disease and autoimmune thyroiditis in children and adolescents with type 1 diabetes mellitus--data from a German/Austrian multicentre survey. *Pediatr Diabetes, 9*(6), 546-553. doi: PDI435 [pii]10.1111/j.1399-5448.2008.00435.x

Fuchtenbusch, M., Karges, W., Standl, E., Dosch, H. M., & Ziegler, A. G. (1997). Antibodies to bovine serum albumin (BSA) in type 1 diabetes and other autoimmune disorders. *Exp Clin Endocrinol Diabetes, 105*(2), 86-91.

Galli-Tsinopoulou, A., Nousia-Arvanitakis, S., Dracoulacos, D., Xefteri, M., & Karamouzis, M. (1999). Autoantibodies predicting diabetes mellitus type I in celiac disease. *Horm Res, 52*(3), 119-124. doi: hre52119 [pii]

Green, P. H. (2005). The many faces of celiac disease: clinical presentation of celiac disease in the adult population. *Gastroenterology, 128*(4 Suppl 1), S74-78. doi: S001650850500185X [pii]

Guvenc, S., Kaymakoglu, S., Gurel, N., Karsidag, K., Demir, K., Dincer, D., et al. (2002). The prevalence of manifest and latent celiac disease in type 1 diabetes mellitus. *Turk J Gastroenterol, 13*(2), 103-107.

Higdon, J., Drake V.J., Shane B. (2007). Folic Acid. *Linus Pauling Micronutrient Information Center*. Retrieved from <http://lpi.oregonstate.edu/infocenter/vitamins/fa/index.html#food_source>

Holick, M.F. “Vitamin D: Importance in the Prevention of Cancers, Type 1 Diabetes, Heart Disease, and Osteoporosis.” Am J Clin Nutr 79 (3) (March 2004): ­362–71.

Ingegnosi, C., Caruso-Nicoletti, M., D'Amato, E., d'Annunzio, G., & Lorini, R. (2008). Hyperglycemia in celiac disease: not always pretype 1 diabetes? *Pediatr Diabetes, 9*(4 Pt 1), 335-337. doi: PDI384 [pii]10.1111/j.1399-5448.2008.00384.x

Jaffe R., M., J. (2009). Diabetes: Food and Nutrients in Primary Practice. In I. Kohlsadt (Ed.), *Food and Nutrients in Disease Management* (pp. 281-300). Boca Raton, FL: CRC Press, Taylor & Francis Group.

Jaffe, R., Mani, J., DeVane, J., & Mani, H. (2006). Tolerance loss in diabetics: association with foreign antigen exposure. *Diabet Med, 23*(8), 924-925. doi: DME1846 [pii] 10.1111/j.1464-5491.2006.01846.x

Jiang, R. Q., Zhang, D. X., & Bai, C. Y. (2007). [Clinical study on Tangweikang in treating diabetic gastroparesis]. *Zhongguo Zhong Xi Yi Jie He Za Zhi, 27*(2), 114-116.

Karaguzel, G., Simsek, S., Deger, O., & Okten, A. (2008). Screening of diabetes, thyroid, and celiac diseases-related autoantibodies in a sample of Turkish children with type 1 diabetes and their siblings. *Diabetes Res Clin Pract, 80*(2), 238-243. doi: S0168-8227(07)00622-5 [pii]10.1016/j.diabres.2007.12.007

Kivling, A., Nilsson, L., Falth-Magnusson, K., Sollvander, S., Johanson, C., & Faresjo, M. (2008). Diverse foxp3 expression in children with type 1 diabetes and celiac disease. *Ann N Y Acad Sci, 1150*, 273-277. doi: NYAS1150018 [pii]10.1196/annals.1447.018

Lammer, C., & Weimann, E. (2008). Early onset of type I diabetes mellitus, Hashimoto's thyroiditis and celiac disease in a 7-yr-old boy with Down's syndrome. *Pediatr Diabetes, 9*(4 Pt 2), 423-425. doi: PDI355 [pii]10.1111/j.1399-5448.2008.00355.x

Mamoulakis, D., Galanakis, E., Dionyssopoulou, E., Evangeliou, A., & Sbyrakis, S. (2004). Carnitine deficiency in children and adolescents with type 1 diabetes. *J Diabetes Complications, 18*(5), 271-274. doi: 10.1016/S1056-8727(03)00091-6S1056872703000916 [pii]

Mani, J. (2003). *Case Study of a 13-Year Old Male with Diabetes*. case study Elisa Act Biotechnologies. Reston VA

Mont-Serrat, C., Hoineff, C., Meirelles, R. M., & Kupfer, R. (2008). [Diabetes and autoimmune diseases: prevalence of celiac disease in children and adolescents with type 1 diabetes]. *Arq Bras Endocrinol Metabol, 52*(9), 1461-1465. doi: S0004-27302008000900009 [pii]

Murray, J. A. (2005). Celiac disease in patients with an affected member, type 1 diabetes, iron-deficiency, or osteoporosis? *Gastroenterology, 128*(4 Suppl 1), S52-56. doi: S0016508505001988 [pii]

Narula, P., Porter, L., Langton, J., Rao, V., Davies, P., Cummins, C., . . . Protheroe, S. (2009). Gastrointestinal symptoms in children with type 1 diabetes screened for celiac disease. *Pediatrics, 124*(3), e489-495. doi: peds.2008-2434 [pii] 10.1542/peds.2008-2434

Neu, J., Reverte, C. M., Mackey, A. D., Liboni, K., Tuhacek-Tenace, L. M., Hatch, M., et al. (2005). Changes in intestinal morphology and permeability in the biobreeding rat before the onset of type 1 diabetes. *J Pediatr Gastroenterol Nutr, 40*(5), 589-595. doi: 00005176-200505000-00011 [pii]

Pappa, K. I., Anagnou, N. P., Salamalekis, E., Bikouvarakis, S., Maropoulos, G., Anogianaki, N., . . . Koumantakis, E. (2005). Gestational diabetes exhibits lack of carnitine deficiency despite relatively low carnitine levels and alterations in ketogenesis. *J Matern Fetal Neonatal Med, 17*(1), 63-68. doi: V30662N13V309271 [pii] 10.1080/14767050400028733

Paronen, J., Knip, M., Savilahti, E., Virtanen, S. M., Ilonen, J., Akerblom, H. K., et al. (2000). Effect of cow's milk exposure and maternal type 1 diabetes on cellular and humoral immunization to dietary insulin in infants at genetic risk for type 1 diabetes. Finnish Trial to Reduce IDDM in the Genetically at Risk Study Group. *Diabetes, 49*(10), 1657-1665.

Prokopova, L. “Celiac Disease—A Severe Disease.” Vnitr Lek 49 (6) (June 2003): ­474–81.

Salardi, S., Volta, U., Zucchini, S., Fiorini, E., Maltoni, G., Vaira, B., & Cicognani, A. (2008). Prevalence of celiac disease in children with type 1 diabetes mellitus increased in the mid-1990 s: an 18-year longitudinal study based on anti-endomysial antibodies. *J Pediatr Gastroenterol Nutr, 46*(5), 612-614. doi: 10.1097/MPG.0b013e31815d697e 00005176-200805000-00024 [pii]

Sanchez, J. C., Cabrera-Rode, E., Sorell, L., Galvan, J. A., Hernandez, A., Molina, G., et al. (2007). Celiac disease associated antibodies in persons with latent autoimmune diabetes of adult and type 2 diabetes. *Autoimmunity, 40*(2), 103-107. doi: 773217245 [pii]10.1080/08916930601118825

San-Pedro, J. I., Bilbao, J. R., Perez de Nanclares, G., Vitoria, J. C., Martul, P., & Castano, L. (2005). Heterogeneity of vitamin D receptor gene association with celiac disease and type 1 diabetes mellitus. *Autoimmunity, 38*(6), 439-444. doi: X020X056517K6T1K [pii]10.1080/08916930500288455

Sapone, A., de Magistris, L., Pietzak, M., Clemente, M. G., Tripathi, A., Cucca, F., et al. (2006). Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. *Diabetes, 55*(5), 1443-1449. doi: 55/5/1443 [pii]

Schuppan, D., & Hahn, E. G. (2001). Celiac disease and its link to type 1 diabetes mellitus. *J Pediatr Endocrinol Metab, 14 Suppl 1*, 597-605.

Secondulfo, M., de Magistris, L., Sapone, A., Di Monda, G., Esposito, P., & Carratu, R. (1999). Intestinal permeability and diabetes mellitus type 2. *Minerva Gastroenterol Dietol, 45*(3), 187-192.

Tamamogullari, N., Silig, Y., Icagasioglu, S., & Atalay, A. (1999). Carnitine deficiency in diabetes mellitus complications. *J Diabetes Complications, 13*(5-6), 251-253. doi: S1056872799000525 [pii]

Tripathi, A., Lammers, K. M., Goldblum, S., Shea-Donohue, T., Netzel-Arnett, S., Buzza, M. S., . . . Fasano, A. (2009). Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. *Proc Natl Acad Sci U S A, 106*(39), 16799-16804. doi: 0906773106 [pii] 10.1073/pnas.0906773106

Vaarala, O. (2002). The gut immune system and type 1 diabetes. *Ann N Y Acad Sci, 958*, 39-46.

Vaarala, O. (2002). The gut immune system and type 1 diabetes. *Ann N Y Acad Sci, 958*, 39-46.

Vaarala, O. (2005). Is type 1 diabetes a disease of the gut immune system triggered by cow's milk insulin? *Adv Exp Med Biol, 569*, 151-156. doi: 10.1007/1-4020-3535-7\_22

Vaarala, O., Atkinson, M. A., & Neu, J. (2008). The "perfect storm" for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. *Diabetes, 57*(10), 2555-2562. doi: 57/10/2555 [pii] 10.2337/db08-0331

Vaarala, O., Saukkonen, T., Savilahti, E., Klemola, T., & Akerblom, H. K. (1995). Development of immune response to cow's milk proteins in infants receiving cow's milk or hydrolyzed formula. *J Allergy Clin Immunol, 96*(6 Pt 1), 917-923. doi: S0091-6749(95)70229-6 [pii]

Ventura, A., Neri, E., Ughi, C., Leopaldi, A., Citta, A., & Not, T. (2000). Gluten-dependent diabetes-related and thyroid-related autoantibodies in patients with celiac disease. *J Pediatr, 137*(2), 263-265. doi: S0022-3476(00)63042-1 [pii]10.1067/mpd.2000.107160

Ventura, A., Neri, E., Ughi, C., Leopaldi, A., Citta, A., & Not, T. (2000). Gluten-dependent diabetes-related and thyroid-related autoantibodies in patients with celiac disease. *J Pediatr, 137*(2), 263-265. doi: S0022-3476(00)63042-1 [pii]10.1067/mpd.2000.107160

Visser, J., Rozing, J., Sapone, A., Lammers, K., & Fasano, A. (2009). Tight junctions, intestinal permeability, and autoimmunity: celiac disease and type 1 diabetes paradigms. *Ann N Y Acad Sci, 1165*, 195-205. doi: NYAS04037 [pii] 10.1111/j.1749-6632.2009.04037.x

Vitoria, J. C., Castano, L., Rica, I., Bilbao, J. R., Arrieta, A., & Garcia-Masdevall, M. D. (1998). Association of insulin-dependent diabetes mellitus and celiac disease: a study based on serologic markers. *J Pediatr Gastroenterol Nutr, 27*(1), 47-52.

Walkowiak J, B.-O. A., Lisowska A, Oralewska B, Pogorzelski A, Cichy W, Sapiejka E, Miroslawa K, Kokrzon M, Szaflarska-Poplawska A. (2010). Cystic fibrosis is a risk factor for celiac disease. *Acta biochimica Polonica, 57*(1), 115-118.

Walkowiak, J., Herzig, K. H., Strzykala, K., Przyslawski, J., & Krawczynski, M. (2002). Fecal elastase-1 is superior to fecal chymotrypsin in the assessment of pancreatic involvement in cystic fibrosis. *Pediatrics, 110*(1 Pt 1), e7.

Wang, W., Uzzau, S., Goldblum, S. E., & Fasano, A. (2000). Human zonulin, a potential modulator of intestinal tight junctions. *J Cell Sci, 113 Pt 24*, 4435-4440.

Watts, T., Berti, I., Sapone, A., Gerarduzzi, T., Not, T., Zielke, R., et al. (2005). Role of the intestinal tight junction modulator zonulin in the pathogenesis of type I diabetes in BB diabetic-prone rats. *Proc Natl Acad Sci U S A, 102*(8), 2916-2921. doi: 0500178102 [pii]10.1073/pnas.0500178102

Zeglaoui, H., Landolsi, H., Mankai, A., Ghedira, I., & Bouajina, E. (2010). Type 1 diabetes mellitus, celiac disease, systemic lupus erythematosus and systemic scleroderma in a 15-year-old girl. *Rheumatol Int, 30*(6), 793-795. doi: 10.1007/s00296-009-0988-2

**Chapter 23: The Gallbladder, Gallstones, and Cholecystectomy**

Arslan Lied, G. (2007). Gastrointestinal food hypersensitivity: symptoms, diagnosis and provocation tests. *Turk J Gastroenterol, 18*(1), 5-13.

Capron, J.P., et al. “Meal Frequency and Duration of Over­night Fast: A Role in Gallstone Formation?” BMJ 283 (1981): ­1435.

Chen, L. “Bile Acid Pool in the Formation of Pigment Stones: An Experimental Study.” Chung Hua Wai Ko Tsa Chih 30, no. 8 (August 1992): ­496–98.

Kraag, N., Thijs, C., & Knipschild, P. (1995). Dyspepsia--how noisy are gallstones? A meta-analysis of epidemiologic studies of biliary pain, dyspeptic symptoms, and food intolerance. *Scand J Gastroenterol, 30*(5), 411-421.

Kratzer, W., et al. “Gallstone Prevalence in Relation to Smoking, Alcohol, Coffee Consumption, and Nutrition.” Scand J Gastroenterol 32 (1997): ­953–58.

Leitzmann, M.F., et al. “The Relation of Physical Activity to Risk for Symptomatic Gallstone Disease in Men.” Ann Intern Med 128, no. 6 (March 15, 1998): ­417–25.

Moerman, C. “Dietary Risk Factors for Clinical Diagnosed Gallstones in Middle-Aged Men: A 25-Year Follow-Up Study.” Ann Epidemiol (1994): ­248–54.

Simon, J.A. “Ascorbic Acid and Cholesterol Gallstones.” Med Hypotheses 40, no. 2 (February 1993): ­81–84.

Simon, J.A., and E.S. Hudes. “Serum Ascorbic Acid and Other Correlates of Gallbladder Disease Among U.S. Adults.” Am J Public Health 88, no. 8 (August 1998): ­1208–12.

Sipos, P., et al. “Effects of Black Radish Root (Raphanus Sativus L. Var Niger) on the Colon Mucosa in Rats Fed a Fat-Rich Diet.” Phytother Res 16 (7) (November 2002): ­677–79.

Tuzhilin, S.A., et al. “The Treatment of Patients with Gallstones by Lecithin.” Am J Gastroenterol 65 (1976): ­231.

**Chapter 24: The Small Intestine**

Arslan Lied, G. (2007). Gastrointestinal food hypersensitivity: symptoms, diagnosis and provocation tests. *Turk J Gastroenterol, 18*(1), 5-13.

Ashwood, P., Anthony, A., Pellicer, A. A., Torrente, F., Walker-Smith, J. A., & Wakefield, A. J. (2003). Intestinal lymphocyte populations in children with regressive autism: evidence for extensive mucosal immunopathology. *J Clin Immunol, 23*(6), 504-517. doi: 474304 [pii]

Atkinson, W. (2004). Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. *Gut, 53*(10), 1459-1464. doi: 10.1136/gut.2003.037697

Bonamico, M., Mariani, P., Danesi, H. M., Crisogianni, M., Failla, P., Gemme, G., et al. (2001). Prevalence and clinical picture of celiac disease in italian down syndrome patients: a multicenter study. *J Pediatr Gastroenterol Nutr, 33*(2), 139-143.

Book, L., Hart, A., Black, J., Feolo, M., Zone, J. J., & Neuhausen, S. L. (2001). Prevalence and clinical characteristics of celiac disease in Downs syndrome in a US study. *Am J Med Genet, 98*(1), 70-74.

Burkitt, D. (1984). Fiber as protective against gastrointestinal diseases. *Am J Gastroenterol, 79*(4), 249-252.

Burkitt, D. P. (1981). The protective properties of dietary fiber. *N C Med J, 42*(7), 467-471.

Burkitt, D. P. (1988). Dietary fiber and cancer. *J Nutr, 118*(4), 531-533.

Burkitt, D. P., & Trowell, H. C. (1977). Dietary fibre and western diseases. *Ir Med J, 70*(9), 272-277.

Cosnes, J., Cosnes, C., Cosnes, A., Contou, J. F., Reijasse, D., Carbonnel, F., et al. (2002). [Undiagnosed celiac disease in childhood]. *Gastroenterol Clin Biol, 26*(6-7), 616-623. doi: MDOI-GCB-6-2002-26-6-7-0399-8320-101019-ART10 [pii]

El Asmar, R., Panigrahi, P., Bamford, P., Berti, I., Not, T., Coppa, G. V., et al. (2002). Host-dependent zonulin secretion causes the impairment of the small intestine barrier function after bacterial exposure. *Gastroenterology, 123*(5), 1607-1615. doi: S0016508502002949 [pii]

Fasano, A. (2009). Surprises from celiac disease. *Sci Am, 301*(2), 54-61.

Fasano, A. “Celiac Disease: How to Handle a Clinical Chameleon.” N Engl J Med 34 (25) (June 19, 2003): ­2568–70.

Green, P. H. (2005). The many faces of celiac disease: clinical presentation of celiac disease in the adult population. *Gastroenterology, 128*(4 Suppl 1), S74-78. doi: S001650850500185X [pii]

Henricksson, A.E.K. “Small Intestinal Bacterial Overgrowth in Patients with Rheumatoid Arthritis.” Ann Rheum Dis 52 (1993): ­503–10.

Kapur, G., et al. “Iron Supplementation in Children with Celiac Disease.” Indian J Pediatr 70 (12) (December 2003): ­955–58.

Karnam, U.S., L.R. Felder, and J.B. Raskin. “Prevalence of Occult Celiac Disease in Patients with Iron-Deficiency Anemia: A Prospective Study.” South Med J 97 (1) (January 2004): ­30–34.

Lin, H. C. (2004). Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. *JAMA, 292*(7), 852-858. doi: 10.1001/jama.292.7.852292/7/852 [pii]

Lundin, K.E., et al. “Oats Induced Villous Atrophy in Coeliac Disease” Gut 52 (11) (November 2003): ­1649–52.

Marie, I., Ducrotte, P., Denis, P., Menard, J. F., & Levesque, H. (2009). Small intestinal bacterial overgrowth in systemic sclerosis. *Rheumatology (Oxford), 48*(10), 1314-1319. doi: kep226 [pii]10.1093/rheumatology/kep226

Petersen Vikki, P. R. (2009). *The Gluten Effect: How "Innocent" Wheat is Ruining Your Health*: True Health Publ.

Pimentel, M. (2008). The prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome: IBS vs healthy controls (not historical definitions). *Gut, 57*(9), 1334-1335; author reply 1335. doi: 57/9/1334-a [pii]

Pimentel, M. (2009). Review of rifaximin as treatment for SIBO and IBS. *Expert Opin Investig Drugs, 18*(3), 349-358. doi: 10.1517/13543780902780175

Pimentel, M., Chow, E. J., & Lin, H. C. (2000). Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. *Am J Gastroenterol, 95*(12), 3503-3506. doi: S0002-9270(00)02161-4 [pii] 10.1111/j.1572-0241.2000.03368.x

Prokopova, L. “Celiac Disease—A Severe Disease.” Vnitr Lek 49 (6) (June 2003): ­474–81.

Vojdani, A., Bazargan, M., Vojdani, E., Samadi, J., Nourian, A. A., Eghbalieh, N., et al. (2004). Heat shock protein and gliadin peptide promote development of peptidase antibodies in children with autism and patients with autoimmune disease. *Clin Diagn Lab Immunol, 11*(3), 515-524. doi: 10.1128/CDLI.11.3.515-524.2004 11/3/515 [pii]

Vojdani, A., O'Bryan, T., Green, J. A., McCandless, J., Woeller, K. N., Vojdani, E., et al. (2004). Immune response to dietary proteins, gliadin and cerebellar peptides in children with autism. *Nutr Neurosci, 7*(3), 151-161.

Vojdani, A., Pangborn, J. B., Vojdani, E., & Cooper, E. L. (2003). Infections, toxic chemicals and dietary peptides binding to lymphocyte receptors and tissue enzymes are major instigators of autoimmunity in autism. *Int J Immunopathol Pharmacol, 16*(3), 189-199. doi: 2 [pii]

Weinstock, L. B., Klutke, C. G., & Lin, H. C. (2008). Small intestinal bacterial overgrowth in patients with interstitial cystitis and gastrointestinal symptoms. *Dig Dis Sci, 53*(5), 1246-1251. doi: 10.1007/s10620-007-0022-z

**Chapter 25: The Colon or Large Intestine**

“Crohn’s Disease Linked to Measles.” Med Trib Med News (May 13, 1993): ­10.

Abdullgaffar, B. (2009). Diverticulosis and diverticulitis of the appendix. *Int J Surg Pathol, 17*(3), 231-237. doi: 1066896909332728 [pii] 10.1177/1066896909332728

Aldoori, W. H., Giovannucci, E. L., Rimm, E. B., Wing, A. L., Trichopoulos, D. V., & Willett, W. C. (1994). A prospective study of diet and the risk of symptomatic diverticular disease in men. *Am J Clin Nutr, 60*(5), 757-764.

Ammon, H. P. (2002). [Boswellic acids (components of frankincense) as the active principle in treatment of chronic inflammatory diseases]. *Wien Med Wochenschr, 152*(15-16), 373-378.

Ammon, H.P. “Boswellic Acids (Components of Frankincense) as the Active Principle in Treatment of Chronic Inflammatory Diseases.” Wien Med Wochenschr 152 (15–16) (2002): ­373–78.

Arslan Lied, G. (2007). Gastrointestinal food hypersensitivity: symptoms, diagnosis and provocation tests. *Turk J Gastroenterol, 18*(1), 5-13.

Ashwood, P., Anthony, A., Pellicer, A. A., Torrente, F., Walker-Smith, J. A., & Wakefield, A. J. (2003). Intestinal lymphocyte populations in children with regressive autism: evidence for extensive mucosal immunopathology. *J Clin Immunol, 23*(6), 504-517. doi: 474304 [pii]

Aslan, A., & Triadafilopoulos, G. (1992). Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. *Am J Gastroenterol, 87*(4), 432-437.

Batmanghelidj, F. (1995). *Your body's many cries for water : you are not sick, you are thirsty! : don't treat thirst with medications* (2nd ed.). Falls Church, VA: Global Health Solutions.

Bazzocchi, G., Gionchetti, P., Almerigi, P. F., Amadini, C., & Campieri, M. (2002). Intestinal microflora and oral bacteriotherapy in irritable bowel syndrome. *Dig Liver Dis, 34 Suppl 2*, S48-53.

Ben-Ayre E., G. E., Wengrower D, Stamper A. Kohn R, Berry E. . (2002). Wheat Grass Juice in the Treatment of Active Distal Ulcerative Colitis: A Randomized Double-blind Placebo-controlled Trial. *Taylor & Francis Health Sciences, 37*, 444-449.

Benninga, M. A., et, & al. (1993). "Biofeedback Training in Chronic Constipation". *Archives of Disease in Childhood,, 68*, 126-129.

Biasco, G., Zannoni, U., Paganelli, G. M., Santucci, R., Gionchetti, P., Rivolta, G., . . . Miglioli, M. (1997). Folic acid supplementation and cell kinetics of rectal mucosa in patients with ulcerative colitis. *Cancer Epidemiol Biomarkers Prev, 6*(6), 469-471.

Bjarnason, I. (1994). Intestinal permeability. *Gut, 35*(1 Suppl), S18-22.

Bolin TD, D. A., Duncombe VM. (1982). A prospective study of persistent diarrhoea. *Aust N Z J Med, 12*(1), 22-26.

Born, P., Vierling, T., & Barina, W. (1991). Fructose malabsorption and the irritable bowel syndrome. *Gastroenterology, 101*(5), 1454.

Borody, T. J., Warren, E. F., Leis, S., Surace, R., & Ashman, O. (2003). Treatment of ulcerative colitis using fecal bacteriotherapy. *J Clin Gastroenterol, 37*(1), 42-47.

Bos, M. A., Vennat, B., Meunier, M. T., Pouget, M. P., Pourrat, A., & Fialip, J. (1996). Procyanidins from tormentil: antioxidant properties towards lipoperoxidation and anti-elastase activity. *Biol Pharm Bull, 19*(1), 146-148.

Brain, O., & Travis, S. P. (2008). Therapy of ulcerative colitis: state of the art. *Curr Opin Gastroenterol, 24*(4), 469-474. doi: 10.1097/MOG.0b013e3282ff0dd5 00001574-200807000-00008 [pii]

Braun, A., Treede, I., Gotthardt, D., Tietje, A., Zahn, A., Ruhwald, R., . . . Ehehalt, R. (2009). Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. *Inflamm Bowel Dis, 15*(11), 1705-1720. doi: 10.1002/ibd.20993

Burkitt, D. (1984). Fiber as protective against gastrointestinal diseases. *Am J Gastroenterol, 79*(4), 249-252.

Burkitt, D. P. (1981). The protective properties of dietary fiber. *N C Med J, 42*(7), 467-471.

Burkitt, D. P. (1988). Dietary fiber and cancer. *J Nutr, 118*(4), 531-533.

Burkitt, D. P., & Meisner, P. (1979). How to manage constipation with high-fiber diet. *Geriatrics, 34*(2), 33-35, 38-40.

Burkitt, D. P., & Trowell, H. C. (1977). Dietary fibre and western diseases. *Ir Med J, 70*(9), 272-277.

Chatterjee, S., Park, S., Low, K., Kong, Y., & Pimentel, M. (2007). The degree of breath methane production in IBS correlates with the severity of constipation. *Am J Gastroenterol, 102*(4), 837-841. doi: AJG1072 [pii] 10.1111/j.1572-0241.2007.01072.x

Corlew-Roath, M., & Di Palma, J. A. (2009). Clinical impact of identifying lactose maldigestion or fructose malabsorption in irritable bowel syndrome or other conditions. *South Med J, 102*(10), 1010-1012. doi: 10.1097/SMJ.0b013e3181b64c7f

Dassopoulos, T., Frangakis, C., Cruz-Correa, M., Talor, M. V., Burek, C. L., Datta, L., . . . Brant, S. R. (2007). Antibodies to saccharomyces cerevisiae in Crohn's disease: higher titers are associated with a greater frequency of mutant NOD2/CARD15 alleles and with a higher probability of complicated disease. *Inflamm Bowel Dis, 13*(2), 143-151. doi: 10.1002/ibd.20031

Dieleman, L.A., and W.D. Heizer. “Nutritional Issues in Inflammatory Bowel Disease.” Gastroenterol Clin North Am 27, no. 2 (June 1998): ­435–51.

Digesu, G. A., Panayi, D., Kundi, N., Tekkis, P., Fernando, R., & Khullar, V. (2010). Validity of the Rome III Criteria in assessing constipation in women. *Int Urogynecol J Pelvic Floor Dysfunct, 21*(10), 1185-1193. doi: 10.1007/s00192-010-1179-0

Drago, S., El Asmar, R., Di Pierro, M., Grazia Clemente, M., Tripathi, A., Sapone, A., . . . Fasano, A. (2006). Gliadin, zonulin and gut permeability: Effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. *Scand J Gastroenterol, 41*(4), 408-419. doi: G66681758U25V63P [pii] 10.1080/00365520500235334

Drisko, J., Bischoff, B., Hall, M., & McCallum, R. (2006). Treating irritable bowel syndrome with a food elimination diet followed by food challenge and probiotics. *J Am Coll Nutr, 25*(6), 514-522. doi: 25/6/514 [pii]

Drossman, D.A., et al. “Irritable Bowel Syndrome and Sexual/Physical Abuse History.” J Gastroenterol Hepatol 9 (4) (April 1997): ­327–30.

Dunlop, S.P., D. Jenkins, and R.C. Spiller. “Distinctive Clinical, Psychological, and Histological Features of Post­infective Irritable Bowel Syndrome.” Am J Gastroenterol 98 (7) (July 2003): ­1578–83.

Dunlop, S.P., et al. “Relative Importance of Enterochromaffin Cell Hyperplasia, Anxiety, and Depression in Postinfectious IBS.” Gastroenterology 125 (6) (December ­2003):1651–59.

Fernandez-Banares, F., et al. “Enteral Nutrition as a Primary Therapy in Crohn’s Disease.” Gut (1994): ­S55–S59.

Fernandez-Banares, F., et al. “Role of Fructose-Sorbitol Malabsorption and Irritable Bowel Syndrome.” Gastroenterology 101, no. 5 (November 1991): ­1453–54.

Floch, M.H. “Probiotics, Irritable Bowel Syndrome, and Inflammatory Bowel Disease.” Curr Treat Options Gastroenterol 6 (4) (August 2003): ­283–88.

Francis, C.W., et al. “Bran and Irritable Bowel Syndrome: Time for Reappraisal.” Lancet 334 (July 2, 1994): ­339–40.

Gershon, M.D. “Serotonin and Its Implication for the Manage­ment of Irritable Bowel Syndrome.” Rev Gastroenterol Disord 3 (Suppl 2) (2003): ­S25–S34.

Grazioli, I., Melzi, G., Balsamo, V., Castellucci, G., Castro, M., Catassi, C., . . . Scotta, S. (1993). [Food intolerance and irritable bowel syndrome of childhood: clinical efficacy of oral sodium cromoglycate and elimination diet]. *Minerva Pediatr, 45*(6), 253-258.

Gross, V., et al. “Free Radicals and Inflammatory Bowel Diseases, Pathophysiology and Therapeutic Implications.” Hepatogastroenterology 41 (1994): ­320–27.

Gryboski, J.D. “Ulcerative Colitis in Children 10 Years Old or Younger.” J Pediatr Gastroenterol Nutr 17, no. 1 (July 1993): ­24–31.

Gupta, I., et al. “Effects of Boswellia Serrata Gum Resin in Patients with Ulcerative Colitis.” Eur J Med Res 2 (1) (January 1997): ­37–43.

Hanauer, S.B. “Inflammatory Bowel Disease: Novel Aspects of Clinical Genetics and Potential for Probiotic Therapy.” Medscape June 7, 2002. ­[www.medscape.com/viewarticle/434522](http://www.medscape.com/viewarticle/434522).

Head, K.A., and J.S. Jurenka. “Inflammatory Bowel Disease, Part 1: Ulcerative Colitis—Pathophysiology and Conventional and Alternative Treatment Options.” Altern Med Rev 8 (3) (August 2003): ­247–83.

Henker, J., Hackbarth, S., & Sprossig, C. (1989). [Fecal chymotrypsin concentration in childhood. Normal values, specificity, sensitivity]. *Helv Paediatr Acta, 43*(5-6), 397-404.

Higdon, J., Drake V.J., Shane B. (2007). Folic Acid. *Linus Pauling Micronutrient Information Center*. Retrieved from <http://lpi.oregonstate.edu/infocenter/vitamins/fa/index.html#food_source>

Holick, M.F. “Vitamin D: Importance in the Prevention of Cancers, Type 1 Diabetes, Heart Disease, and Osteoporosis.” Am J Clin Nutr 79 (3) (March 2004): ­362–71.

Hotz, J., and K. Plein. “Effectiveness of Plantago Seed Husks in Comparison with Wheat Bran on Stool Frequency and Manifestations of Irritable Colon Syndrome with Constipation.” Med Klin 89, no. 12 (December 15, 1994): ­645–51.

Huber, R., Ditfurth, A. V., Amann, F., Guthlin, C., Rostock, M., Trittler, R., . . . Merfort, I. (2007). Tormentil for active ulcerative colitis: an open-label, dose-escalating study. *J Clin Gastroenterol, 41*(9), 834-838. doi: 10.1097/MCG.0b013e31804b2173 00004836-200710000-00008 [pii]

Hwang, L., Low, K., Khoshini, R., Melmed, G., Sahakian, A., Makhani, M., . . . Pimentel, M. (2009). Evaluating Breath Methane as a Diagnostic Test for Constipation-Predominant IBS. *Dig Dis Sci*. doi: 10.1007/s10620-009-0778-4

Hyphantis, T., Antoniou, K., Tomenson, B., Tsianos, E., Mavreas, V., & Creed, F. (2010). Is the personality characteristic "impulsive sensation seeking" correlated to differences in current smoking between ulcerative colitis and Crohn's disease patients? *Gen Hosp Psychiatry, 32*(1), 57-65. doi: S0163-8343(09)00176-5 [pii] 10.1016/j.genhosppsych.2009.09.002

Jacobs, E.J., and E. White. “Constipation, Laxative Use, and Colon Cancer Among Middle-Aged Adults.” Epidemiology 9, no. 4 (1998): ­385–91.

Johanson, J. F. (2007). Review of the treatment options for chronic constipation. *MedGenMed, 9*(2), 25.

Kalliomaki, M., & Isolauri, E. (2003). Role of intestinal flora in the development of allergy. *Curr Opin Allergy Clin Immunol, 3*(1), 15-20. doi: 10.1097/01.all.0000053262.39029.a1

Kalliomaki, M., Collado, M. C., Salminen, S., & Isolauri, E. (2008). Early differences in fecal microbiota composition in children may predict overweight. *Am J Clin Nutr, 87*(3), 534-538. doi: 87/3/534 [pii]

Kikuchi, H., Itoh, J., & Fukuda, S. (2008). Chronic nicotine stimulation modulates the immune response of mucosal T cells to Th1-dominant pattern via nAChR by upregulation of Th1-specific transcriptional factor. *Neurosci Lett, 432*(3), 217-221. doi: S0304-3940(07)01297-9 [pii] 10.1016/j.neulet.2007.12.027

Kim, H.J., et al. “A Randomized Controlled Trial of a Probiotic, VSL#3, on Gut Transit and Symptoms in Diarrhea-Predominant Irritable Bowel Syndrome.” Aliment Pharmacol Ther 17 (7) (April 2003): ­895–904.

Kimikazu, I., J. Kiyonana, and M. Ishikawa. Studies on Gamma-Oryzanol II—The Anti-Ulcerogenic Action, Research Institute. Tokushima, Japan: Otsuka Pharmaceutical Co., ­Ltd.

Langmead, L., Dawson, C., Hawkins, C., Banna, N., Loo, S., & Rampton, D. S. (2002). Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease: an in vitro study. *Aliment Pharmacol Ther, 16*(2), 197-205. doi: 1157 [pii]

Langmead, L., et al. “Randomized, Double-Blind, Placebo-Controlled Trial of Oral Aloe Vera Gel for Active Ulcerative Colitis.” Aliment Pharmacol Ther 19 (7) (April 1, 2004): ­739–47.

Lazzari, R., et al. “Sideropenic Anemia and Celiac Disease.” Pediatr Med Chir 16, no. 6 (November–December 1994): ­549–50.

Lee, G. H., Kim, C. G., Kim, J. S., Jung, H. C., & Song, I. S. (2005). [Frequency analysis of NOD2 gene mutations in Korean patients with Crohn's disease]. *Korean J Gastroenterol, 45*(3), 162-168. doi: 200503313 [pii]

Lee, G., & Buchman, A. L. (2009). DNA-driven nutritional therapy of inflammatory bowel disease. *Nutrition, 25*(9), 885-891. doi: S0899-9007(09)00257-3 [pii] 10.1016/j.nut.2009.06.011

Lichtenstein, G.R., and R.P. MacDermott. “Recent Advances in the Treatment of Inflammatory Bowel Disease: The Role of biologics and Immunomodulators.” Medscape 2002. ­www.medscape.com/viewarticle/434521

Lin, H.C., et al. “Slowing of Gastrointestinal Transit by Oleic Acid: A Preliminary Report of a Novel, Nutrient-Based Treatment in Humans.” Dig Dis Sci 46 (2) (2001): ­223–29.

Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006). Functional bowel disorders. *Gastroenterology, 130*(5), 1480-1491. doi: S0016-5085(06)00512-9 [pii] 10.1053/j.gastro.2005.11.061

Maier, K. P. (2007). [Diverticulosis--diverticulitis]. *Praxis (Bern 1994), 96*(5), 153-157.

Maruyama, K., and K. Kashiwzaki. “Clinical Trial of Gamma-Oryzanol on Gastrointestinal Symptoms at 375 Hospitals.” Japan: Department of Internal Medicine, Keio University, ­1977.

Mayo, C. S. (2010). Ischemic Colitis. *MayoClinic.com*. Retrieved from <http://www.mayoclinic.com/health/ischemic-colitis/DS00794>

McRorie, J.W., et al. “Psyllium Is Superior to Docusate Sodium for Treatment of Chronic Constipation.” Aliment Pharmacol Ther 12 (1998): ­491–97.

Mendeloff, A.I., and J.E. Everhart. “Diverticular Disease of the Colon.” In Digestive Diseases in the United States: Epidemiology and Impact. Washington, D.C.: U.S. Department of Health and Human Services, National Institutes of Health, ­1994.

Meurs-Szojda, M. M., Terhaar sive Droste, J. S., Kuik, D. J., Mulder, C. J., & Felt-Bersma, R. J. (2008). Diverticulosis and diverticulitis form no risk for polyps and colorectal neoplasia in 4,241 colonoscopies. *Int J Colorectal Dis, 23*(10), 979-984. doi: 10.1007/s00384-008-0510-4

Minakuchi, C., et al. “Effectiveness of Gamma-Oryzanol on Various Gastrointestinal Complaints.” Shinyaku to Rinsho 25, no. 10 (1976): ­29.

Munsell MA., M. G. (2009). Inflammatory Bowel Disease: Food and Nutrient Approaches. In I. Kohlstadt (Ed.), *Food and Nutrients in Disease Management* (pp. 217-240). Boca Raton: CRC Press.

Nastaskin, I., Mehdikhani, E., Conklin, J., Park, S., & Pimentel, M. (2006). Studying the overlap between IBS and GERD: a systematic review of the literature. *Dig Dis Sci, 51*(12), 2113-2120. doi: 10.1007/s10620-006-9306-y

Nellist, C.C. “Elemental Diet Therapy a Good Option for Crohn’s.” Fam Pract News (March 1, 1994): 7.

Nolan, A., et al. “Recurrent Apthous Ulceration: Vitamin B1, B2, and B6 Status and Response to Replacement Therapy.” J Oral Path Med 20, no. 8 (September 1991): ­389–91.

Ozick, L.A., C. Salazar, and S.S. Donelson. “Pathogenesis, Diagnosis and Treatment of Diverticular Disease of the Colon.” Gastroenterologist 2, no. 4 (December 1994): ­299–310.

Pimentel, M. (2008). The prevalence of small intestinal bacterial overgrowth in irritable bowel syndrome: IBS vs healthy controls (not historical definitions). *Gut, 57*(9), 1334-1335; author reply 1335. doi: 57/9/1334-a [pii]

Pimentel, M. (2009). Review of rifaximin as treatment for SIBO and IBS. *Expert Opin Investig Drugs, 18*(3), 349-358. doi: 10.1517/13543780902780175

Pimentel, M., Chatterjee, S., Chow, E. J., Park, S., & Kong, Y. (2006). Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study. *Dig Dis Sci, 51*(8), 1297-1301. doi: 10.1007/s10620-006-9104-6

Pimentel, M., Chow, E. J., & Lin, H. C. (2000). Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. *Am J Gastroenterol, 95*(12), 3503-3506. doi: S0002-9270(00)02161-4 [pii] 10.1111/j.1572-0241.2000.03368.x

Pimentel, M., Chow, E. J., & Lin, H. C. (2003). Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. *Am J Gastroenterol, 98*(2), 412-419. doi: S0002927002059026 [pii] 10.1111/j.1572-0241.2003.07234.x

Prudden, J.F., and L.L. Balassa. “The Biological Activity of Bovine Cartilage Preparations.” Semin Arthritis Rheum 3, no. 4 (Summer 1974): ­287–320.

Rachmilewitz, D., et al. “Toll-Like Receptor 9 Signaling Mediates the Anti-Inflammatory Effects of Probiotics in Murine Experimental Colitis.” Gastroenterology 126 (2) (February 2004): ­520–28.

Reinisch, W., et al. “Extracorporeal Photochemotherapy in Patients with Steroid-Dependent Crohn’s Disease: A Prospective Pilot Study.” Aliment Pharmacol Ther 15 (2001): ­1313–22.

Resnick, C. “The Effects of Gamma-Oryzanol on Ulcers, Gastritis, Hyperlipidemias, and Menopausal Disorders.” Research review. Tyler Encapsulations, ­1993.

Rinas, U., & Adamek, H. E. (2006). [Diverticulitis and diverticulosis]. *MMW Fortschr Med, 148*(29-30), 37-41; quiz 42.

Rioux, K. P., Madsen, K. L., & Fedorak, R. N. (2005). The role of enteric microflora in inflammatory bowel disease: human and animal studies with probiotics and prebiotics. *Gastroenterol Clin North Am, 34*(3), 465-482, ix. doi: S0889-8553(05)00051-8 [pii] 10.1016/j.gtc.2005.05.005

Robinson, R.J., et al. “Effect of a Low-Impact Exercise Program on Bone Mineral Density in Crohn’s Disease: A Randomized Controlled Trial.” Gastroenterology 115 (1998): ­36–41.

Roediger, W.E.W. “Decreased Sulfur Amino Acid Intake in Ulcerative Colitis.” Lancet 351 (May 23, 1998): ­1555.

Rumessen, J.J. “Functional Bowel Disease: The Role of Fructose and Sorbitol.” Gastroenterology 101 (1991): ­1452–60.

Schechter, S., Mulvey, J., & Eisenstat, T. E. (1999). Management of uncomplicated acute diverticulitis: results of a survey. *Dis Colon Rectum, 42*(4), 470-475; discussion 475-476.

Scheppach, W., et al. “Effect of Butyrate Enemas on the Colonic Mucosa in Distal Ulcerative Colitis.” Gastroenterology 103 (1992): ­51–56.

Seigel, J. “Inflammatory Bowel Disease: Another Possible Effect of the Allergic Diathesis.” Ann Allergy 47, no. 2 (August 1981): ­92–94.

Seigel, M.A., and B.A. Balciunas. “Medication Can Induce Severe Ulcers.” J Am Dent Assoc 122, no. 10 (September 1991): ­75–77.

Shabert, J. The Ultimate Nutrient Glutamine. Garden City Park, N.Y.: Avery, ­1994.

Shah, S. (2007). Dietary Factors in the Modulation of Inflammatory Bowel Disease Activity. *Medscape General Medicine, 9 (1):60*. Retrieved from [www.medscape.com](http://www.medscape.com) website: <http://www.medsccape.com/viewarticles/553039_print>

Shanahan, F., “Host-Flora Interactions in Inflammatory Bowel Disease.” Inflamm Bowel Dis vol. 10, Suppl 1, (February 2004): ­S16–S24.

Shepherd, S. J., & Gibson, P. R. (2006). Fructose malabsorption and symptoms of irritable bowel syndrome: guidelines for effective dietary management. *J Am Diet Assoc, 106*(10), 1631-1639. doi: S0002-8223(06)01704-4 [pii] 10.1016/j.jada.2006.07.010

Singhal, S., Dian, D., Keshavarzian, A., Fogg, L., Fields, J. Z., & Farhadi, A. (2010). The Role of Oral Hygiene in Inflammatory Bowel Disease. *Dig Dis Sci*. doi: 10.1007/s10620-010-1263-9

Smith, J. S., Ediss, I., Mullinger, M. A., & Bogoch, A. (1971). Fecal chymotrypsin and trypsin determinations. *Can Med Assoc J, 104*(8), 691-694 passim.

Stremmel, W., Braun, A., Hanemann, A., Ehehalt, R., Autschbach, F., & Karner, M. (2010). Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study. *J Clin Gastroenterol, 44*(5), e101-107. doi: 10.1097/MCG.0b013e3181c29860

Stremmel, W., Hanemann, A., Ehehalt, R., Karner, M., & Braun, A. (2010). Phosphatidylcholine (lecithin) and the mucus layer: evidence of therapeutic efficacy in ulcerative colitis? *Dig Dis, 28*(3), 490-496. doi: 000320407 [pii] 10.1159/000320407

Tamboli, C. P., Neut, C., Desreumaux, P., & Colombel, J. F. (2004a). Dysbiosis as a prerequisite for IBD. *Gut, 53*(7), 1057.

Tamboli, C. P., Neut, C., Desreumaux, P., & Colombel, J. F. (2004b). Dysbiosis in inflammatory bowel disease. *Gut, 53*(1), 1-4.

Tamboli, C.P., et al. “Dysbiosis in Inflammatory Bowel Disease.” Gut 53 (1) (January 2004): ­1–4.

Thompson, N.P., et al. “Is Measles Vaccination a Risk Factor for Inflammatory Bowel Disease?” Lancet 345 (1995): ­1071–74.

Tiwana, H., et al. “Antibody Responses to Gut Bacteria in Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn’s Disease, and Ulcerative Colitis.” Rheumatol Int 17, no. 1 (1997): ­11–16.

Tomas-Ridocci, M., et al. “The Efficacy of Plantago, Ovata as a Regulator of Intestinal Transit.” Rev Esp Enferm Dig 82, no. 1 (July 1992): ­17–22.

Vennat, B., Bos, M. A., Pourrat, A., & Bastide, P. (1994). Procyanidins from tormentil: fractionation and study of the anti-radical activity towards superoxide anion. *Biol Pharm Bull, 17*(12), 1613-1615.

Vernia, P., et al. “Lactose Intolerance and Irritable Bowel Syndrome: Relative Weight in Inducing Abdominal Symptoms in High Prevalence Area.” Gastroenterology 102, no. 4, Part II (April 1992): ­A5–30.

Von Tirpitz, C., et al. “Osteoporosis in Inflammatory Bowel Disease—Results of a Survey Among Members of the German Crohn’s and Ulcerative Colitis Association.” Z Gastroenterol 41 (12) (December 2003): ­1145–50.

Walker, D.M., et al. “Effect of Gluten-Free Diet on Recurrent Apthous Ulceration.” Br J Derm 103, no. 1 (July 1980): ­111.

Weisberger, L., & Jamieson, B. (2009). Clinical inquiries: How can you help prevent a recurrence of diverticulitis? *J Fam Pract, 58*(7), 381-382. doi: jfp\_5807h [pii]

Wilhelmsen, I., and A. Berstad. “Quality of Life and Relapse of Duodenal Ulcer Before and After Eradication of Helicobacter pylori.” Scand J Gastroenterol 29, no. 10 (October 1994): ­874–79.

Wilson, J.M. “Hand Washing Reduces Diarrhea Episodes: A Study in Lombok Indonesia.” Transactions of the Royal Society of Tropical Medicine and Hygiene 85 (1991): ­819–21.

Wong, R. K., Palsson, O. S., Turner, M. J., Levy, R. L., Feld, A. D., von Korff, M., & Whitehead, W. E. (2010). Inability of the Rome III Criteria to Distinguish Functional Constipation From Constipation-Subtype Irritable Bowel Syndrome. *Am J Gastroenterol*. doi: ajg2010200 [pii] 10.1038/ajg.2010.200

Yakoob J., J. W., Jafri N., Khan R., Islam M., Beg A., Zaman V. (2004). Irritable bowel syndrome: in search of an etiology: Role of Blastocystis hominis. *Am. J. Trop. Med 70*(4), 383-385.

Yesilada, E., I. Gurbuz, and H. Shibata. “Screening of Turkish Anti-Ulcerogenic Folk Remedies for Anti-Helicobacter pylori Activity.” J Ethnopharmacol 66 (3) (September 1999): ­289–93.

Yoshinari, T. “Usefulness of Hi-Z Fine Granule (Gamma-Oryzanol) for the Treatment of Autonomic Instability in Gastrointestinal System.” Shinyaku to Rinsho 225, no. 3 (1976): ­56.

**Chapter 26: Arthritis**

———. “Essential Fatty Acid and Prostaglandin Metabolism in Sjögren’s Syndrome, Systemic Sclerosis and Rheumatoid Arthritis.” Scand J Rheumatol 61 (Suppl) (1986): ­242–45.

“Methylsulfonylmethane (MSM).” Monograph Altern Med Rev 8 (4) (November 2003): ­438–41.

“The Neglect of Glucosamine as a Treatment for Osteoarthritis—A Personal Perspective.” Med Hypotheses 42, no. 5 (May 1994): ­323–27.

Abyad, A., and J.T. Boyer. “Arthritis and Aging.” Curr Opin Rheumatol 4, no. 2 (April 1992): ­153–59.

Aggarwal BB, H. K. (2008). Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. *Intl J of Biochemistry and Cell Biology*, doi:10.1016/j.biocel.2008.06.010

Aggarwal, B.B., A. Kumar, and A.C. Bharti. “Anticancer Potential of Curcumin: Preclinical and Clinical Studies.” Anticancer Res 23 (1A) (January–February 2003): ­363–98.

Amital, H., Govoni, M., Maya, R., Meroni, P. L., Ori, B., Shoenfeld, Y., et al. (2008). Role of infectious agents in systemic rheumatic diseases. *Clin Exp Rheumatol, 26*(1 Suppl 48), S27-32. doi: 2279 [pii]

Ammon, H. P. (2002). [Boswellic acids (components of frankincense) as the active principle in treatment of chronic inflammatory diseases]. *Wien Med Wochenschr, 152*(15-16), 373-378.

Ammon, H.P. “Boswellic Acids (Components of Frankincense) as the Active Principle in Treatment of Chronic Inflammatory Diseases.” Wien Med Wochenschr 152 (15–16) (2002): ­373–78.

Appleboom, T., and P. Durez. “Effect of Milk Product Deprivation on Spondyloarthropathy.” Ann Rheum Dis 53, no. 11 (1994): ­481–82.

Arslan Lied, G. (2007). Gastrointestinal food hypersensitivity: symptoms, diagnosis and provocation tests. *Turk J Gastroenterol, 18*(1), 5-13.

Banerjee, M., Tripathi, L. M., Srivastava, V. M., Puri, A., & Shukla, R. (2003). Modulation of inflammatory mediators by ibuprofen and curcumin treatment during chronic inflammation in rat. *Immunopharmacol Immunotoxicol, 25*(2), 213-224.

Bjarnason, I. (1994). Intestinal permeability. *Gut, 35*(1 Suppl), S18-22.

Borman, P., Babaoglu, S., Gur, G., Bingol, S., & Bodur, H. (2008). Bone mineral density and bone turnover in patients with psoriatic arthritis. *Clin Rheumatol, 27*(4), 443-447. doi: 10.1007/s10067-007-0725-8

Bottiglieri, T. “S-Adenosyl-L-Methionine (SAMe): From the Bench to the Bedside—Molecular Basis of a Pleiotrophic Molecule.” Am J Clin Nutr 76 (5) (November 2002): ­1151S-57S.

Brzeski, M., et al. “Evening Primrose Oil in Patients with Rheumatoid Arthritis and Side Effect of Non-Steroidal Anti-Inflammatory Drugs.” Br J Rheumatol 30 (1991): ­370–72.

Chang, D. M., Chang, W. Y., Kuo, S. Y., & Chang, M. L. (1997). The effects of traditional antirheumatic herbal medicines on immune response cells. *J Rheumatol, 24*(3), 436-441.

Chou, C. T., Uksila, J., & Toivanen, P. (1998). Enterobacterial antibodies in Chinese patients with rheumatoid arthritis and ankylosing spondylitis. *Clin Exp Rheumatol, 16*(2), 161-164.

Darlington, L.G. “Dietary Therapy for Arthritis.” Nutr Rheumatic Dis 17, no. 2 (May 1991): ­273–85.

Darlington, L.G., and N.W. Ramsey. “Clinical Review of Dietary Therapy for Rheumatoid Arthritis.” Br J Rheumatol 32 (1993): ­507–14.

de Witte, T. J., Geerdink, P. J., Lamers, C. B., Boerbooms, A. M., & van der Korst, J. K. (1979). Hypochlorhydria and hypergastrinaemia in rheumatoid arthritis. *Ann Rheum Dis, 38*(1), 14-17.

Deal, C.L., et al. “Treatment of Arthritis Pain with Topical Capsaicin: A Double-Blind Trial.” Clinical Therapy 13, no. 3 (1991): ­383–95.

Disilvestro, R.A. “Effects of Copper Supplementation on Ceruloplasmin and Copper-Zinc Superoxide Dismutase in Free-Living Rheumatoid Arthritis Patients.” J Am Coll Nutr 11, no. 23 (1992): ­177–80.

Dobryniewski, J., Szajda, S. D., Waszkiewicz, N., & Zwierz, K. (2007). [The gamma-linolenic acid (GLA)--the therapeutic value]. *Przegl Lek, 64*(2), 100-102.

Dominguez-Lopez, M.L., et al. “IgG Antibodies to Entero­bacteria 60 kDa Heat Shock Proteins in the Sera of HLA-B27 Positive Ankylosing Spondylitis Patients.” Scand J Rheumatol 31 (5) (2002): ­260–65.

Etzel, R. “Special Extract of Boswellia Serrata (H-15) in the Treatment of Rheumatoid Arthritis.” Phytomedicine 3, no. 1 (1996): ­91–94.

Flynn, M. “The Effect of Folate and Cobalamine on Osteoarthritis and Hands.” J Am Coll Nutr 13, no. 4 (1994): ­351–56.

Food intolerance and rheumatoid arthritis. (1988). *Lancet, 2*(8625), 1419-1420.

Gaby, A.R. “Natural Treatments for Osteoarthritis.” Altern Med Rev 4 (5) (October 1999): ­330–41.

Garfinkel, M.S., et al. “Evaluation of a Yoga-Based Regimen for Treatment of Osteoarthritis of the Hands.” J Rheumatol 21 (12) (December 1994): ­2341–43.

Germain, B.F. “Silicone Breast Implants and Rheumatic Disease.” Bull Rheum Dis 41, no. 6 (October 1992): ­1–4.

Guillen Fiel, G., Gonzalez-Granado, L. I., Mosqueda, R., Negreira, S., & Giangaspro, E. (2009). [Arthritis caused by Candida in an immunocompetent infant with a history of systemic candidiasis in the neonatal period]. *An Pediatr (Barc), 70*(4), 383-385. doi: S1695-4033(08)00107-0 [pii]10.1016/j.anpedi.2008.12.001

Harrison, B. J., Hutchinson, C. E., Adams, J., Bruce, I. N., & Herrick, A. L. (2002). Assessing periarticular bone mineral density in patients with early psoriatic arthritis or rheumatoid arthritis. *Ann Rheum Dis, 61*(11), 1007-1011.

Hatakka, K., Martio, J., Korpela, M., Herranen, M., Poussa, T., Laasanen, T., et al. (2003). Effects of probiotic therapy on the activity and activation of mild rheumatoid arthritis--a pilot study. *Scand J Rheumatol, 32*(4), 211-215.

Haugen, M., Kjeldsen-Kragh, J., Nordvag, B. Y., & Forre, O. (1991). Diet and disease symptoms in rheumatic diseases--results of a questionnaire based survey. *Clin Rheumatol, 10*(4), 401-407.

Henricksson, A.E.K. “Small Intestinal Bacterial Overgrowth in Patients with Rheumatoid Arthritis.” Ann Rheum Dis 52 (1993): ­503–10.

Hesslink, R., Jr., et al. “Cetylated Fatty Acids Improve Knee Function in Patients with Osteoarthritis.” J Rheumatol 29 (8) (August 2002): ­1708–12.

Higdon, J., Drake V.J., Shane B. (2007). Folic Acid. *Linus Pauling Micronutrient Information Center*. Retrieved from <http://lpi.oregonstate.edu/infocenter/vitamins/fa/index.html#food_source>

Ho LJ, L. J. (2004). Chinese herbs as immunomodulators and potential disease-modifying antirheumatic drugs in autoimmune disorders. *Curr Drug Metab., Apr;5*(2), 181-192.

Hofbauer, L. C., Schoppet, M., Christ, M., Teichmann, J., & Lange, U. (2006). Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis. *Rheumatology (Oxford), 45*(10), 1218-1222. doi: kel108 [pii]10.1093/rheumatology/kel108

Holden, W., T. Orchard, and P. Wordsworth. “Enteropathic Arthritis.” Rheum Dis Clin North Am 29 (3) (August 2003): 513–30, ­viii.

Houston, L. “Dietary Change in Arthritis.” Practitioner 238 (June 1994): ­443–48.

Hvatum, M., Kanerud, L., Hallgren, R., & Brandtzaeg, P. (2006). The gut-joint axis: cross reactive food antibodies in rheumatoid arthritis. *Gut, 55*(9), 1240-1247. doi: gut.2005.076901 [pii]10.1136/gut.2005.076901

Joe, B., and B.R. Lokesh. “Effect of Curcumin and Capsaicin on Arachidonic Acid Metabolism and Lysosomal Enzyme Secretion by Rat Peritoneal Macrophages.” Lipids 32, no. 11 (1997): ­1173–80.

Katargina, L. A., Starikova, A. V., & Iastrebova, N. E. (2002). [Clinical and pathogenetic significance of Proteus mirabilis antibodies in uveitis associated with joint lesions in children and adolescents]. *Vestn Oftalmol, 118*(3), 28-30.

Katz, J.P., and G.R. Lichtenstein. “Rheumatologic Manifestations of Gastrointestinal Diseases.” Gastroenterol Clin North Am 27 (3) (September 1998): 533–62, v.

Keough, C. Natural Relief for Arthritis. New York: Pocket Books, ­1983.

Kimmatkar, N., et al. “Efficacy and Tolerability of Boswellia Serrata Extract in Treatment of Osteoarthritis of Knee—A Randomized Double-Blind, Placebo-Controlled Trial.” Phytomedicine 10 (1) (January 2003): ­3–7.

Kjeldsen-Kraugh, J. “Dietary Treatment of Rheumatoid Arthritis.” Scand J Rheumatol (1996): ­63.

Lahesmaa, R., et al. “Molecular Mimicry: Any Role in the Pathogenesis of Spondyloarthropathies?” Immunol Res 12, no. 2 (1993): ­193–208.

Lamm, S.H. “Silicone Breast Implants and Long-Term Health Effects: When Are Data Adequate?” J Clin Epidemiol 48, no. 4 (April 1995): ­507–11.

Lawrence, R.C., et al. “Estimates of the Prevalence of Arthritis and Selected Musculoskeletal Disorders in the United States.” Arthritis Rheum 41, no. 5 (May 1998): ­778–99.

Lee, C. H., Oh, J. M., Oh, S. R., Yoo, M., & Lee, M. S. (2010). Candida Arthritis after Arthroscopic Arthroplasty in a Patient without Predisposing Factors. *Open Rheumatol J, 4*, 7-9. doi: 10.2174/1874312901004010007

Leirisalo-Repo, M. “Enteropathic Arthritis, Whipple’s Disease, Juvenile Spondyloarthropathy, and Uveitis.” Curr Opin Rheumatol 6, no. 4 (July 1994): ­385–90.

Leventhal, L.J., et al. “Treatment of Rheumatoid Arthritis with Gamma-Linolenic Acid.” Ann Intern Med 119, no. 9 (November 1, 1993): ­867–73.

Liu, Y., Xu, B., & Cai, X. (1995). [The role of intestinal permeability in the pathogenesis of ankylosing spondylitis]. *Zhonghua Nei Ke Za Zhi, 34*(2), 91-94.

Machtey, I. “Vitamin E and Arthritis/Vitamin E and Rheumatoid Arthritis.” Arthritis Rheum 34, no. 9 (September 1991): ­1205.

Malin, M., Verronen, P., Korhonen, H., Syvaoja, E. L., Salminen, S., Mykkanen, H., et al. (1997). Dietary therapy with Lactobacillus GG, bovine colostrum or bovine immune colostrum in patients with juvenile chronic arthritis: evaluation of effect on gut defence mechanisms. *Inflammopharmacology, 5*(3), 219-236. doi: 10.1007/s10787-997-0001-1

McCarthy, G., and D. Kenny. “Dietary Fish Oil and Rheumatic Diseases.” Semin Arthritis Rheum 21, no. 6 (June 1992): ­368–75.

Mielants, H., De Vos, M., Cuvelier, C., & Veys, E. M. (1996). The role of gut inflammation in the pathogenesis of spondyloarthropathies. *Acta Clin Belg, 51*(5), 340-349.

Moller, I., Perez, M., Monfort, J., Benito, P., Cuevas, J., Perna, C., et al. (2010). Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study. *Osteoarthritis Cartilage, 18 Suppl 1*, S32-40. doi: S1063-4584(10)00090-7 [pii]10.1016/j.joca.2010.01.018

Mulbert, A.E., et al. “Identification of Nonsteroidal Anti-Inflammatory Drug-Induced Gastroduodenal Injury in Children with Juvenile Rheumatoid Arthritis.” J Pediatr (April 1993): ­645–46.

Muller, H., de Toledo, F. W., & Resch, K. L. (2001). Fasting followed by vegetarian diet in patients with rheumatoid arthritis: a systematic review. *Scand J Rheumatol, 30*(1), 1-10.

Musnick, D. (2009). Osteoarthritis. In I. Kohlstadt (Ed.), *Food & Nutrients in Disease Management* (pp. 539-556). Boca Raton, FL: CCR.

Nielsen, G.L., et al. “The Effects of Dietary Supplementation with N-3 Polyunsaturated Fatty Acids in Patients with Rheumatoid Arthritis.” Eur J Clin Investig 22 (1992): ­687–91.

Palladino, M.A., et al. “Anti-TNF-Alpha Therapies: The Next Generation.” Nat Rev Drug Discov 2 (9) (September 2003): ­736–46.

Pattison, D. J., Symmons, D. P., & Young, A. (2004). Does diet have a role in the aetiology of rheumatoid arthritis? *Proc Nutr Soc, 63*(1), 137-143.

Petersen Vikki, P. R. (2009). *The Gluten Effect: How "Innocent" Wheat is Ruining Your Health*: True Health Publ.

Picco, P., et al. “Increased Gut Permeability in Juvenile Chronic Arthritides. A Multivariate Analysis of the Diagnostic Parameters.” Clin Exp Rheumatol 18 (6) (November–December 2000): ­773–78.

Pignet, M., and A. Lecomte. “The Effects of Harpogophytum Capsules in Degenerative Rheumatology.” Medicine Actuelle 12, no. 4 (1985): ­65–76.

Polli, E., et al. “Pharmacological and Clinical Aspects of Sadenosylmethionine (SAMe) in Primary Degenerative Arthropathy.” Minerva Medical 66, no. 83 (December 5, 1975): ­4443–59.

Rashid, T., & Ebringer, A. (2008). Rheumatoid arthritis in smokers could be linked to Proteus urinary tract infections. *Med Hypotheses, 70*(5), 975-980. doi: S0306-9877(07)00573-7 [pii]10.1016/j.mehy.2007.08.026

Rister, M., & Bauermeister, K. (1982). [Superoxide-dismutase and superoxide-radical-release in rheumatoid arthritis (author's transl)]. *Klin Wochenschr, 60*(11), 561-565.

Seignalet, J. “Diet, Fasting, and Rheumatoid Arthritis.” Lancet 339 (January 4, 1993): ­68–69.

Shapiro, J. A., Koepsell, T. D., Voigt, L. F., Dugowson, C. E., Kestin, M., & Nelson, J. L. (1996). Diet and rheumatoid arthritis in women: a possible protective effect of fish consumption. *Epidemiology, 7*(3), 256-263.

Sigthorsson, G., Tibble, J., Hayllar, J., Menzies, I., Macpherson, A., Moots, R., . . . Bjarnason, I. (1998). Intestinal permeability and inflammation in patients on NSAIDs. *Gut, 43*(4), 506-511.

Silverio Amancio, O. M., Alves Chaud, D. M., Yanaguibashi, G., & Esteves Hilario, M. O. (2003). Copper and zinc intake and serum levels in patients with juvenile rheumatoid arthritis. *Eur J Clin Nutr, 57*(5), 706-712.

Singh, G. “Recent Considerations in Nonsteroidal Anti-Inflammatory Drug Gastropathy.” Am J Med 105, no. 1B (July 27, 1998): ­31S–38S.

Soeken, K.L., et al. “Safety and Efficacy of S-Adenosylmethio­nine (SAMe) for Osteoarthritis.” J Fam Pract 51 (5) (May 2002): ­425–30.

Srivastava, K. C., & Mustafa, T. (1992). Ginger (Zingiber officinale) in rheumatism and musculoskeletal disorders. *Med Hypotheses, 39*(4), 342-348.

Srivastava, K.C., and T. Mustafa. “Ginger (Zingiber officinale) in Rheumatism and Musculoskeletal Disorders.” Med Hypotheses 39 (1992): ­342–48.

Stokes, D.G., and J.M. Kremer. “Potential of Tumor Necrosis Factor Neutralization Strategies in Rheumatologic Disorders Other than Rheumatoid Arthritis.” Semin Arthritis Rheum 33 (1) (August 2003): ­1–18.

Sundrarjun, T., Komindr, S., Archararit, N., Dahlan, W., Puchaiwatananon, O., Angthararak, S., et al. (2004). Effects of n-3 fatty acids on serum interleukin-6, tumour necrosis factor-alpha and soluble tumour necrosis factor receptor p55 in active rheumatoid arthritis. *J Int Med Res, 32*(5), 443-454.

Tao, X., Cush, J. J., Garret, M., & Lipsky, P. E. (2001). A phase I study of ethyl acetate extract of the chinese antirheumatic herb Tripterygium wilfordii hook F in rheumatoid arthritis. *J Rheumatol, 28*(10), 2160-2167.

Tiwana, H., et al. “Antibody Responses to Gut Bacteria in Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn’s Disease, and Ulcerative Colitis.” Rheumatol Int 17, no. 1 (1997): ­11–16.

Togrol, R. E., Nalbant, S., Solmazgul, E., Ozyurt, M., Kaplan, M., Kiralp, M. Z., et al. (2009). The significance of coeliac disease antibodies in patients with ankylosing spondylitis: a case-controlled study. *J Int Med Res, 37*(1), 220-226.

Trock, D.H., et al. “A Double-Blind Trial of the Clinical Effects of Pulsed Electromagnetic Fields in Osteoarthritis.” J Rheumatol 20, no. 3 (1993): ­456–60.

Wallace, D.J. “Silicone Breast Implants Do Not Cause Rheumatic Diseases, but Can They Influence Them?” Arthritis Rheum 46 (9) (September 2002): ­25–45.

Weber, P., Brune, T., Ganser, G., & Zimmer, K. P. (2003). Gastrointestinal symptoms and permeability in patients with juvenile idiopathic arthritis. *Clin Exp Rheumatol, 21*(5), 657-662.

Weber, P., et al. “Gastrointestinal Symptoms and Permeability in Patients with Juvenile Idiopathic Arthritis.” Clin Exp Rheumatol 21 (5) (September–October 2003): ­657–62.

Witte, S., R. Lasek, and N.Victor. “Meta-Analysis of the Efficacy of Adenosylmethionine and Oxaceprol in the Treatment of Osteoarthritis.” Orthopade 31 (11) (November 2002): ­1058–65.

Wray, D. “Gluten-Sensitive Recurrent Arthritis Stomatitis.” Dig Dis Sci 26, no. 8 (August 1981): ­737–40.

**Part V: Natural Therapies for the Diverse Consequences of Faulty Digestion**

**Chapter 27: Autoimmune Disorders**

Amital, H., Govoni, M., Maya, R., Meroni, P. L., Ori, B., Shoenfeld, Y., et al. (2008). Role of infectious agents in systemic rheumatic diseases. *Clin Exp Rheumatol, 26*(1 Suppl 48), S27-32. doi: 2279 [pii]

Arbuckle, M. R., McClain, M. T., Rubertone, M. V., Scofield, R. H., Dennis, G. J., James, J. A., et al. (2003). Development of autoantibodies before the clinical onset of systemic lupus erythematosus. *N Engl J Med, 349*(16), 1526-1533. doi: 10.1056/NEJMoa021933 349/16/1526 [pii]

Arslan Lied, G. (2007). Gastrointestinal food hypersensitivity: symptoms, diagnosis and provocation tests. *Turk J Gastroenterol, 18*(1), 5-13.

Bjarnason, I. (1994). Intestinal permeability. *Gut, 35*(1 Suppl), S18-22.

Brown, J. M., Pfau, J. C., Pershouse, M. A., & Holian, A. (2005). Silica, apoptosis, and autoimmunity. *J Immunotoxicol, 1*(3), 177-187. doi: 714111397 [pii]10.1080/15476910490911922

Burkitt, D. (1984). Fiber as protective against gastrointestinal diseases. *Am J Gastroenterol, 79*(4), 249-252.

Burkitt, D. P. (1981). The protective properties of dietary fiber. *N C Med J, 42*(7), 467-471.

Burkitt, D. P. (1988). Dietary fiber and cancer. *J Nutr, 118*(4), 531-533.

Burkitt, D. P., & Trowell, H. C. (1977). Dietary fibre and western diseases. *Ir Med J, 70*(9), 272-277.

Chang, D. M., Chang, W. Y., Kuo, S. Y., & Chang, M. L. (1997). The effects of traditional antirheumatic herbal medicines on immune response cells. *J Rheumatol, 24*(3), 436-441.

Costenbader, K. H., Feskanich, D., Holmes, M., Karlson, E. W., & Benito-Garcia, E. (2008). Vitamin D intake and risks of systemic lupus erythematosus and rheumatoid arthritis in women. *Annals of the rheumatic diseases, 67*(4), 530.

De Block, C. E. (2000). [Diabetes mellitus type 1 and associated organ-specific autoimmunity]. *Verh K Acad Geneeskd Belg, 62*(4), 285-328.

Dubois, P. C., & van Heel, D. A. (2008). Translational mini-review series on the immunogenetics of gut disease: immunogenetics of coeliac disease. *Clin Exp Immunol, 153*(2), 162-173. doi: CEI3704 [pii]10.1111/j.1365-2249.2008.03704.x

Ebringer, A., & Wilson, C. (2000). HLA molecules, bacteria and autoimmunity. *J Med Microbiol, 49*(4), 305-311.

Ebringer, A., and C. Wilson. “HLA Molecules, Bacteria and Autoimmunity.” J Med Microbiol 49 (4) (April 2000): ­305–11.

Frohlich-Reiterer, E. E., Hofer, S., Kaspers, S., Herbst, A., Kordonouri, O., Schwarz, H. P., et al. (2008). Screening frequency for celiac disease and autoimmune thyroiditis in children and adolescents with type 1 diabetes mellitus--data from a German/Austrian multicentre survey. *Pediatr Diabetes, 9*(6), 546-553. doi: PDI435 [pii]10.1111/j.1399-5448.2008.00435.x

Fuchtenbusch, M., Karges, W., Standl, E., Dosch, H. M., & Ziegler, A. G. (1997). Antibodies to bovine serum albumin (BSA) in type 1 diabetes and other autoimmune disorders. *Exp Clin Endocrinol Diabetes, 105*(2), 86-91.

Galli-Tsinopoulou, A., Nousia-Arvanitakis, S., Dracoulacos, D., Xefteri, M., & Karamouzis, M. (1999). Autoantibodies predicting diabetes mellitus type I in celiac disease. *Horm Res, 52*(3), 119-124. doi: hre52119 [pii]

Guillen Fiel, G., Gonzalez-Granado, L. I., Mosqueda, R., Negreira, S., & Giangaspro, E. (2009). [Arthritis caused by Candida in an immunocompetent infant with a history of systemic candidiasis in the neonatal period]. *An Pediatr (Barc), 70*(4), 383-385. doi: S1695-4033(08)00107-0 [pii]10.1016/j.anpedi.2008.12.001

Haugen, M., Kjeldsen-Kragh, J., Nordvag, B. Y., & Forre, O. (1991). Diet and disease symptoms in rheumatic diseases--results of a questionnaire based survey. *Clin Rheumatol, 10*(4), 401-407.

Hedberg, N. (Producer). (2010). Understanding Autoimmune Diseases. [Webinar]

Ho LJ, L. J. (2004). Chinese herbs as immunomodulators and potential disease-modifying antirheumatic drugs in autoimmune disorders. *Curr Drug Metab., Apr;5*(2), 181-192.

Holick, M.F. “Vitamin D: Importance in the Prevention of Cancers, Type 1 Diabetes, Heart Disease, and Osteoporosis.” Am J Clin Nutr 79 (3) (March 2004): ­362–71.

Huisman, A.M., et al. “Vitamin D Levels in Women with Systemic Lupus Erythematosus and Fibromyalgia.” J Rheumatol 28 (11) (November 2001): ­2535–39.

Karaguzel, G., Simsek, S., Deger, O., & Okten, A. (2008). Screening of diabetes, thyroid, and celiac diseases-related autoantibodies in a sample of Turkish children with type 1 diabetes and their siblings. *Diabetes Res Clin Pract, 80*(2), 238-243. doi: S0168-8227(07)00622-5 [pii]10.1016/j.diabres.2007.12.007

Katz, J.P., and G.R. Lichtenstein. “Rheumatologic Manifestations of Gastrointestinal Diseases.” Gastroenterol Clin North Am 27 (3) (September 1998): 533–62, v.

Lai, J. H. (2002). Immunomodulatory effects and mechanisms of plant alkaloid tetrandrine in autoimmune diseases. *Acta Pharmacol Sin, 23*(12), 1093-1101.

Marshak-Rothstein, A. (2006). Toll-like receptors in systemic autoimmune disease. *Nature Reviews Immunology, 6*(11), 823-835. doi: 10.1038/nri1957

McCarthy, G., and D. Kenny. “Dietary Fish Oil and Rheumatic Diseases.” Semin Arthritis Rheum 21, no. 6 (June 1992): ­368–75.

Miller, F.W., and D.R. Germolec. “Occupational Exposures and Autoimmune Diseases.” Cooper Int Immunopharmacol 2 (2002): ­303–13.

Mont-Serrat, C., Hoineff, C., Meirelles, R. M., & Kupfer, R. (2008). [Diabetes and autoimmune diseases: prevalence of celiac disease in children and adolescents with type 1 diabetes]. *Arq Bras Endocrinol Metabol, 52*(9), 1461-1465. doi: S0004-27302008000900009 [pii]

Noy, S., et al. “Schizophrenia and Autoimmunity—A Possible Etiological Mechanism?” Neuropsycbobiology 30 (1994): ­157–59.

Paronen, J., Knip, M., Savilahti, E., Virtanen, S. M., Ilonen, J., Akerblom, H. K., et al. (2000). Effect of cow's milk exposure and maternal type 1 diabetes on cellular and humoral immunization to dietary insulin in infants at genetic risk for type 1 diabetes. Finnish Trial to Reduce IDDM in the Genetically at Risk Study Group. *Diabetes, 49*(10), 1657-1665.

Pignet, M., and A. Lecomte. “The Effects of Harpogophytum Capsules in Degenerative Rheumatology.” Medicine Actuelle 12, no. 4 (1985): ­65–76.

Rensch, M. J., Szyjkowski, R., Shaffer, R. T., Fink, S., Kopecky, C., Grissmer, L., et al. (2001). The prevalence of celiac disease autoantibodies in patients with systemic lupus erythematosus. *Am J Gastroenterol, 96*(4), 1113-1115. doi: S0002-9270(01)02316-4 [pii]10.1111/j.1572-0241.2001.03753.x

Salardi, S., Volta, U., Zucchini, S., Fiorini, E., Maltoni, G., Vaira, B., & Cicognani, A. (2008). Prevalence of celiac disease in children with type 1 diabetes mellitus increased in the mid-1990 s: an 18-year longitudinal study based on anti-endomysial antibodies. *J Pediatr Gastroenterol Nutr, 46*(5), 612-614. doi: 10.1097/MPG.0b013e31815d697e 00005176-200805000-00024 [pii]

San-Pedro, J. I., Bilbao, J. R., Perez de Nanclares, G., Vitoria, J. C., Martul, P., & Castano, L. (2005). Heterogeneity of vitamin D receptor gene association with celiac disease and type 1 diabetes mellitus. *Autoimmunity, 38*(6), 439-444. doi: X020X056517K6T1K [pii]10.1080/08916930500288455

Sazanova, N.E., et al. “Immunological Aspects of Food Intolerance in Children During First Years of Life.” Pediatriia 3 (1992): ­14–18.

Sinaii, N., Cleary, S. D., Ballweg, M. L., Nieman, L. K., & Stratton, P. (2002). High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis. *Hum Reprod, 17*(10), 2715-2724.

Stokes, D.G., and J.M. Kremer. “Potential of Tumor Necrosis Factor Neutralization Strategies in Rheumatologic Disorders Other than Rheumatoid Arthritis.” Semin Arthritis Rheum 33 (1) (August 2003): ­1–18.

Vaarala, O. (2002). The gut immune system and type 1 diabetes. *Ann N Y Acad Sci, 958*, 39-46.

Vaarala, O. (2005). Is type 1 diabetes a disease of the gut immune system triggered by cow's milk insulin? *Adv Exp Med Biol, 569*, 151-156. doi: 10.1007/1-4020-3535-7\_22

Vaarala, O., Atkinson, M. A., & Neu, J. (2008). The "perfect storm" for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. *Diabetes, 57*(10), 2555-2562. doi: 57/10/2555 [pii] 10.2337/db08-0331

Vaarala, O., Saukkonen, T., Savilahti, E., Klemola, T., & Akerblom, H. K. (1995). Development of immune response to cow's milk proteins in infants receiving cow's milk or hydrolyzed formula. *J Allergy Clin Immunol, 96*(6 Pt 1), 917-923. doi: S0091-6749(95)70229-6 [pii]

Ventura, A., Neri, E., Ughi, C., Leopaldi, A., Citta, A., & Not, T. (2000). Gluten-dependent diabetes-related and thyroid-related autoantibodies in patients with celiac disease. *J Pediatr, 137*(2), 263-265. doi: S0022-3476(00)63042-1 [pii]10.1067/mpd.2000.107160

Visser, J., Rozing, J., Sapone, A., Lammers, K., & Fasano, A. (2009). Tight junctions, intestinal permeability, and autoimmunity: celiac disease and type 1 diabetes paradigms. *Ann N Y Acad Sci, 1165*, 195-205. doi: NYAS04037 [pii] 10.1111/j.1749-6632.2009.04037.x

Vojdani, A., Bazargan, M., Vojdani, E., Samadi, J., Nourian, A. A., Eghbalieh, N., et al. (2004). Heat shock protein and gliadin peptide promote development of peptidase antibodies in children with autism and patients with autoimmune disease. *Clin Diagn Lab Immunol, 11*(3), 515-524. doi: 10.1128/CDLI.11.3.515-524.2004 11/3/515 [pii]

Wang, S. J., Kao, C. H., Chen, D. U., & Lan, J. L. (1992). Intestinal permeability test in systemic lupus erythematosus. *Zhonghua Yi Xue Za Zhi (Taipei), 49*(1), 29-33.

Zeglaoui, H., Landolsi, H., Mankai, A., Ghedira, I., & Bouajina, E. (2010). Type 1 diabetes mellitus, celiac disease, systemic lupus erythematosus and systemic scleroderma in a 15-year-old girl. *Rheumatol Int, 30*(6), 793-795. doi: 10.1007/s00296-009-0988-2

**Chapter 28: Behcet’s Disease**

Arslan Lied, G. (2007). Gastrointestinal food hypersensitivity: symptoms, diagnosis and provocation tests. *Turk J Gastroenterol, 18*(1), 5-13.

Bjarnason, I. (1994). Intestinal permeability. *Gut, 35*(1 Suppl), S18-22.

Chambers, J.C., D.O. Haskard, and J.S. Kooner. “Vascular Endothelial Function and Oxidative Stress Mechanisms in Patients with Behcet’s Syndrome.” J Am Coll Cardiol 37 (2) (February 2001): ­517–20.

Delilbasi E., et al. “Selenium and Behcet’s Disease.” Biol Trace Elem Res 28 (1) (January 1991): ­21–25.

Fresko, I., et al. “Intestinal Permeability in Behcet’s Syndrome.” Ann Rheum Dis 60 (1) (January 2001): ­65–66.

Fresko, I., Hamuryudan, V., Demir, M., Hizli, N., Sayman, H., Melikoglu, M., . . . Yazici, H. (2001). Intestinal permeability in Behcet's syndrome. *Ann Rheum Dis, 60*(1), 65-66.

Kamaeva, O. I., Reznikov Iu, P., Pimenova, N. S., & Dobritsyna, L. V. (1998). [Antigliadin antibodies in the absence of celiac disease]. *Klin Med (Mosk), 76*(2), 33-35.

Kokcam, I., and M. Naziroglu. “Effects of Vitamin E Supplementation on Blood Antioxidants Levels in Patients with Behcet’s Disease.” Clin Biochem 35 (8) (November 2002): ­633–39.

Noyan, T., et al. “Serum Vitamin C Levels in Behcet’s Disease.” Yonsei Med J 44 (5) (October 30, 2003): ­771–78.

Orem, A., et al. “The Evaluation of Autoantibodies Against Oxidatively Modified Low-Density Lipoprotein (LDL), Susceptibility of LDL to Oxidation, Serum Lipids and Lipid Hydroperoxide Levels, Total Antioxidant Status, Antioxidant Enzyme Activities, and Endothelial Dysfunction in Patients with Behcet’s Disease.” Clin Biochem 35 (3) (May 2002): ­217–24.

Pronai, L., and S. Arimori. “BG-104 Enhances the Decreased Plasma Superoxide Scavenging Activity in Patients with Behcet’s Disease, Sjögren’s Syndrome or Hematological Malignancy.” Biotherapy 3 (4) (1991): ­365–71.

Saglam, K., et al. “Trace Elements and Antioxidant Enzymes in Behcet’s Disease.” Rheumatol Int 22 (3) (July 2002): ­93–96.

Sancak, B., et al. “Nitric Oxide Levels in Behcet’s Disease.” J Eur Acad Dermatol Venereol 17 (1) (January 2003): ­7–9.

Triolo, G., et al. “Humoral and Cell Mediated Immune Response to Cow’s Milk Proteins in Behcet’s Disease.” Ann Rheum Dis 61 (5) (May 2002): ­459–62.

Uyar, F. A., Saruhan-Direskeneli, G., & Gul, A. (2004). Common Crohn's disease-predisposing variants of the CARD15/NOD2 gene are not associated with Behcet's disease in Turkey. *Clin Exp Rheumatol, 22*(4 Suppl 34), S50-52.

Yu, P., et al. “Effects of Acupuncture on Humoral Immunologic Function and Trace Elements in 20 Cases of Behcet’s Disease.” J Tradit Chin Med 21 (2) (June 2001): ­100–102.

Zeis, J. “Behcet’s Disease.” website: ­www.behcetsdisease.com/basics.htm#WhatisBD

**Chapter 29: Cardiovascular Disease – The GI Connection**

Delaney, B. C., Hobbs, F. D., & Holder, R. (1996). Association of Helicobacter pylori infection with coronary heart disease. Eradication of the infection on grounds of cardiovascular risk is not supported by current evidence. *BMJ, 312*(7025), 251-252.

de Luis, D. A., Lahera, M., Canton, R., Boixeda, D., San Roman, A. L., Aller, R., et al. (1998). Association of Helicobacter pylori infection with cardiovascular and cerebrovascular disease in diabetic patients. *Diabetes Care, 21*(7), 1129-1132.

de Oliveira, C., Watt, R., & Hamer, M. (2010). Toothbrushing, inflammation, and risk of cardiovascular disease: results from Scottish Health Survey. *BMJ, 340*, c2451.

Gillum, R. F. (2004). Infection with Helicobacter pylori, coronary heart disease, cardiovascular risk factors, and systemic inflammation: the Third National Health and Nutrition Examination Survey. *J Natl Med Assoc, 96*(11), 1470-1476.

Haider, A. W., Wilson, P. W., Larson, M. G., Evans, J. C., Michelson, E. L., Wolf, P. A., et al. (2002). The association of seropositivity to Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus with risk of cardiovascular disease: a prospective study. *J Am Coll Cardiol, 40*(8), 1408-1413. doi: S0735109702022726 [pii]

Kitchell, B. B. (1984). Heart and liver lipid fatty acid and behavior changes in mice after a diet change. *Life Sci, 34*(17), 1613-1620.

Murray, L. J., Bamford, K. B., O'Reilly, D. P., McCrum, E. E., & Evans, A. E. (1995). Helicobacter pylori infection: relation with cardiovascular risk factors, ischaemic heart disease, and social class. *Br Heart J, 74*(5), 497-501.

Okada, T., Ayada, K., Usui, S., Yokota, K., Cui, J., Kawahara, Y., et al. (2007). Antibodies against heat shock protein 60 derived from Helicobacter pylori: diagnostic implications in cardiovascular disease. *J Autoimmun, 29*(2-3), 106-115. doi: S0896-8411(07)00067-4 [pii]10.1016/j.jaut.2007.05.004

Patel, P., Mendall, M. A., Carrington, D., Strachan, D. P., Leatham, E., Molineaux, N., et al. (1995). Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. *BMJ, 311*(7007), 711-714.

Pellicano, R., Oliaro, E., Fagoonee, S., Astegiano, M., Berrutti, M., Saracco, G., et al. (2009). Clinical and biochemical parameters related to cardiovascular disease after Helicobacter pylori eradication. *Int Angiol, 28*(6), 469-473. doi: R34092448 [pii]

Pellicano, R., Oliaro, E., Gandolfo, N., Aruta, E., Mangiardi, L., Orzan, F., et al. (2000). Ischemic cardiovascular disease and Helicobacter pylori. Where is the link? *J Cardiovasc Surg (Torino), 41*(6), 829-833.

**Chapter 30: Chronic Fatigue Syndrome**

———. “A Follow-Up on Malic Acid: CFIDS Buyer’s Club.” Health Watch 3, no. 1 (Spring 1993): ­1–3.

———. “Intravenous Nutrient Therapy: The ‘Meyers’ cocktail.’” Altern Med Rev 7 (5) (2002): ­389–403.

Arslan Lied, G. (2007). Gastrointestinal food hypersensitivity: symptoms, diagnosis and provocation tests. *Turk J Gastroenterol, 18*(1), 5-13.

Bland, J. “Advancement in Clinical Nutrition HealthComm.” Taken from Komaroff, A.L. “Clinical Presentations of Chronic Fatigue Syndrome.” In Chronic Fatigue Syndrome, edited by Bock and Whelan. New York: Wiley and Sons Ltd., ­1993.

Bottiglieri, T. “S-Adenosyl-L-Methionine (SAMe): From the Bench to the Bedside—Molecular Basis of a Pleiotrophic Molecule.” Am J Clin Nutr 76 (5) (November 2002): ­1151S-57S.

Bou-Holaigah, I., et al. “The Relationship Between Neurally Mediated Hypotension and the Chronic Fatigue Syndrome.” JAMA 74, no. 12 (September 27, 1995): ­961–67.

Briggs, N.C., and P.H. Levine. “A Comparative Review of Systemic and Neurological Symptomatology of 12 Outbreaks Collectively Described as Chronic Fatigue Syndrome, Epidemic Neuromyasthenia, and Myalgic Encephalo­myelitis.” Clin Infect Dis 18 (Suppl) (January 1994): ­S32–S42.

Brunello, N., Akiskal, H., Boyer, P., Gessa, G. L., Howland, R. H., Langer, S. Z., et al. (1999). Dysthymia: clinical picture, extent of overlap with chronic fatigue syndrome, neuropharmacological considerations, and new therapeutic vistas. *J Affect Disord, 52*(1-3), 275-290.

Dykman, K.D., et al. “The Effects of Nutritional Supplements on the Symptoms of Fibromyalgia and Chronic Fatigue Syndrome.” Integr Physiol Behav Sci 33, no. 1 (January–March 1998): ­61–71.

Forsyth, L.M., et al. “Therapeutic Effects of Oral NADH on the Symptoms of Patients with Chronic Fatigue Syndrome.” Ann Allergy Asthma Immunol 82, no. 2 (February ­1999).

Galland, L., et al. “Giardia Lamblia Infection as a Cause of Chronic Fatigue.” J Nutr Med (1990): ­27–31.

Goldenberg, D.L. “Fibromyalgia, Chronic Fatigue Syndrome, and Myofascial Pain Syndrome.” Curr Opin Rheumatol 6, no. 2 (March 1994): ­223–33.

Gray, J.B., and A.M. Martinovic. “Ecoisanoids and Essential Fatty Acid Modulation in Chronic Disease and Chronic Fatigue Syndrome.” Med Hypotheses 43 (July 1994): ­31–42.

Jammes, Y., Steinberg, J. G., Delliaux, S., & Bregeon, F. (2009). Chronic fatigue syndrome combines increased exercise-induced oxidative stress and reduced cytokine and Hsp responses. *J Intern Med, 266*(2), 196-206. doi: JIM2079 [pii]10.1111/j.1365-2796.2009.02079.x

Jammes, Y., Steinberg, J. G., Mambrini, O., Bregeon, F., & Delliaux, S. (2005). Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise. *J Intern Med, 257*(3), 299-310. doi: JIM1452 [pii]10.1111/j.1365-2796.2005.01452.x

Kuratsune, H., et al. “Acylcarnitine and Chronic Fatigue Syndrome.” Carnitine Today 10 (1997): ­195–213.

Lapp, C.W., and P. Cheney. “Chronic Fatigue Syndrome: Self-Care Manual, February 1991.” The CFDS Chronicle Physicians’ Forum 1, no. 1 (March 1991): ­14–17.

Logan, A. C., & Wong, C. (2001). Chronic fatigue syndrome: oxidative stress and dietary modifications. *Altern Med Rev, 6*(5), 450-459.

Maes, M. (2010, July 4. epub ahead of print). An intriguing and hitherto unexplained co-occurrence: Depression and chronic fatigue syndrome are manifestations of shared inflammatory, oxidative and nitrosative (IO&NS) pathways. *Prog Neuropsychopharmacol Biol Psychiatry.*

McSherry, J. “Chronic Fatigue Syndrome: A Fresh Look at an Old Problem.” Can Fam Phys 39 (February 1993): ­336–40.

Moldofsky, H. “Fibromyalgia, Sleep Disorder and Chronic Fatigue Syndrome.” Ciba Foundation Symposium 173 (1993): 262–71, ­272–79.

Myhill, S., Booth, N. E., & McLaren-Howard, J. (2009). Chronic fatigue syndrome and mitochondrial dysfunction. *Int J Clin Exp Med, 2*(1), 1-16.

Shafran, S.D., et al. “Chronic Fatigue Syndrome.” Am J Med 90 (June 1991): ­730–40.

Sinaii, N., Cleary, S. D., Ballweg, M. L., Nieman, L. K., & Stratton, P. (2002). High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis. *Hum Reprod, 17*(10), 2715-2724.

Sullivan, A., Nord, C. E., & Evengard, B. (2009). Effect of supplement with lactic-acid producing bacteria on fatigue and physical activity in patients with chronic fatigue syndrome. *Nutr J, 8*, 4. doi: 1475-2891-8-4 [pii]10.1186/1475-2891-8-4

Teitelbaum JE, J. C., St Cyr J. (2006). The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. *J Altern Complement Med., Nov (12)*(9), 857-862.

Teitelbaum, J. E. (2009). Fibromyalgia and Chronic Fatigue Syndrome. In I. Kohlstadt (Ed.), *Food & Nutrients in Disease Management* (pp. 557-564). Boca Raton, FL: CCR.

**Chapter 31: Eczema or Atopic Dermatitis**

Ali, B.H., and G. Blunden. “Pharmacological and Toxicological Properties of Nigella Sativa.” Phytother Res 17 (4) (April 2003): ­299–305.

Arslan Lied, G. (2007). Gastrointestinal food hypersensitivity: symptoms, diagnosis and provocation tests. *Turk J Gastroenterol, 18*(1), 5-13.

Black, P. N. (2005). Does atopy protect against enteric infections? *Allergy, 60*(1), 30-34.

Breuer, K., Heratizadeh, A., Wulf, A., Baumann, U., Constien, A., Tetau, D., et al. (2004). Late eczematous reactions to food in children with atopic dermatitis. *Clin Exp Allergy, 34*(5), 817-824.

Burks, W.A., et al. “Atopic Dermatitis and Food Hypersen­sitivity Reactions.” J Pediatr 132 (1998): ­132–36.

Elisa/Act Patient Handbook. Reston, Va.: Serammune Laborato­ries, ­2000.

Fischer, S., Ring, J., & Abeck, D. (2003). [Atopic eczema. Spectrum of provocation factors and possibilities for their effective reduction and elimination]. *Hautarzt, 54*(10), 914-924.

Horrobin, D. F. (2000). Essential fatty acid metabolism and its modification in atopic eczema. *Am J Clin Nutr, 71*(1 Suppl), 367S-372S.

Kalimo, K. “Yeast Allergy in Adult Atopic Dermatitis.” Immunol Pharmacol Aspects 4 (1991): ­164–67.

Kalus, U., et al. “Effect of Nigella Sativa (Black Seed) on Subjective Feeling in Patients with Allergic Diseases.” Phytother Res 17 (10) (December 2003): ­1209–14.

Kay, J., Gawkrodger, D. J., Mortimer, M. J., & Jaron, A. G. (1994). The prevalence of childhood atopic eczema in a general population. *J Am Acad Dermatol, 30*(1), 35-39.

Khoo, J., et al. “Pattern of Sensitization to Common Environmental Allergens Amongst Atopic Singapore Children in the First 3 Years of Life.” Asian Pac J Allergy Immunol 19 (4) (December 2001): ­225–29.

Kirjavainen, P. V., Salminen, S. J., & Isolauri, E. (2003). Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. *J Pediatr Gastroenterol Nutr, 36*(2), 223-227.

Menzel, I., and H. Holzmann. “Reflections on Seborrheic Scalp Eczema and Psoriasis Capillitii in Relation to Intestinal Mycoses.” Z Hautkr 61, no. 7 (April 1986): ­451–54.

Mortz, C. G., Lauritsen, J. M., Bindslev-Jensen, C., & Andersen, K. E. (2001). Prevalence of atopic dermatitis, asthma, allergic rhinitis, and hand and contact dermatitis in adolescents. The Odense Adolescence Cohort Study on Atopic Diseases and Dermatitis. *Br J Dermatol, 144*(3), 523-532.

Mortz, C. G., Lauritsen, J. M., Bindslev-Jensen, C., & Andersen, K. E. (2002). Contact allergy and allergic contact dermatitis in adolescents: prevalence measures and associations. The Odense Adolescence Cohort Study on Atopic Diseases and Dermatitis (TOACS). *Acta Derm Venereol, 82*(5), 352-358.

Mortz, C. G., Lauritsen, J. M., Bindslev-Jensen, C., & Andersen, K. E. (2002). Nickel sensitization in adolescents and association with ear piercing, use of dental braces and hand eczema. The Odense Adolescence Cohort Study on Atopic Diseases and Dermatitis (TOACS). *Acta Derm Venereol, 82*(5), 359-364.

Niggemann, B. (2004). Role of oral food challenges in the diagnostic work-up of food allergy in atopic eczema dermatitis syndrome. *Allergy, 59 Suppl 78*, 32-34.

Oliwiecki, S., et al. “Levels of Essential and Other Fatty Acids in Plasma and Red Cell Phospholipids from Normal Controls in Patients with Atopic Eczema.” Acta Derm Venereol (Stockholm) 71 (1990): ­224–28.

Patzelt-Wenczler, R., & Ponce-Poschl, E. (2000). Proof of efficacy of Kamillosan(R) cream in atopic eczema. *Eur J Med Res, 5*(4), 171-175.

Patzelt-Wenczler, R., and E. Ponce-Poschl. “Proof of Efficacy of Kamillosan® Cream in Atopic Eczema.” Eur J Med Res 5 (4) (April 19, 2000): ­171–5.

Resch, A., Schlipkoter, U., Crispin, A., Behrendt, H., Heinrich, J., Wichmann, H. E., et al. (2004). Atopic disease and its determinants -- a focus on the potential role of childhood infection. *Clin Exp Allergy, 34*(8), 1184-1191.

Rosenfeldt, V., Benfeldt, E., Nielsen, S. D., Michaelsen, K. F., Jeppesen, D. L., Valerius, N. H., et al. (2003). Effect of probiotic Lactobacillus strains in children with atopic dermatitis. *J Allergy Clin Immunol, 111*(2), 389-395. doi: S0091674902913734 [pii]

Rottem, M., Darawsha, J., & Zarfin, J. (2004). Atopic dermatits in infants and children in Israel: clinical presentation, allergies and outcome. *Isr Med Assoc J, 6*(4), 209-212.

Rupprecht, M., et al. “Physical Stress-Induced Secretion of Adrenal and Pituitary Hormones in Patients with Atopic Eczema Compared with Normal Controls.” Clin Endocrinol Diabetes 105 (1997): ­39–45.

Saeedi, M., K. Morteza-Semnani, and M.R. Ghoreishi. “The Treatment of Atopic Dermatitis with Licorice Gel.” J Dermatolog Treat 14 (3) (September 2003): ­153–57.

Sampson, H. A. (1992). The immunopathogenic role of food hypersensitivity in atopic dermatitis. *Acta Derm Venereol Suppl (Stockh), 176*, 34-37.

Sampson, H.A. “The Immunopathogenic Role of Food Hypersensitivity in Atopic Dermatitis.” Acta Derm Venereol Suppl (Stockholm) 176 (1992): ­34–37.

Schafer, T., et al. “Epidemiology of Food Allergy/Food Intolerance in Adults: Associations with Other Manifestations of Atopy.” Allergy 56 (12) (December 2001): ­1172–79.

Schmidt, W. P. (2004). Model of the epidemic of childhood atopy. *Med Sci Monit, 10*(2), HY5-9.

Sinaii, N., Cleary, S. D., Ballweg, M. L., Nieman, L. K., & Stratton, P. (2002). High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis. *Hum Reprod, 17*(10), 2715-2724.

Soyland, E., et al. “Dietary Supplementation with Very Long-Chain Omega-3 Fatty Acids in Patients with Atopic Dermatitis.” Br J Dermatol 130 (1994): ­757–64.

Tan, B. B., et al. “Double-Blind Controlled Trial of Effect of Housedust-Mite Allergen Avoidance on Atopic Dermatitis.” Lancet 347 (January 26, 1996): ­15–18.

Turjanmaa, K. (2002). "Atopy patch tests" in the diagnosis of delayed food hypersensitivity. *Allerg Immunol (Paris), 34*(3), 95-97.

**Chapter 32: Fibromyalgia**

———. “A Follow-Up on Malic Acid: CFIDS Buyer’s Club.” Health Watch 3, no. 1 (Spring 1993): ­1–3.

———. “Intravenous Nutrient Therapy: The ‘Meyers’ cocktail.’” Altern Med Rev 7 (5) (2002): ­389–403.

Al-Allaf, A.W., et al. “Bone Health in Patients with Fibromyalgia.” Rheumatology (Oxford) 42 (10) (October ­2003): 1202–6.

Bottiglieri, T. “S-Adenosyl-L-Methionine (SAMe): From the Bench to the Bedside—Molecular Basis of a Pleiotrophic Molecule.” Am J Clin Nutr 76 (5) (November 2002): ­1151S-57S.

Brady, D. M., & Schneider, M. J. (2001). Fibromyalgia syndrome: a new paradigm for differential diagnosis and treatment. *J Manipulative Physiol Ther, 24*(8), 529-541. doi: S0161-4754(01)17587-1 [pii] 10.1067/mmt.2001.118202

Bramwell, B., et al. “The Use of Ascorbigen in the Treatment of Fibromyalgia Patients: a Preliminary Trial.” Altern Med Rev 5 (5) (October 2000): ­455–62.

Deluze, C., et al. “Electroacupuncture in Fibromyalgia: Results of a Controlled Trial.” BMJ 305 (November 21, 1992): ­1249–51.

Dykman, K.D., et al. “The Effects of Nutritional Supplements on the Symptoms of Fibromyalgia and Chronic Fatigue Syndrome.” Integr Physiol Behav Sci 33, no. 1 (January–March 1998): ­61–71.

Eisinger, J., et al. “Glycolysis Abnormalities in Fibromyalgia.” J Am Coll Nutr 13, no. 2 (1994): ­144–48.

Elisa/Act Patient Handbook. Reston, Va.: Serammune Laborato­ries, ­2000.

Faivelson, S. “Electroacupuncture Tried for Pain of Fibromyalgia.” Med Trib Med News (December 24, 1992): ­24.

Fibromyalgia Symptoms Improve with Chlorella pyrenoidosa. (2000). *The Integrative Medicine Consult, 2*(8), 85.

Fitzcharles, M. A., & Boulos, P. (2003). Inaccuracy in the diagnosis of fibromyalgia syndrome: analysis of referrals. *Rheumatology (Oxford), 42*(2), 263-267.

Goldenberg, D.L. “Fibromyalgia, Chronic Fatigue Syndrome, and Myofascial Pain Syndrome.” Curr Opin Rheumatol 6, no. 2 (March 1994): ­223–33.

Grassetto, M., and A. Varotto. “Primary Fibromyalgia Is Responsive to S-Adenosyl-L-Methionine.” Curr Ther Res Clin Exp 55, no. 7 (July 1994): ­797–806.

Huisman, A.M., et al. “Vitamin D Levels in Women with Systemic Lupus Erythematosus and Fibromyalgia.” J Rheumatol 28 (11) (November 2001): ­2535–39.

Ianniello, A., et al. “S-Adenosyl-L-Methionine in Sjögren’s Syndrome and Fibromyalgia.” Curr Ther Res Clin Exp 55, no. 6 (June 1994): ­699–706.

Lukaczer, D., Schlitz B., LIska D. (2000). A pilot trial evaluating the effect of an inflammatory modulating medical food in patients with fibromyalgia. *Clin Pract Altern Med, 1*(3), 148-156.

McCarty, D.J., et al. “Treatment of Pain Due to Fibromyalgia with Topical Capsaicin: A Pilot Study.” Semin Arthritis Rheum 23, no. 6 (Suppl) (June 1994): ­41–47.

Moldofsky, H. “Fibromyalgia, Sleep Disorder and Chronic Fatigue Syndrome.” Ciba Foundation Symposium 173 (1993): 262–71, ­272–79.

Moreshead, J., and R. Jaffe. “Fibromyalgia: Clinical Success Through Enhanced Host Defenses: A Case-Controlled Outcome Study.” IAACN Syllabus, Dallas, Tex., September ­1994.

Pimentel, M., Wallace, D., Hallegua, D., Chow, E., Kong, Y., Park, S., et al. (2004). A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. *Ann Rheum Dis, 63*(4), 450-452.

Schneider, M. J., Brady, D. M., & Perle, S. M. (2006). Commentary: differential diagnosis of fibromyalgia syndrome: proposal of a model and algorithm for patients presenting with the primary symptom of chronic widespread pain. *J Manipulative Physiol Ther, 29*(6), 493-501. doi: S0161-4754(06)00154-0 [pii]10.1016/j.jmpt.2006.06.010

Shabert, J. The Ultimate Nutrient Glutamine. Garden City Park, N.Y.: Avery, ­1994.

Sinaii, N., Cleary, S. D., Ballweg, M. L., Nieman, L. K., & Stratton, P. (2002). High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis. *Hum Reprod, 17*(10), 2715-2724.

Yunus, M.B., et al. “Plasma Tryptophan and Other Amino Acids in Primary Fibromyalgia: A Controlled Study.” J Rheumatol 19, no. 1 (1992): ­90–94.

**Chapter 33: Interstitial Cystitis**

Dunlop, S.P., D. Jenkins, and R.C. Spiller. “Distinctive Clinical, Psychological, and Histological Features of Post­infective Irritable Bowel Syndrome.” Am J Gastroenterol 98 (7) (July 2003): ­1578–83.

**Chapter 34: Migraine Headaches**

———. “Intravenous Nutrient Therapy: The ‘Meyers’ cocktail.’” Altern Med Rev 7 (5) (2002): ­389–403.

21st Century Prevention and Management of Migraine Headaches, Clinical Courier, 9; September 8, 2001. NINDS and Amer Acad ­Neurol. www.ninds.nih.gov/doctors/OP129D\_
Clinical\_Courier\_fa.pdf

Arslan Lied, G. (2007). Gastrointestinal food hypersensitivity: symptoms, diagnosis and provocation tests. *Turk J Gastroenterol, 18*(1), 5-13.

Bates, B. “Low-Fat, High-Carbohydrate Diet Averts Migraines.” Fam Pract News (August 1, 1996): ­16.

Bianchi, A., Salomone, S., Caraci, F., Pizza, V., Bernardini, R., & D'Amato, C. C. (2004). Role of magnesium, coenzyme Q10, riboflavin, and vitamin B12 in migraine prophylaxis. *Vitam Horm, 69*, 297-312. doi: 10.1016/S0083-6729(04)69011-X S008367290469011X [pii]

Bigal, M. E., & Krymchantowski, A. V. (2006). Migraine triggered by sucralose--a case report. *Headache, 46*(3), 515-517. doi: HED386\_1 [pii] 10.1111/j.1526-4610.2006.00386\_1.x

Bigal, M.E., et al. “Intravenous Magnesium Sulphate in the Acute Treatment of Migraine Without Aura and Migraine with Aura: A Randomized, Double-Blind, Placebo-
Controlled Study.” Cephalalgia 22 (5) (June 2002): ­345–53.

Biggs, M. J., Johnson, E. S., Persaud, N. P., & Ratcliffe, D. M. (1982). Platelet aggregation in patients using feverfew for migraine. *Lancet, 2*(8301), 776.

Black, M. “Nicotinic Acid and Headache.” Cortlandt Forum (August 1990): ­26–30.

Bland, J. (2009 ). Intercellular Signal Transduction: Mechanical, Electrical, Chemical [Monthly audio-visual series. ]. Gig Harbor, WA: Synthesis by Jeffrey Bland.

Brun, J., Claustrat, B., Saddier, P., & Chazot, G. (1995). Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses. *Cephalalgia, 15*(2), 136-139; discussion 179.

Bubenik, G. A., Blask, D. E., Brown, G. M., Maestroni, G. J., Pang, S. F., Reiter, R. J., et al. (1998). Prospects of the clinical utilization of melatonin. *Biol Signals Recept, 7*(4), 195-219. doi: bsi07195 [pii]

Cady, R. K., Schreiber, C. P., Beach, M. E., & Hart, C. C. (2005). Gelstat Migraine (sublingually administered feverfew and ginger compound) for acute treatment of migraine when administered during the mild pain phase. *Med Sci Monit, 11*(9), PI65-69. doi: 7013 [pii]

Cete, Y., Dora, B., Ertan, C., Ozdemir, C., & Oktay, C. (2005). A randomized prospective placebo-controlled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attacks in the Emergency Department. *Cephalalgia, 25*(3), 199-204. doi: CHA840 [pii]10.1111/j.1468-2982.2004.00840.x

Ciancarelli, I., Di Massimo, C., Tozzi-Ciancarelli, M. G., De Matteis, G., Marini, C., & Carolei, A. (2002). Helicobacter pylori infection and migraine. *Cephalalgia, 22*(3), 222-225. doi: 354 [pii]

Claustrat, B., Brun, J., Chiquet, C., Chazot, G., & Borson-Chazot, F. (2004). Melatonin secretion is supersensitive to light in migraine. *Cephalalgia, 24*(2), 128-133. doi: 645 [pii]

Claustrat, B., Loisy, C., Brun, J., Beorchia, S., Arnaud, J. L., & Chazot, G. (1989). Nocturnal plasma melatonin levels in migraine: a preliminary report. *Headache, 29*(4), 242-245.

Corbo, J., et al. “Randomized Clinical Trial of Intravenous Magnesium Sulfate as an Adjunctive Medication for Emergency Department Treatment of Migraine Headache.” Ann Emerg Med 38 (6) (December 2001): ­621–27.

Danesch, U., & Rittinghausen, R. (2003). Safety of a patented special butterbur root extract for migraine prevention. *Headache, 43*(1), 76-78. doi: hed03015 [pii]

Demirkaya, S., Vural, O., Dora, B., & Topcuoglu, M. A. (2001). Efficacy of intravenous magnesium sulfate in the treatment of acute migraine attacks. *Headache, 41*(2), 171-177. doi: hed01029 [pii]

Diener, H. C., Pfaffenrath, V., Schnitker, J., Friede, M., & Henneicke-von Zepelin, H. H. (2005). Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention--a randomized, double-blind, multicentre, placebo-controlled study. *Cephalalgia, 25*(11), 1031-1041. doi: CHA950 [pii]10.1111/j.1468-2982.2005.00950.x

Diener, H. C., Rahlfs, V. W., & Danesch, U. (2004). The first placebo-controlled trial of a special butterbur root extract for the prevention of migraine: reanalysis of efficacy criteria. *Eur Neurol, 51*(2), 89-97. doi: 10.1159/000076535 ENE2004051002089 [pii]

Diener, H.C., V.W. Rahlfs, and U. Danesch. “The First Placebo-Controlled Trial of a Special Butterbur Root Extract for the Prevention of Migraine: Reanalysis of Efficacy Criteria.” Eur Neurol 51 (2) (January 2004): ­89–97.

Egger, J., Carter, C. M., Wilson, J., Turner, M. W., & Soothill, J. F. (1983). Is migraine food allergy? A double-blind controlled trial of oligoantigenic diet treatment. *Lancet, 2*(8355), 865-869.

Elisa/Act Patient Handbook. Reston, Va.: Serammune Laborato­ries, ­2000.

Facchinetti, F., Sances, G., Borella, P., Genazzani, A. R., & Nappi, G. (1991). Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. *Headache, 31*(5), 298-301.

Gabrielli, M., Fiore, G., Candelli, M., Giacovazzo, M., Pola, P., Gasbarrini, G., et al. (2002). Re: "Chronic Helicobacter pylori infection and migraine: a case-control study" (Pinessi L, Savi L, Pellicano R, et al. Headache. 2000;40:836-839). *Headache, 42*(3), 236-237; author reply 235-236.

Gallai, V., Sarchielli, P., Morucci, P., & Abbritti, G. (1993). Red blood cell magnesium levels in migraine patients. *Cephalalgia, 13*(2), 94-81; discussion 73.

Gasbarrini, A., De Luca, A., Fiore, G., Gambrielli, M., Franceschi, F., Ojetti, V., et al. (1998). Beneficial effects of Helicobacter pylori eradication on migraine. *Hepatogastroenterology, 45*(21), 765-770.

Gasbarrini, A., Gabrielli, M., Fiore, G., Candelli, M., Bartolozzi, F., De Luca, A., et al. (2000). Association between Helicobacter pylori cytotoxic type I CagA-positive strains and migraine with aura. *Cephalalgia, 20*(6), 561-565.

Goldenberg, D.L. “Fibromyalgia, Chronic Fatigue Syndrome, and Myofascial Pain Syndrome.” Curr Opin Rheumatol 6, no. 2 (March 1994): ­223–33.

Grant, E. C. (1979). Food allergies and migraine. *Lancet, 1*(8123), 966-969.

Guariso, G., Bertoli, S., Cernetti, R., Battistella, P. A., Setari, M., & Zacchello, F. (1993). [Migraine and food intolerance: a controlled study in pediatric patients]. *Pediatr Med Chir, 15*(1), 57-61.

Gupta, V. K. (2004). Magnesium therapy for migraine: do we need more trials or more reflection? *Headache, 44*(5), 445-446. doi: 10.1111/j.1526-4610.2004.04098\_2.x HED04098\_2 [pii]

Harel, Z., et al. “Supplementation with Omega-3 Polyunsaturated Fatty Acids in the Management of Recurrent Migraines in Adolescents.” J Adolesc Health 31 (2) (August 2002): ­154–61.

Harel, Z., Gascon, G., Riggs, S., Vaz, R., Brown, W., & Exil, G. (2002). Supplementation with omega-3 polyunsaturated fatty acids in the management of recurrent migraines in adolescents. *J Adolesc Health, 31*(2), 154-161.

Henneicke-von Zepelin, H. H. (2006). Feverfew for migraine prophylaxis. *Headache, 46*(3), 531. doi: HED391\_5 [pii]10.1111/j.1526-4610.2006.00391\_5.x

Hershey, A. D., Powers, S. W., Vockell, A. L., Lecates, S. L., Ellinor, P. L., Segers, A., et al. (2007). Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. *Headache, 47*(1), 73-80. doi: HED652 [pii]10.1111/j.1526-4610.2007.00652.x

Hesse, J., et al. “Acupuncture Compared with Metoprolol for Migraine Gave Mixed Results.” Ann Intern Med 235 (May 1994): ­451–56.

Hesse, J., et al. “Acupuncture Versus Metoprolol in Migraine Prophylaxis: A Randomized Trial of Trigger Point Inactivation.” J Intern Med 235 (1994): ­451–56.

Heuser, G., et al. “Candida albicans and Migraine Headaches: A Possible Link.” J Adv Med 5, no. 3 (Fall 1992): ­177–87.

Johnson, E. S., Kadam, N. P., Anderson, D., Jenkinson, P. C., Dewdney, R. S., & Blowers, S. D. (1987). Investigation of possible genetoxic effects of feverfew in migraine patients. *Hum Toxicol, 6*(6), 533-534.

Johnson, E. S., Kadam, N. P., Hylands, D. M., & Hylands, P. J. (1985). Efficacy of feverfew as prophylactic treatment of migraine. *Br Med J (Clin Res Ed), 291*(6495), 569-573.

Johnson, E.S., et al. “Efficacy of Feverfew as Prophylactic Treatment of Migraine.” BMJ 2291, no. 6495 (August 31, 1985): ­569–73.

Johnson, S. “The Multifaceted and Widespread Pathology of Magnesium Deficiency.” Med Hypotheses 56 (2) (February 2001): ­163–70.

Jones, M. “Migraine Headaches and Food.” NOHA News 14, no. 2 (Spring ­1989).

Kalin, P. (2003). [The common butterbur (Petasites hybridus)--portrait of a medicinal herb]. *Forsch Komplementarmed Klass Naturheilkd, 10 Suppl 1*, 41-44.

Kalin, P. “The Common Butterbur (Petasites hybridus)—Portrait of a Medicinal Herb.” Forsch Komplementarmed Klass Naturheilkd 10 (Suppl 1) (April 2003): ­41–44.

Koseoglu, E., Talaslioglu, A., Gonul, A. S., & Kula, M. (2008). The effects of magnesium prophylaxis in migraine without aura. *Magnes Res, 21*(2), 101-108.

Li, W., Zheng, T., Altura, B. M., & Altura, B. T. (2001). Sex steroid hormones exert biphasic effects on cytosolic magnesium ions in cerebral vascular smooth muscle cells: possible relationships to migraine frequency in premenstrual syndromes and stroke incidence. *Brain Res Bull, 54*(1), 83-89. doi: S0361-9230(00)00428-7 [pii]

Lipton, R. B., Gobel, H., Einhaupl, K. M., Wilks, K., & Mauskop, A. (2004). Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. *Neurology, 63*(12), 2240-2244. doi: 63/12/2240 [pii]

Maizels, M., Blumenfeld, A., & Burchette, R. (2004). A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. *Headache, 44*(9), 885-890. doi: 10.1111/j.1526-4610.2004.04170.x HED04170 [pii]

Martelletti, P. “T Cells Expressing IL-2 Receptor in Migraine.” Acta Neurol 13, no. 5 (October 1991): ­448–56.

Mauskop, A., Altura, B. T., & Altura, B. M. (2002). Serum ionized magnesium levels and serum ionized calcium/ionized magnesium ratios in women with menstrual migraine. *Headache, 42*(4), 242-248. doi: hed02075 [pii]

Mauskop, A., Altura, B. T., Cracco, R. Q., & Altura, B. M. (1995). Intravenous magnesium sulphate relieves migraine attacks in patients with low serum ionized magnesium levels: a pilot study. *Clin Sci (Lond), 89*(6), 633-636.

Mavromichalis, I. (2003). The role of Helicobacter pylori infection in migraine. *Cephalalgia, 23*(3), 240; author reply 240-241. doi: 499\_1 [pii]

Miano, S., Parisi, P., Pelliccia, A., Luchetti, A., Paolino, M. C., & Villa, M. P. (2008). Melatonin to prevent migraine or tension-type headache in children. *Neurol Sci, 29*(4), 285-287. doi: 10.1007/s10072-008-0983-5

Millichap, J. G., & Yee, M. M. (2003). The diet factor in pediatric and adolescent migraine. *Pediatr Neurol, 28*(1), 9-15.

Murialdo, G., Fonzi, S., Costelli, P., Solinas, G. P., Parodi, C., Marabini, S., et al. (1994). Urinary melatonin excretion throughout the ovarian cycle in menstrually related migraine. *Cephalalgia, 14*(3), 205-209.

National Institute of Neurological Disorders and Stroke, ­www.ninds.nih.gov/health\_and\_medical/pubs/
migraineupdate.htm

Patel, R. M., Sarma, R., & Grimsley, E. (2006). Popular sweetner sucralose as a migraine trigger. *Headache, 46*(8), 1303-1304. doi: HED543\_1 [pii]10.1111/j.1526-4610.2006.00543\_1.x

Peres, M. F., Masruha, M. R., Zukerman, E., Moreira-Filho, C. A., & Cavalheiro, E. A. (2006). Potential therapeutic use of melatonin in migraine and other headache disorders. *Expert Opin Investig Drugs, 15*(4), 367-375. doi: 10.1517/13543784.15.4.367

Peres, M. F., Zukerman, E., da Cunha Tanuri, F., Moreira, F. R., & Cipolla-Neto, J. (2004). Melatonin, 3 mg, is effective for migraine prevention. *Neurology, 63*(4), 757. doi: 63/4/757 [pii]

Pfaffenrath, V., Diener, H. C., Fischer, M., Friede, M., & Henneicke-von Zepelin, H. H. (2002). The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis--a double-blind, multicentre, randomized placebo-controlled dose-response study. *Cephalalgia, 22*(7), 523-532. doi: 396 [pii]

Pfaffenrath, V., et al. “The Efficacy and Safety of Tanacetum Parthenium (Feverfew) in Migraine Prophylaxis—A Double-Blind, Multicentre, Randomized, Placebo-Controlled Dose-Response Study.” Cephalalgia 22 (7) (September 2002): ­523–32.

Pfaffenrath, V., Wessely, P., Meyer, C., Isler, H. R., Evers, S., Grotemeyer, K. H., et al. (1996). Magnesium in the prophylaxis of migraine--a double-blind placebo-controlled study. *Cephalalgia, 16*(6), 436-440.

Pittler, M. H., & Ernst, E. (2004). Feverfew for preventing migraine. *Cochrane Database Syst Rev*(1), CD002286. doi: 10.1002/14651858.CD002286.pub2

Pittler, M. H., Vogler, B. K., & Ernst, E. (2000). Feverfew for preventing migraine. *Cochrane Database Syst Rev*(3), CD002286. doi: CD002286 [pii]10.1002/14651858.CD002286

Pittler, M., and E. Ernst. “Feverfew for Preventing Migraine.” Cochrane Database Syst Rev. 1 (2004): ­CD002286.

Pothmann, R., & Danesch, U. (2005). Migraine prevention in children and adolescents: results of an open study with a special butterbur root extract. *Headache, 45*(3), 196-203. doi: HED05044 [pii]10.1111/j.1526-4610.2005.05044.x

Prusinski, A., Durko, A., & Niczyporuk-Turek, A. (1999). [Feverfew as a prophylactic treatment of migraine]. *Neurol Neurochir Pol, 33 Suppl 5*, 89-95.

Rios, J., & Passe, M. M. (2004). Evidenced-based use of botanicals, minerals, and vitamins in the prophylactic treatment of migraines. *J Am Acad Nurse Pract, 16*(6), 251-256.

Robbins, L. “Precipitating Factors in Migraine: A Retrospective Review of 494 Patients.” Headache 34, no. 4 (April 1994): ­214–16.

Rozen, T. D., Oshinsky, M. L., Gebeline, C. A., Bradley, K. C., Young, W. B., Shechter, A. L., et al. (2002). Open label trial of coenzyme Q10 as a migraine preventive. *Cephalalgia, 22*(2), 137-141. doi: 335 [pii]

Russell, G., Abu-Arafeh, I., & Symon, D. N. (2002). Abdominal migraine: evidence for existence and treatment options. *Paediatr Drugs, 4*(1), 1-8.

Sandor, P. S., Di Clemente, L., Coppola, G., Saenger, U., Fumal, A., Magis, D., et al. (2005). Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. *Neurology, 64*(4), 713-715. doi: 64/4/713 [pii]10.1212/01.WNL.0000151975.03598.ED

Schoenen, J., et al. “Effectiveness of High-Dose Riboflavin in Migraine Prophylaxis: A Randomized Controlled Trial.” Neurology 50 (1998): ­466–70.

Schoenen, J., et al. “High-Dose Riboflavin as a Prophylactic Treatment of Migraine: Results of an Open Pilot Study.” Cephalalgia 14 (1994): ­328–29.

Schoenen, J., Sianard-Gainko, J., & Lenaerts, M. (1991). Blood magnesium levels in migraine. *Cephalalgia, 11*(2), 97-99.

Serratrice, J., Disdier, P., de Roux, C., Christides, C., & Weiller, P. J. (1998). Migraine and coeliac disease. *Headache, 38*(8), 627-628.

Shealy, N. (1994). Magnesium and migraine. *Headache, 34*(7), 445.

Shimomura, T., et al. “Platelet Superoxide Dismutase in Migraine and Tension Type Headaches.” Cephalalgia 14 (1994): ­215–18.

Silberstein, S.D., and R.B. Lipton. “Epidemiology of Migraine.” Neuroepidemiol 12, no. 3 (1993): ­179–84.

Smith, R. “Chronic Headaches in Family Practice.” J Am Board Fam Pract 5, no. 6 (November–December 1992): ­589–99.

Soriani, S., et al. “Serum and Red Blood Cell Magnesium Levels in Juvenile Migraine Patients.” Headache 35, no. 1 (January 1995): ­14–16.

Steven Sinclair, N. S., LAc. (1999). Migraine Headaches: Nutrirional, Botanical and Other Alternative Approaches. *Alternative Medicine Review, 4*(2), 86-95.

Stewart, W.F., A. Schechter, and B.K. Rasmussen. “Migraine Prevalence. A Review of Population-Based Studies.” Neurology 44, no. 6 (Suppl 4) (June 1994): ­S17–S23.

Sun-Edelstein, C., & Mauskop, A. (2009). Role of magnesium in the pathogenesis and treatment of migraine. *Expert Rev Neurother, 9*(3), 369-379. doi: 10.1586/14737175.9.3.369

Taubert, K. “Magnesium in Migraine. Results of a Multicenter Pilot Study.” Portschreit Medizin 112, no. 24 (August 30, 1994): ­228–30.

Thomas, J., et al. “Migraine Treatment by Oral Magnesium Intake and Correction of the Irritation of Buccofacial and Cervical Muscles as a Side Effect of Mandibular Imbalance.” Magnes Res 7, no. 2 (June 1994): ­123–27.

Thomas, J., Tomb, E., Thomas, E., & Faure, G. (1994). Migraine treatment by oral magnesium intake and correction of the irritation of buccofacial and cervical muscles as a side effect of mandibular imbalance. *Magnes Res, 7*(2), 123-127.

Tietjen, G. E., Brandes, J. L., Peterlin, B. L., Eloff, A., Dafer, R. M., Stein, M. R., et al. (2010). Childhood maltreatment and migraine (part III). Association with comorbid pain conditions. *Headache, 50*(1), 42-51. doi: HED1558 [pii]10.1111/j.1526-4610.2009.01558.x

Toglia, J. U. (1986). Is migraine due to a deficiency of pineal melatonin? *Ital J Neurol Sci, 7*(3), 319-323.

Toglia, J. U. (2001). Melatonin: a significant contributor to the pathogenesis of migraine. *Med Hypotheses, 57*(4), 432-434. doi: 10.1054/mehy.2001.1337 S0306-9877(01)91337-4 [pii]

Trauninger, A., Pfund, Z., Koszegi, T., & Czopf, J. (2002). Oral magnesium load test in patients with migraine. *Headache, 42*(2), 114-119. doi: hed02026 [pii]

Tunca, A., Ardicoglu, Y., Kargili, A., & Adam, B. (2007). Migraine, Helicobacter pylori, and oxidative stress. *Helicobacter, 12*(1), 59-62. doi: HEL470 [pii]10.1111/j.1523-5378.2007.00470.x

Tunca, A., Turkay, C., Tekin, O., Kargili, A., & Erbayrak, M. (2004). Is Helicobacter pylori infection a risk factor for migraine? A case-control study. *Acta Neurol Belg, 104*(4), 161-164.

Van der Kuy, P.H., et al, “Hydroxocobalamin, a Nitric Oxide Scavenger, in the Prophylaxis of Migraine: An Open, Pilot Study,” Cephalalgia 22 (2002): ­513–19.

Vogler, B. K., Pittler, M. H., & Ernst, E. (1998). Feverfew as a preventive treatment for migraine: a systematic review. *Cephalalgia, 18*(10), 704-708.

Vogler, B., Rapoport, A. M., Tepper, S. J., Sheftell, F., & Bigal, M. E. (2006). Role of melatonin in the pathophysiology of migraine: implications for treatment. *CNS Drugs, 20*(5), 343-350. doi: 2051 [pii]

Wager, W., and U. Nootbaar-Wagner. “Prophylactic Treatment of Migraine with Gamma-Linolenic and Alpha-Linolenic Acids.” Cephalalgia 17 (1997): ­127–30.

Waller, P. C., & Ramsay, L. E. (1985). Efficacy of feverfew as prophylactic treatment of migraine. *Br Med J (Clin Res Ed), 291*(6502), 1128.

Wang, F., Van Den Eeden, S. K., Ackerson, L. M., Salk, S. E., Reince, R. H., & Elin, R. J. (2003). Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. *Headache, 43*(6), 601-610.

Weaver, K. (1990). Magnesium and migraine. *Headache, 30*(3), 168.

Welch, K. M., & Ramadan, N. M. (1995). Mitochondria, magnesium and migraine. *J Neurol Sci, 134*(1-2), 9-14.

Yiannopoulou, K. G., Efthymiou, A., Karydakis, K., Arhimandritis, A., Bovaretos, N., & Tzivras, M. (2007). Helicobacter pylori infection as an environmental risk factor for migraine without aura. *J Headache Pain, 8*(6), 329-333. doi: 10.1007/s10194-007-0422-7

**Chapter 35: Obesity, Metabolic Syndrome and the GI Connection**

Arslan Lied, G. (2007). Gastrointestinal food hypersensitivity: symptoms, diagnosis and provocation tests. *Turk J Gastroenterol, 18*(1), 5-13.

Bellocchio, L., Cervino, C., Pasquali, R., & Pagotto, U. (2008). The endocannabinoid system and energy metabolism. *J Neuroendocrinol, 20*(6), 850-857. doi: JNE1728 [pii] 10.1111/j.1365-2826.2008.01728.x

Bellocchio, L., Mancini, G., Vicennati, V., Pasquali, R., & Pagotto, U. (2006). Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases. *Curr Opin Pharmacol, 6*(6), 586-591. doi: S1471-4892(06)00165-2 [pii] 10.1016/j.coph.2006.09.001

Bellocchio, L., Vicennati, V., Cervino, C., Pasquali, R., & Pagotto, U. (2007). The endocannabinoid system in the regulation of cardiometabolic risk factors. *Am J Cardiol, 100*(12A), 7P-17P. doi: S0002-9149(07)02068-1 [pii] 10.1016/j.amjcard.2007.10.009

Bjarnason, I. (1994). Intestinal permeability. *Gut, 35*(1 Suppl), S18-22.

Cani, P. D., Amar, J., Iglesias, M. A., Poggi, M., Knauf, C., Bastelica, D., et al. (2007). Metabolic endotoxemia initiates obesity and insulin resistance. *Diabetes, 56*(7), 1761-1772. doi: db06-1491 [pii]10.2337/db06-1491

Cani, P. D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A. M., Delzenne, N. M., et al. (2008). Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. *Diabetes, 57*(6), 1470-1481. doi: db07-1403 [pii]10.2337/db07-1403

Cani, P. D., & Delzenne, N. M. (2009). Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota. *Curr Opin Pharmacol, 9*(6), 737-743. doi: S1471-4892(09)00092-7 [pii]10.1016/j.coph.2009.06.016

Cani, P. D., & Delzenne, N. M. (2010). Involvement of the gut microbiota in the development of low grade inflammation associated with obesity: focus on this neglected partner. *Acta Gastroenterol Belg, 73*(2), 267-269.

Cani, P. D., Delzenne, N. M., Amar, J., & Burcelin, R. (2008). Role of gut microflora in the development of obesity and insulin resistance following high-fat diet feeding. *Pathol Biol (Paris), 56*(5), 305-309. doi: S0369-8114(07)00221-0 [pii]10.1016/j.patbio.2007.09.008

Creations, G. (Producer). (2010, 9-1-10). Human Endocannibinoid System. Retrieved from <http://www.genovation-creations.com/2010/06/25/human-endocannibinoid-system/>

de La Serre, C. B., Ellis, C. L., Lee, J., Hartman, A. L., Rutledge, J. C., & Raybould, H. E. (2010). Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. *Am J Physiol Gastrointest Liver Physiol, 299*(2), G440-448. doi: ajpgi.00098.2010 [pii]10.1152/ajpgi.00098.2010

Duncan, S. H., Lobley, G. E., Holtrop, G., Ince, J., Johnstone, A. M., Louis, P., et al. (2008). Human colonic microbiota associated with diet, obesity and weight loss. *Int J Obes (Lond), 32*(11), 1720-1724. doi: ijo2008155 [pii]10.1038/ijo.2008.155

Fabian, E., & Elmadfa, I. (2006). Influence of daily consumption of probiotic and conventional yoghurt on the plasma lipid profile in young healthy women. *Ann Nutr Metab, 50*(4), 387-393. doi: ANM2006050004387 [pii]10.1159/000094304

Haas, E. M., & Stauth, C. (2000). *The false fat diet : the revolutionary 21-day program for losing the weight you think is fat* (1st ed.). New York: Ballantine Books.

Hyman, M. (2008). *UltraMetabolism : the simple plan for automatic weight loss*. Emmaus, Pa.: Rodale.

Isolauri, E., Kalliomaki, M., Rautava, S., Salminen, S., & Laitinen, K. (2009). Obesity - extending the hygiene hypothesis. *Nestle Nutr Workshop Ser Pediatr Program, 64*, 75-85; discussion 85-79, 251-257. doi: 000235784 [pii]10.1159/000235784

Kalliomaki, M., Collado, M. C., Salminen, S., & Isolauri, E. (2008). Early differences in fecal microbiota composition in children may predict overweight. *Am J Clin Nutr, 87*(3), 534-538. doi: 87/3/534 [pii]

Ley, R. E., Backhed, F., Turnbaugh, P., Lozupone, C. A., Knight, R. D., & Gordon, J. I. (2005). Obesity alters gut microbial ecology. *Proc Natl Acad Sci U S A, 102*(31), 11070-11075. doi: 0504978102 [pii]10.1073/pnas.0504978102

Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006). Microbial ecology: human gut microbes associated with obesity. *Nature, 444*(7122), 1022-1023. doi: 4441022a [pii]10.1038/4441022a

Ooi, L. G., & Liong, M. T. (2010). Cholesterol-lowering effects of probiotics and prebiotics: a review of in vivo and in vitro findings. *Int J Mol Sci, 11*(6), 2499-2522. doi: 10.3390/ijms11062499

Pagotto, U., Cervino, C., Vicennati, V., Marsicano, G., Lutz, B., & Pasquali, R. (2006). How many sites of action for endocannabinoids to control energy metabolism? *Int J Obes (Lond), 30 Suppl 1*, S39-43. doi: 0803277 [pii]10.1038/sj.ijo.0803277

Pagotto, U., Marsicano, G., Cota, D., Lutz, B., & Pasquali, R. (2006). The emerging role of the endocannabinoid system in endocrine regulation and energy balance. *Endocr Rev, 27*(1), 73-100. doi: er.2005-0009 [pii]10.1210/er.2005-0009

Pagotto, U., & Pasquali, R. (2006). Endocannabinoids and energy metabolism. *J Endocrinol Invest, 29*(3 Suppl), 66-76.

Pagotto, U., Vicennati, V., & Pasquali, R. (2005). The endocannabinoid system and the treatment of obesity. *Ann Med, 37*(4), 270-275. doi: MQ5760402V13R055 [pii]10.1080/07853890510037419

Sadrzadeh-Yeganeh, H., Elmadfa, I., Djazayery, A., Jalali, M., Heshmat, R., & Chamary, M. (2010). The effects of probiotic and conventional yoghurt on lipid profile in women. *Br J Nutr, 103*(12), 1778-1783. doi: S0007114509993801 [pii]10.1017/S0007114509993801

Sanchez, J. C., Cabrera-Rode, E., Sorell, L., Galvan, J. A., Hernandez, A., Molina, G., et al. (2007). Celiac disease associated antibodies in persons with latent autoimmune diabetes of adult and type 2 diabetes. *Autoimmunity, 40*(2), 103-107. doi: 773217245 [pii]10.1080/08916930601118825

Secondulfo, M., de Magistris, L., Sapone, A., Di Monda, G., Esposito, P., & Carratu, R. (1999). Intestinal permeability and diabetes mellitus type 2. *Minerva Gastroenterol Dietol, 45*(3), 187-192.

Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006). An obesity-associated gut microbiome with increased capacity for energy harvest. *Nature, 444*(7122), 1027-1031. doi: nature05414 [pii]10.1038/nature05414

**Chapter 36: Osteoporosis – The GI Connection**

Bonamico, M., Mariani, P., Danesi, H. M., Crisogianni, M., Failla, P., Gemme, G., . . . Romano, C. (2001). Prevalence and clinical picture of celiac disease in italian down syndrome patients: a multicenter study. *J Pediatr Gastroenterol Nutr, 33*(2), 139-143.

Dawson-Hughes, B., et al. “Rates of Bone Loss in Postmenopausal Women Randomly Assigned to One of Two Dosages of the Vitamin D.” Am J Clin Nutr 6 (1) (1995): ­1140–45.

Duerksen, D. R., & Leslie, W. D. (2010). Positive celiac disease serology and reduced bone mineral density in adult women. *Can J Gastroenterol, 24*(2), 103-107.

Green, P. H. (2005). The many faces of celiac disease: clinical presentation of celiac disease in the adult population. *Gastroenterology, 128*(4 Suppl 1), S74-78. doi: S001650850500185X [pii]

Holick, M.F. “Vitamin D: Importance in the Prevention of Cancers, Type 1 Diabetes, Heart Disease, and Osteoporosis.” Am J Clin Nutr 79 (3) (March 2004): ­362–71.

Laroche, M., Lassoued, S., Billey, T., Bernard, J., & Mazi, B. (2007). Male osteoporosis with vertebral fractures? Look for ankylosing spondylitis! A report of 10 cases. *J Rheumatol, 34*(11), 2271-2272. doi: 07/13/104 [pii]

Long, F. (2008). When the gut talks to bone. *Cell, 135*(5), 795-796. doi: S0092-8674(08)01393-7 [pii]10.1016/j.cell.2008.11.007

Long, F. (2008). When the gut talks to bone. Cell, 135(5), 795-796. doi: S0092-8674(08)01393-7 [pii]10.1016/j.cell.2008.11.007

Looker, A.C., et al. “Prevalence of Low Femoral Bone Density in Older U.S. Adults from NHANES III.” J Bone Miner Res 12 (11) (November 1997): ­1761–68.

Melton, L.J., III. “The Prevalence of Osteoporosis: Gender and Racial Comparison.” Calcif Tissue Int 69 (4) (October 2001): ­179–81.

Murray, J. A. (2005). Celiac disease in patients with an affected member, type 1 diabetes, iron-deficiency, or osteoporosis? *Gastroenterology, 128*(4 Suppl 1), S52-56. doi: S0016508505001988 [pii]

Von Tirpitz, C., et al. “Osteoporosis in Inflammatory Bowel Disease—Results of a Survey Among Members of the German Crohn’s and Ulcerative Colitis Association.” Z Gastroenterol 41 (12) (December 2003): ­1145–50.

Wehren, L.E., et al. “Gender Differences in Mortality After Hip Fracture: The Role of Infection.” J Bone Miner Res 18 (12) (December 2003): ­2231–37.

**Chapter 37: Psoriasis**

Abenavoli, L., Leggio, L., Gasbarrini, G., & Addolorato, G. (2007). Celiac disease and skin: psoriasis association. *World J Gastroenterol, 13*(14), 2138-2139.

Addolorato, G., Parente, A., de Lorenzi, G., D'Angelo Di Paola, M. E., Abenavoli, L., Leggio, L., et al. (2003). Rapid regression of psoriasis in a coeliac patient after gluten-free diet. A case report and review of the literature. *Digestion, 68*(1), 9-12. doi: 10.1159/000073220 DIG2003068001009 [pii]

Alteras, I. “The Incidence of Skin Manifestations by Dermatophytes in Patients with Psoriasis.” Mycopathologia 95, no. 1 (July 1986): ­37–39.

Calderon, H. P., Valdes, A. P., Zemelman, D. V., Poniachik, T. J., Hurtado, H. C., Garmendia, M. M., et al. (2007). [Frequency of celiac disease among patients with psoriasis]. *Rev Med Chil, 135*(10), 1296-1303. doi: S0034-98872007001000010 [pii]/S0034-98872007001000010

Corrocher, R., et al. “Effect of Fish Oil Supplementation on Erythrocyte Lipid Pattern, Malondialdehyde Production and Glutathione-Peroxidase Activity in Psoriasis.” Clin Chim Acta 179, no. 2 (February 15, 1989): ­121–31.

Dochao, A., et al. “Therapeutic Effects of Vitamin D and Vitamin A in Psoriasis: A 20-Year Experiment.” Actas Dermosfiliogr 66, nos. 3, 4 (1975): ­121–30.

Ellis, C. “Hot Pepper Cure: Capsaicin Relieves Psoriatic Itch.” Mod Med 61 (1993): ­31.

Fairris, G.M., et al. “The Effect of Supplementation with ­Selenium and Vitamin E in Psoriasis.” Ann Clin Biochem 26, Part 1 (January 1989): ­83–88.

Gaby, A. (2003). High-dose folic acid for psoriasis. *Townsend Newsletter for Doctors, May*. Retrieved from BNET: CBS interactive business network website

Gao, Z., Tseng, C. H., Strober, B. E., Pei, Z., & Blaser, M. J. (2008). Substantial alterations of the cutaneous bacterial biota in psoriatic lesions. *PLoS One, 3*(7), e2719. doi: 10.1371/journal.pone.0002719

Gaston, L., et al. “Psychological Stress and Psoriasis: Experimental and Prospective Correlation Studies.” Acta Derm Venereol (Suppl 156) (1994): ­37–43.

Grimminger, F., et al. “A Double-Blind Randomized, Placebo-Controlled Trial of N-3 Fatty Acid Based Lipid Infusion in Acute, Extended Guttate Psoriasis: Rapid Improvement of Clinical Manifestations and Changes in Neutrophil Leukotriene Profile.” Clin Investig 71 (1993): ­634–43.

Harvima, R.J., et al. “Screening of Effects of ­Selenomethionine-Enriched Yeast Supplementation on Various Immunological and Chemical Parameters of Skin and Blood in Psoriatic Patients.” Acta Derm Venereol 73, no. 2 (April 1993): ­88–91.

Higdon, J., Drake V.J., Shane B. (2007). Folic Acid. *Linus Pauling Micronutrient Information Center*. Retrieved from <http://lpi.oregonstate.edu/infocenter/vitamins/fa/index.html#food_source>

Humbert, P., Bidet, A., Treffel, P., Drobacheff, C., & Agache, P. (1991). Intestinal permeability in patients with psoriasis. *J Dermatol Sci, 2*(4), 324-326.

Javitz, H.S., et al. “The Direct Cost of Care for Psoriasis and Psoriatic Arthritis in the United States.” J Am Acad Dermatol 46 (6) (June 2002): ­850–60.

Kharaeva, Z., Gostova, E., De Luca, C., Raskovic, D., & Korkina, L. (2009). Clinical and biochemical effects of coenzyme Q(10), vitamin E, and selenium supplementation to psoriasis patients. *Nutrition, 25*(3), 295-302. doi: S0899-9007(08)00420-6 [pii]10.1016/j.nut.2008.08.015

Kurkcuoglu, N., and F. Alaybeyi. “Topical Capsaicin for Psoriasis.” Br J Dermatol 123, no. 4 (October 1990): ­549–50.

Leung, R.S., et al. “Neutrophil Zinc Levels in Psoriasis and Seborrheoic Dermatitis.” Br J Dermatol 123, no. 3 (September 1990): ­319–23.

Li, W. F., & Wang, P. (2008). [Clinical analysis of 47 patients with psoriasis arthropathy treated by traditional Chinese medicine syndrome differentiation and integrative medicine]. *Zhongguo Zhong Xi Yi Jie He Za Zhi, 28*(10), 928-931.

McCarty, M.F. “Glucosamine for Psoriasis?” Med Hypotheses 48 (1997): ­437–41.

McMillan, E.M., et al. “Diurnal Stage of Circadian Rhythm of Plasma Zinc in Healthy and Psoriatic Volunteers.” Prog Clin Biolog Res 227B (1987): ­295–303.

Menzel, I., and H. Holzmann. “Reflections on Seborrheic Scalp Eczema and Psoriasis Capillitii in Relation to Intestinal Mycoses.” Z Hautkr 61, no. 7 (April 1986): ­451–54.

Michaelsson, G., Ahs, S., Hammarstrom, I., Lundin, I. P., & Hagforsen, E. (2003). Gluten-free diet in psoriasis patients with antibodies to gliadin results in decreased expression of tissue transglutaminase and fewer Ki67+ cells in the dermis. *Acta Derm Venereol, 83*(6), 425-429. doi: 10.1080/00015550310015022 YB7LCQCLVAWGBTBK [pii]

Michaelsson, G., and L.K. Ljunghall. “Patients with Dermatitis Herpetiformis, Acne, Psoriasis, and Darier’s Disease Have Low Epidermal Zinc Concentrations.” Acta Derm Venereol 70, no. 4 (1990): ­304–8.

Michaelsson, G., et al. “Selenium in Whole Blood and Plasma Is Decreased in Patients with Moderate and Severe Psoriasis.” Acta Derm Venereol 69, no. 1 (1989): ­29–34.

Moller, I., Perez, M., Monfort, J., Benito, P., Cuevas, J., Perna, C., et al. (2010). Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double-blind, placebo-controlled study. *Osteoarthritis Cartilage, 18 Suppl 1*, S32-40. doi: S1063-4584(10)00090-7 [pii]10.1016/j.joca.2010.01.018

Murray M., B. P. (2006). Psoriasis. In P. J. Murray M. (Ed.), *Textbook of Natural Medicine* (Vol. 2, pp. 2079-2087). St. Louis, MO: Churchill Livingstone/Elsevier.

Nigam, P. K. (2005). Serum zinc and copper levels and Cu: Zn ratio in psoriasis. *Indian J Dermatol Venereol Leprol, 71*(3), 205-206.

Ojetti, V., Aguilar Sanchez, J., Guerriero, C., Fossati, B., Capizzi, R., De Simone, C., et al. (2003). High prevalence of celiac disease in psoriasis. *Am J Gastroenterol, 98*(11), 2574-2575. doi: S0002927003017179 [pii]10.1111/j.1572-0241.2003.08684.x

Petersen Vikki, P. R. (2009). *The Gluten Effect: How "Innocent" Wheat is Ruining Your Health*: True Health Publ.

Pietrzak, A., Jastrzebska, I., Chodorowska, G., Maciejewski, R., Dybiec, E., Juszkiewicz-Borowiec, M., et al. (2009). Psoriasis vulgaris and digestive system disorders: is there a linkage? *Folia Histochem Cytobiol, 47*(3), 517-524. doi: 544150M64W4633V6 [pii]10.2478/v10042-009-0107-y

Singh, S., Sonkar, G. K., & Usha. (2010). Celiac disease-associated antibodies in patients with psoriasis and correlation with HLA Cw6. *J Clin Lab Anal, 24*(4), 269-272. doi: 10.1002/jcla.20398

Smetsers, T. F., van de Westerlo, E. M., ten Dam, G. B., Overes, I. M., Schalkwijk, J., van Muijen, G. N., et al. (2004). Human single-chain antibodies reactive with native chondroitin sulfate detect chondroitin sulfate alterations in melanoma and psoriasis. *J Invest Dermatol, 122*(3), 707-716. doi: 10.1111/j.0022-202X.2004.22316.x JID22316 [pii]

Sukenik, S., et al. “Treatment of Psoriatic Arthritis at the Dead Sea.” J Rheumatol 21, no. 7 (July 1994): ­130–59.

Syed, T.A., et al. “Management of Psoriasis with Aloe Vera Extract in a Hydrophilic Cream: A Placebo-Controlled, Double-Blind Study.” Trop Med Intern Health 1, no. 4 (August 1996): ­505–9.

Troughton, P.R., and A.W. Morgan. “Laboratory Findings and Pathology of Psoriatic Arthritis.” Baillieres Clinical Rheumatology 8, no. 2 (May 1994): ­439–63.

Verges, J., Montell, E., Herrero, M., Perna, C., Cuevas, J., Perez, M., et al. (2004). [Clinical and histopathological improvement of psoriasis in patients with osteoarthritis treated with chondroitin sulfate: report of 3 cases]. *Med Clin (Barc), 123*(19), 739-742. doi: 13069310 [pii]

Verges, J., Montell, E., Herrero, M., Perna, C., Cuevas, J., Perez, M., et al. (2005). Clinical and histopathological improvement of psoriasis with oral chondroitin sulfate: a serendipitous finding. *Dermatol Online J, 11*(1), 31.

Wolters, M. (2005). Diet and psoriasis: experimental data and clinical evidence. *Br J Dermatol, 153*(4), 706-714. doi: BJD6781 [pii]10.1111/j.1365-2133.2005.06781.x

Wolters, M. (2006). [The significance of diet and associated factors in psoriasis]. *Hautarzt, 57*(11), 999-1004. doi: 10.1007/s00105-006-1164-1

**Chapter 38: Rosacea**

Parodi, A., Paolino, S., Greco, A., Drago, F., Mansi, C., Rebora, A., et al. (2008). Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. *Clin Gastroenterol Hepatol, 6*(7), 759-764. doi: S1542-3565(08)00155-9 [pii]10.1016/j.cgh.2008.02.054

**Chapter 39: Schizophrenia**

Arslan Lied, G. (2007). Gastrointestinal food hypersensitivity: symptoms, diagnosis and provocation tests. *Turk J Gastroenterol, 18*(1), 5-13.

Arvindakshan, M., et al. “Supplementation with a Combination of Omega-3 Fatty Acids and Antioxidants (Vitamins E and C) Improves the Outcome of Schizophrenia.” Schizophr Res 62 (3) (August 1, 2003): ­195–204.

Bonamico, M., Mariani, P., Danesi, H. M., Crisogianni, M., Failla, P., Gemme, G., . . . Romano, C. (2001). Prevalence and clinical picture of celiac disease in italian down syndrome patients: a multicenter study. *J Pediatr Gastroenterol Nutr, 33*(2), 139-143.

Clarke, M. C., Tanskanen, A., Huttunen, M., Whittaker, J. C., & Cannon, M. (2009). Evidence for an interaction between familial liability and prenatal exposure to infection in the causation of schizophrenia. *Am J Psychiatry, 166*(9), 1025-1030. doi: appi.ajp.2009.08010031 [pii]10.1176/appi.ajp.2009.08010031

Dohan, F. C. (1981). Schizophrenia, celiac disease, gluten antibodies, and the importance of beta. *Biol Psychiatry, 16*(11), 1115-1117.

Emsley, R., P. Oosthuizen, and S.J. van Rensburg. “Clinical Potential of Omega-3 Fatty Acids in the Treatment of ­Schizophrenia.” CNS Drugs 17 (15) ­(2003): 1081–91.

Fasano, A. (2009). Surprises from celiac disease. *Sci Am, 301*(2), 54-61.

Fasano, A. “Celiac Disease: How to Handle a Clinical Chameleon.” N Engl J Med 34 (25) (June 19, 2003): ­2568–70.

Fenton, W.S., J. Hibbeln, and M. Knable. “Essential Fatty Acids, Lipid Membrane Abnormalities, and the Diagnosis and Treatment of Schizophrenia.” Biol Psychiatry 47 (1) (January 1, 2000): ­8–21.

Gluten in schizophrenia. (1983). *Lancet, 1*(8327), 744-745.

Godfrey, P.S., et al. “Enhancement of Recovery from Psychiatric Illness by Methylfolate.” Lancet 336, no. 8712 (August 1990): ­392–95.

Green, P. H. (2005). The many faces of celiac disease: clinical presentation of celiac disease in the adult population. *Gastroenterology, 128*(4 Suppl 1), S74-78. doi: S001650850500185X [pii]

Jenner, F. A., & Vlissides, D. N. (1987). Gluten sensitivity in schizophrenia. *Br J Psychiatry, 150*, 559.

Jungerius, B. J., Bakker, S. C., Monsuur, A. J., Sinke, R. J., Kahn, R. S., & Wijmenga, C. (2008). Is MYO9B the missing link between schizophrenia and celiac disease? *Am J Med Genet B Neuropsychiatr Genet, 147*(3), 351-355. doi: 10.1002/ajmg.b.30605

Kalaydjian, A. E., Eaton, W., Cascella, N., & Fasano, A. (2006). The gluten connection: the association between schizophrenia and celiac disease. *Acta Psychiatr Scand, 113*(2), 82-90. doi: ACP687 [pii] 10.1111/j.1600-0447.2005.00687.x

Kaminski, S., Cieslinska, A., & Kostyra, E. (2007). Polymorphism of bovine beta-casein and its potential effect on human health. *J Appl Genet, 48*(3), 189-198. doi: 394 [pii]

Kanofsky, J.D. “Magnesium Deficiency in Chronic Schizophrenia.” Int J Neurosci 61 (1991): ­87–90.

King, D. S. (1985). Statistical power of the controlled research on wheat gluten and schizophrenia. *Biol Psychiatry, 20*(7), 785-787.

Kraft, B. D., & Westman, E. C. (2009). Schizophrenia, gluten, and low-carbohydrate, ketogenic diets: a case report and review of the literature. *Nutr Metab (Lond), 6*, 10. doi: 1743-7075-6-10 [pii]10.1186/1743-7075-6-10

Messamore, E. “Relationship Between the Niacin Skin Flush Response and Essential Fatty Acids in Schizophrenia.” Prostaglandins Leukot Essent Fatty Acids 69 (6) (December 2003): ­413–19.

Messamore, E., W.F. Hoffman, and A. Janowsky. “The Niacin Skin Flush Abnormality in Schizophrenia: A Quantitative Dose-Response Study.” Schizophr Res 62 (3) (August 1, 2003): ­251–58.

Noy, S., et al. “Schizophrenia and Autoimmunity—A Possible Etiological Mechanism?” Neuropsycbobiology 30 (1994): ­157–59.

Ozdemir, V., Jamal, M. M., Osapay, K., Jadus, M. R., Sandor, Z., Hashemzadeh, M., et al. (2007). Cosegregation of gastrointestinal ulcers and schizophrenia in a large national inpatient discharge database: revisiting the "brain-gut axis" hypothesis in ulcer pathogenesis. *J Investig Med, 55*(6), 315-320.

Peet, M., et al. “Essential Fatty Acid Deficiency in Erythrocyte Membranes from Chronic Schizophrenic Patients, and the Clinical Effects of Dietary Supplementation.” Prostaglandins Leukot Essent Fatty Acids 55, nos. 1, 2 (1996): ­71–75.

Petersen Vikki, P. R. (2009). *The Gluten Effect: How "Innocent" Wheat is Ruining Your Health*: True Health Publ.

Pfeiffer, C. C. (1984). Schizophrenia and wheat gluten enteropathy. *Biol Psychiatry, 19*(3), 279-280.

Procter, A. “Enhancement of Recovery from Psychiatric Illness by Methylfolate.” Br J Psychiatry 159 (August 1991): ­271–72.

Prokopova, L. “Celiac Disease—A Severe Disease.” Vnitr Lek 49 (6) (June 2003): ­474–81.

Puri, B.K., et al. “A Volumetric Biochemical Niacin Flush-Based Index That Noninvasively Detects Fatty Acid Deficiency in Schizophrenia.” Prog Neuropsychopharmacol Biol Psychiatry 26 (1) (January 2002): ­49–52.

Reddy, R., M. Keshavan, and J.K. Yao. “Reduced Plasma Antioxidants in First-Episode Patients with Schizophrenia.” Schizophr Res 62 (3) (August 1, 2003): ­205–12.

Reichelt, K. L., & Landmark, J. (1995). Specific IgA antibody increases in schizophrenia. *Biol Psychiatry, 37*(6), 410-413. doi: 0006-3223(94)00176-4 [pii]10.1016/0006-3223(94)00176-4

Ross-Smith, P., & Jenner, F. A. (1980). Diet (gluten) and schizophrenia. *J Hum Nutr, 34*(2), 107-112.

Samaroo, D., Dickerson, F., Kasarda, D. D., Green, P. H., Briani, C., Yolken, R. H., et al. (2010). Novel immune response to gluten in individuals with schizophrenia. *Schizophr Res, 118*(1-3), 248-255. doi: S0920-9964(09)00385-5 [pii]10.1016/j.schres.2009.08.009

Sengh, M. M., & Kay, S. R. (1987). Gluten sensitivity in schizophrenia. *Br J Psychiatry, 150*, 130-131.

Sharma, R.P., et al. “Acute Dietary Tryptophan Depletion: Effects on Schizophrenic Positive and Negative Symptoms.” Neuropsychobiology 35 (1997): ­5–10.

Study of gluten effect in schizophrenia. (1983). *Arch Gen Psychiatry, 40*(3), 345-346.

Tret'iakov, A., Karpov, A. G., Polushin, P. I., & Zakharchenko, S. P. (2005). [Ulcer disease in schizophrenia: variants of combination and particular features of the course]. *Eksp Klin Gastroenterol*(6), 88-93, 114.

Tret'iakov, A., Karpov, A. G., Polushin, P. I., & Zakharchenko, S. P. (2006). [Gastric ulcer accompanying schizophrenia: variants of combination and particulars of development]. *Eksp Klin Gastroenterol*(2), 50-55, 127.

Tsaluchidu, S., Cocchi, M., Tonello, L., & Puri, B. K. (2008). Fatty acids and oxidative stress in psychiatric disorders. *BMC Psychiatry, 8 Suppl 1*, S5. doi: 1471-244X-8-S1-S5 [pii]10.1186/1471-244X-8-S1-S5

Wood, N.C., et al. “Abnormal Intestinal Permeability. An Aetiological Factor in Chronic Psychiatric Disorders.” Br J Psychiatry 150 (June 1987): ­853–56.

Young, G., & Conquer, J. (2005). Omega-3 fatty acids and neuropsychiatric disorders. *Reprod Nutr Dev, 45*(1), 1-28.

**Chapter 40: Scleroderma (Systemic Sclerosis)**

———. “Essential Fatty Acid and Prostaglandin Metabolism in Sjögren’s Syndrome, Systemic Sclerosis and Rheumatoid Arthritis.” Scand J Rheumatol 61 (Suppl) (1986): ­242–45.

Allanore, Y., Wipff, J., Kahan, A., & Boileau, C. (2007). Genetic basis for systemic sclerosis. *Joint Bone Spine, 74*(6), 577-583. doi: S1297-319X(07)00196-0 [pii] 10.1016/j.jbspin.2007.04.005

Al-Mogairen, S. M. (2010). Role of sodium silicate in induction of scleroderma-related autoantibodies in brown Norway rats through oral and subcutaneous administration. *Rheumatol Int*. doi: 10.1007/s00296-009-1327-3

Arslan Lied, G. (2007). Gastrointestinal food hypersensitivity: symptoms, diagnosis and provocation tests. *Turk J Gastroenterol, 18*(1), 5-13.

Bonamico, M., Mariani, P., Danesi, H. M., Crisogianni, M., Failla, P., Gemme, G., . . . Romano, C. (2001). Prevalence and clinical picture of celiac disease in italian down syndrome patients: a multicenter study. *J Pediatr Gastroenterol Nutr, 33*(2), 139-143.

Brocard, A., Quereux, G., Moyse, D., & Dreno, B. (2010). Localized scleroderma and zinc: a pilot study. *Eur J Dermatol, 20*(2), 172-174. doi: ejd.2010.0879 [pii] 10.1684/ejd.2010.0879

Calvaruso, C., Turpault, M. P., Leclerc, E., Ranger, J., Garbaye, J., Uroz, S., et al. (2010). Influence of forest trees on the distribution of mineral weathering-associated bacterial communities of the Scleroderma citrinum mycorrhizosphere. *Appl Environ Microbiol, 76*(14), 4780-4787. doi: AEM.03040-09 [pii]10.1128/AEM.03040-09

Caramaschi, P., et al. “Homocysteine Plasma Concentration Is Related to Severity of Lung Impairment in Scleroderma.” J Rheumatol 30 (2) (February 2003): ­298–304.

Caramaschi, P., Volpe, A., Canestrini, S., Bambara, L. M., Faccini, G., Carletto, A., et al. (2007). Correlation between homocysteine plasma levels and nailfold videocapillaroscopic patterns in systemic sclerosis. *Clin Rheumatol, 26*(6), 902-907. doi: 10.1007/s10067-006-0425-9

Chen, M., & von Mikecz, A. (2005). Xenobiotic-induced recruitment of autoantigens to nuclear proteasomes suggests a role for altered antigen processing in scleroderma. *Ann N Y Acad Sci, 1051*, 382-389. doi: 1051/1/382 [pii]10.1196/annals.1361.080

Clegg, D. O., Reading, J. C., Mayes, M. D., Seibold, J. R., Harris, C., Wigley, F. M., et al. (1994). Comparison of aminobenzoate potassium and placebo in the treatment of scleroderma. *J Rheumatol, 21*(1), 105-110.

Czirjak, L., et al. “Localized Scleroderma After Exposure to Organic Solvents.” Dermatology 189, no. 4 (1994): ­399–401.

Dobryniewski, J., Szajda, S. D., Waszkiewicz, N., & Zwierz, K. (2007). [The gamma-linolenic acid (GLA)--the therapeutic value]. *Przegl Lek, 64*(2), 100-102.

Ebert, E. C. (2008). Gastric and enteric involvement in progressive systemic sclerosis. *J Clin Gastroenterol, 42*(1), 5-12. doi: 10.1097/MCG.0b013e318042d625 00004836-200801000-00003 [pii]

Failli, P., et al. “Effect of N-Acetyl-L-Cysteine on Peroxyni­trite and Superoxide Anion Production of Lung Alveolar Macrophages in Systemic Sclerosis.” Nitric Oxide 7 (4) (December 2002): ­277–82.

Fallahzadeh, M. K., Namazi, M. R., & Gupta, R. C. (2010). Taurine: a potential novel addition to the anti-systemic sclerosis weaponry. *Arch Med Res, 41*(1), 59-61. doi: S0188-4409(09)00212-4 [pii]10.1016/j.arcmed.2009.11.005

Fasano, A. (2009). Surprises from celiac disease. *Sci Am, 301*(2), 54-61.

Fasano, A. “Celiac Disease: How to Handle a Clinical Chameleon.” N Engl J Med 34 (25) (June 19, 2003): ­2568–70.

Gabay, C., and M.F. Kahn. “Male-Type Scleroderma: The Role of Occupational Exposure.” Schweiz Med Wocheschr 122, no. 46 (November 14, 1992): ­1746–52.

Gaby, A. R. (2006). Natural remedies for scleroderma. *Altern Med Rev, 11*(3), 188-195.

Germain, B.F. “Silicone Breast Implants and Rheumatic Disease.” Bull Rheum Dis 41, no. 6 (October 1992): ­1–4.

Green, P. H. (2005). The many faces of celiac disease: clinical presentation of celiac disease in the adult population. *Gastroenterology, 128*(4 Suppl 1), S74-78. doi: S001650850500185X [pii]

Hendel, L., et al. “Esophageal Candidosis in Progressive Systemic Sclerosis: Occurrence, Significance, and Treatment with Fluconazole.” Scand J Gastroenterol 23, no. 10 (December 1988): ­1182–86.

Hernando-Harder, A. C., Booken, N., Goerdt, S., Singer, M. V., & Harder, H. (2009). Helicobacter pylori infection and dermatologic diseases. *Eur J Dermatol, 19*(5), 431-444. doi: ejd.2009.0739 [pii]10.1684/ejd.2009.0739

Herrick, A. L., Rieley, F., Schofield, D., Hollis, S., Braganza, J. M., & Jayson, M. I. (1994). Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. *J Rheumatol, 21*(8), 1477-1483.

Herrick, A.L., et al. “Dietary Intake of Micronutrient Antioxidants in Relation to Blood Levels in Patients with Systemic Sclerosis.” J Rheumatol 23 (4) (April 1996): ­650–53.

Herrick, A.L., et al. “Micronutrient Antioxidant Status in Patients with Primary Raynaud’s Phenomenon and Systemic Sclerosis.” J Rheumatol 21 (8) (August 1994): ­1477–83.

Higdon, J., Drake V.J., Shane B. (2007). Folic Acid. *Linus Pauling Micronutrient Information Center*. Retrieved from <http://lpi.oregonstate.edu/infocenter/vitamins/fa/index.html#food_source>

Katayama, H., Ohsawa, K., & Yaoita, H. (1984). Improvement of progressive systemic sclerosis (PSS) with estriol treatment. *Acta Derm Venereol, 64*(2), 168-171.

La Montagna, G., et al. “Dehydroepiandrosterone Sulphate Serum Levels in Systemic Sclerosis.” Clin Exp Rheumatol 19 (1) (January–February 2001): ­21–26.

Lafyatis, R., & York, M. (2009). Innate immunity and inflammation in systemic sclerosis. *Curr Opin Rheumatol, 21*(6), 617-622. doi: 10.1097/BOR.0b013e32832fd69e

Lamm, S.H. “Silicone Breast Implants and Long-Term Health Effects: When Are Data Adequate?” J Clin Epidemiol 48, no. 4 (April 1995): ­507–11.

Levy, Y., Rotman-Pikielny, P., Ehrenfeld, M., & Shoenfeld, Y. (2009). Silicone breast implantation-induced scleroderma: description of four patients and a critical review of the literature. *Lupus, 18*(13), 1226-1232. doi: 18/13/1226 [pii]10.1177/0961203309347795

Lundberg, A.C., A. Akesson, and B. Akesson. “Dietary Intake and Nutritional Status in Patients with Systemic Sclerosis.” Ann Rheum Dis 51 (10) (October 1992): ­1143–48.

Magnant, J., & Diot, E. (2006). [Systemic sclerosis: epidemiology and environmental factors]. *Presse Med, 35*(12 Pt 2), 1894-1901. doi: S0755-4982(06)74923-5 [pii]

Magnant, J., de Monte, M., Guilmot, J. L., Lasfargues, G., Diot, P., Asquier, E., et al. (2005). Relationship between occupational risk factors and severity markers of systemic sclerosis. *J Rheumatol, 32*(9), 1713-1718. doi: 0315162X-32-1713 [pii]

Makol, A., Reilly, M. J., & Rosenman, K. D. (2010). Prevalence of connective tissue disease in silicosis (1985-2006)-a report from the state of michigan surveillance system for silicosis. *Am J Ind Med*. doi: 10.1002/ajim.20917

Marasini, B., Casari, S., Bestetti, A., Maioli, C., Cugno, M., Zeni, S., et al. (2000). Homocysteine concentration in primary and systemic sclerosis associated Raynaud's phenomenon. *J Rheumatol, 27*(11), 2621-2623.

Marasini, B., et al. “Homocysteine Concentration in Primary and Systemic Sclerosis Associated Raynaud’s Phenomenon,” J Rheumatol 27 (2000): ­2621–23.

Marie, I., Ducrotte, P., Denis, P., Menard, J. F., & Levesque, H. (2009). Small intestinal bacterial overgrowth in systemic sclerosis. *Rheumatology (Oxford), 48*(10), 1314-1319. doi: kep226 [pii]10.1093/rheumatology/kep226

McCormic, Z. D., Khuder, S. S., Aryal, B. K., Ames, A. L., & Khuder, S. A. (2010). Occupational silica exposure as a risk factor for scleroderma: a meta-analysis. *Int Arch Occup Environ Health, 83*(7), 763-769. doi: 10.1007/s00420-009-0505-7

Mora, G. F. (2009). Systemic sclerosis: environmental factors. *J Rheumatol, 36*(11), 2383-2396. doi: jrheum.090207 [pii]10.3899/jrheum.090207

Nietert, Paul J., et al. “Is Occupational Organic Solvent Exposure a Risk Factor for Scleroderma?” Arthritis Rheum 41, no. 6 (June 1998): ­1111–18.

Pelmear, P.L., J.O. Roos, and W.M. Maehle. “Occupationally Induced Scleroderma.” J Occup Med 34, no. 1 (January 1992): ­20–25.

Prokopova, L. “Celiac Disease—A Severe Disease.” Vnitr Lek 49 (6) (June 2003): ­474–81.

Quatresooz, P., Paquet, P., Pierard-Franchimont, C., & Pierard, G. E. (2007). [How I explore...the revisited toxic path of scleroderma]. *Rev Med Liege, 62*(3), 170-174.

Randone, S. B., Guiducci, S., & Cerinic, M. M. (2008). Systemic sclerosis and infections. *Autoimmun Rev, 8*(1), 36-40. doi: S1568-9972(08)00135-3 [pii]10.1016/j.autrev.2008.07.022

Ranque, B., & Mouthon, L. (2010). Geoepidemiology of systemic sclerosis. *Autoimmun Rev, 9*(5), A311-318. doi: S1568-9972(09)00181-5 [pii]10.1016/j.autrev.2009.11.003

Rosato, E., De Nitto, D., Rossi, C., Libanori, V., Donato, G., Di Tola, M., et al. (2009). High incidence of celiac disease in patients with systemic sclerosis. *J Rheumatol, 36*(5), 965-969. doi: jrheum.081000 [pii]10.3899/jrheum.081000

Sanchez-Roman, J., et al. “Multiple Clinical and Biological Autoimmune Manifestations in 50 Workers After Occupational Exposure to Silica.” Ann Rheum Dis 52, no 7 (July 1993): ­534–38.

Shiel WC, D. C. (2010). Scleroderma. *Medicine.net*. Retrieved from

Simonini, G., et al. “Emerging Potentials for an Antioxidant Therapy as a New Approach to the Treatment of Systemic Sclerosis.” Toxicol 155 (1–3) (November 30, 2000): ­1–15.

Slimani, S., Ben Ammar, A., & Ladjouze-Rezig, A. (2010). Connective tissue diseases after heavy exposure to silica: a report of nine cases in stonemasons. *Clin Rheumatol, 29*(5), 531-533. doi: 10.1007/s10067-009-1371-0

Straub, R.H., et al. “High Prolactin and Low Dehydroepiandrosterone Sulphate Serum Levels in Patients with Severe Systemic Sclerosis.” Br J Rheumatol 36 (4) (April 1997): ­426–32.

Tikly, M., Channa, K., Theodorou, P., & Gulumian, M. (2006). Lipid peroxidation and trace elements in systemic sclerosis. *Clin Rheumatol, 25*(3), 320-324. doi: 10.1007/s10067-005-0013-4

Vilela, F. A., Carneiro, S., & Ramos-e-Silva, M. (2010). Treatment of morphea or localized scleroderma: review of the literature. *J Drugs Dermatol, 9*(10), 1213-1219.

Wallace, D.J. “Silicone Breast Implants Do Not Cause Rheumatic Diseases, but Can They Influence Them?” Arthritis Rheum 46 (9) (September 2002): ­25–45.

Wang, W. L., Su, Y. M., Yang, R. Y., Zhang, J., & Xu, Y. (2005). Follow-up efficacy of integrative Chinese and Western drugs on localized scleroderma with vitamine B6 and Xuefu Zhuyu decoction. *Chin J Integr Med, 11*(1), 34-36.

Yamaguchi, K., Iwakiri, R., Hara, M., Kikkawa, A., Fujise, T., Ootani, H., et al. (2008). Reflux esophagitis and Helicobacter pylori infection in patients with scleroderma. *Intern Med, 47*(18), 1555-1559. doi: JST.JSTAGE/internalmedicine/47.1128 [pii]

Yasuda, M., Amano, H., Yamanaka, M., Tamura, A., & Ishikawa, O. (2008). Coincidental association of mycosis fungoides and occupational systemic sclerosis? *J Dermatol, 35*(1), 21-24. doi: JDE405 [pii]10.1111/j.1346-8138.2007.00405.x

Zarafonetis, C. J., Dabich, L., Devol, E. B., Skovronski, J. J., Negri, D., & Yuan, W. Y. (1989). Retrospective studies in scleroderma: pulmonary findings and effect of potassium p-aminobenzoate on vital capacity. *Respiration, 56*(1-2), 22-33.

Zarafonetis, C. J., Dabich, L., Negri, D., Skovronski, J. J., DeVol, E. B., & Wolfe, R. (1988). Retrospective studies in scleroderma: effect of potassium para-aminobenzoate on survival. *J Clin Epidemiol, 41*(2), 193-205. doi: 0895-4356(88)90094-7 [pii]

Zeglaoui, H., Landolsi, H., Mankai, A., Ghedira, I., & Bouajina, E. (2010). Type 1 diabetes mellitus, celiac disease, systemic lupus erythematosus and systemic scleroderma in a 15-year-old girl. *Rheumatol Int, 30*(6), 793-795. doi: 10.1007/s00296-009-0988-2

**Chapter 41: Sjogren’s Syndrome**

———. “Essential Fatty Acid and Prostaglandin Metabolism in Sjögren’s Syndrome, Systemic Sclerosis and Rheumatoid Arthritis.” Scand J Rheumatol 61 (Suppl) (1986): ­242–45.

Arslan Lied, G. (2007). Gastrointestinal food hypersensitivity: symptoms, diagnosis and provocation tests. *Turk J Gastroenterol, 18*(1), 5-13.

El Miedany, Y. M., Baddour, M., Ahmed, I., & Fahmy, H. (2005). Sjogren's syndrome: concomitant H. pylori infection and possible correlation with clinical parameters. *Joint Bone Spine, 72*(2), 135-141. doi: S1297319X04001083 [pii]10.1016/j.jbspin.2004.04.005

Ergun, S., Cekici, A., Topcuoglu, N., Migliari, D. A., Kulekci, G., Tanyeri, H., et al. (2010). Oral status and Candida colonization in patients with Sjogren's Syndrome. *Med Oral Patol Oral Cir Bucal, 15*(2), e310-315. doi: 2923 [pii]

Hammar, O., Ohlsson, B., Wollmer, P., & Mandl, T. (2010). Impaired Gastric Emptying in Primary Sjogren's Syndrome. *J Rheumatol*. doi: jrheum.100280 [pii]10.3899/jrheum.100280

Ianniello, A., et al. “S-Adenosyl-L-Methionine in Sjögren’s Syndrome and Fibromyalgia.” Curr Ther Res Clin Exp 55, no. 6 (June 1994): ­699–706.

Kawamoto, S., Ichinose, M., Ito, Y., Takahashi, H., Kawamura, T., & Hosoya, T. (2005). [Interstitial pneumonia and nephritis with Sjogren's syndrome: successful treatment with corticosteroid therapy]. *Nippon Jinzo Gakkai Shi, 47*(4), 451-457.

Liden, M., Kristjansson, G., Valtysdottir, S., Venge, P., & Hallgren, R. (2008). Cow's milk protein sensitivity assessed by the mucosal patch technique is related to irritable bowel syndrome in patients with primary Sjogren's syndrome. *Clin Exp Allergy, 38*(6), 929-935. doi: CEA2983 [pii]10.1111/j.1365-2222.2008.02983.x

Luft, L. M., Barr, S. G., Martin, L. O., Chan, E. K., & Fritzler, M. J. (2003). Autoantibodies to tissue transglutaminase in Sjogren's syndrome and related rheumatic diseases. *J Rheumatol, 30*(12), 2613-2619. doi: 0315162X-30-2613 [pii]

Pronai, L., and S. Arimori. “BG-104 Enhances the Decreased Plasma Superoxide Scavenging Activity in Patients with Behcet’s Disease, Sjögren’s Syndrome or Hematological Malignancy.” Biotherapy 3 (4) (1991): ­365–71.

Radfar, L., Shea, Y., Fischer, S. H., Sankar, V., Leakan, R. A., Baum, B. J., et al. (2003). Fungal load and candidiasis in Sjogren's syndrome. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 96*(3), 283-287. doi: 10.1016/S1079210403002245 S1079210403002245 [pii]

Soto-Rojas, A. E., Villa, A. R., Sifuentes-Osornio, J., Alarcon-Segovia, D., & Kraus, A. (1998). Oral candidiasis and Sjogren's syndrome. *J Rheumatol, 25*(5), 911-915.

Sweet, S. P., Denbury, A. N., & Challacombe, S. J. (2001). Salivary calprotectin levels are raised in patients with oral candidiasis or Sjogren's syndrome but decreased by HIV infection. *Oral Microbiol Immunol, 16*(2), 119-123. doi: omi160209 [pii]

Szodoray, P., Horvath, I. F., Papp, G., Barath, S., Gyimesi, E., Csathy, L., et al. (2010). The immunoregulatory role of vitamins A, D and E in patients with primary Sjogren's syndrome. *Rheumatology (Oxford), 49*(2), 211-217. doi: kep374 [pii]10.1093/rheumatology/kep374

Tishler, M., Paran, D., & Yaron, M. (1998). Allergic disorders in primary Sjogren's syndrome. *Scand J Rheumatol, 27*(3), 166-169.